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Mass spectrometry is a versatile, sensitive and fast technique with which to probe
biophysical properties in biological systems and one of the most important an-
alytical tools in the multidisciplinary field of proteomics. The study of native-
state proteins and their complexes in the gas-phase is well established and di-
rect infusion electrospray ionisation mass spectrometry (DI-ESI-MS) techniques are
becoming increasingly popular as a tool for screening and determining quantita-
tive information on protein-protein and protein-ligand interactions. However, com-
plexes retained by ESI-MS are not always representative of those in solution and
care must be taken in interpreting purely gas-phase results. This thesis details
modification and advancement of solution phase techniques devised by Gross et
al. utilising ESI-MS and Fitzgerald et al. applying matrix assisted laser desorp-
tion ionisation (MALDI)-MS termed PLIMSTEX (protein-ligand interactions by
mass spectrometry, titration and hydrogen-deuterium-exchange)[1] and SUPREX
(Stability of unpurified proteins from rates of H/D exchange)[2] to quantify these
interactions with regards to high throughput analysis.
The first part of this thesis describes the different developmental stages of the de-
vised HPLC-front ends and their optimisation with myoglobin and insulin. The suc-
cessfully developed HPLC-front end in conjunction with PLIMSTEX and SUPREX
and ESI-MS then gets tested with self expressed and purified cyclophilin A(CypA)-
cyclosporin A (CsA) system, followed by a test screen with potential CypA binding
ligands. Dissociation constants (Kd’s) within one order of magnitude to reported
values are determined.
In the third part of this thesis the application of the devised ESI-SUPREX method-
ology has been applied to anterior gradient 2 (AGr2) and the factor H complement
control proteins module 19-20 (fH19-20) exhibiting binding potential to a tagged-
hexapeptide and a synthetic pentasaccharide, respectively, resulting in thermody-
namical data for these protein-ligand interactions. For the AGr2 system another
dimension of investigation has been added by temperature controlling the devised
ESI-SUPREX approach, revealing a phase transition in the protein at higher tem-
peratures.
The final part of this thesis describes the application of the ESI-SUPREX method-
ology to probe folding properties of CypA in the presence of the self expressed and
purified E. coli chaperonin groEL. Thereby the denaturing properties of groEL have
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Mass spectrometry (MS) is a powerful technique for identifying unknown com-
pounds, studying molecular structure, and probing fundamental molecular inter-
actions. It is essentially a technique for ”weighing” molecules based on the motion
of an ion in an electric or magnetic field. The mass to charge ratio (m/z ), often
referred to as Thomson [3], describes the properties of observed ions where m is
mass and z is the charge of the ion. The charge of a given molecule can be obtained,
if some knowledge of the chemical nature is known and hence the mass calculated.
Most mass spectrometers consist of three regions: an ion source to generate
analyte ions, a mass analyser which separates the ions; and a detector (Fig 1.1).
However, as the field of MS rapidly expands into other disciplines, especially Life
Sciences, changes and additions have been made to adapt the technique initially
devised to analyse small molecules. Chromatographic front ends allow separation
before analysis (Section 1.1.4). Ion mobility enables gas phase separation after
ionisation and a variety of post acquisition methods aid a researcher’s life today. As
work presented in this thesis solely employs ESI-mass spectrometry in conjunction
with high-performance liquid chromatography (HPLC) the relevant background to




























Figure 1.1: Components of a Mass Spectrometer (acronyms defined in glossary).
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1.1.1 Ionisation
A variety of ionisation techniques (Fig. 1.1) are used in the field of MS to produce
analyte ions, which ideally are selected based on the sample to be analysed. Elec-
tron impact (EI) and atmospheric pressure chemical ionisation (APCI) involve gas
phase ionisation and hence require volatile analytes, whereas fast atom bombard-
ment (FAB), secondary ion mass spectrometry (SIMS), ESI and MALDI are used
to ionise condensed phase samples [4].
EI bombards the analyte with electrons to generate ions [5, 6]. This is useful for
analysis of non-polar compounds but is often destructive to the analyte structure.
FAB and SIMS use high energy atoms (about 5 keV) to sputter and ionise the sam-
ple in a single step by focusing a beam of rare gas neutrals (FAB) or ions (SIMS) on
the liquid or solid sample. As there is no heating required, these sputter techniques
are appropriate for thermally sensitive compounds [7, 8].
Atmospheric pressure ionisation (API) sources ionise the sample at atmospheric
pressure and transfer the ions into the MS. This is used to ionise thermally labile
samples such as peptides, proteins and polymers directly from the condensed phase
via a liquid-chromatography (LC) system at a flow rate of a few hundred µL/min.
The sample is introduced through a series of differentially pumped stages resulting
in a large pressure difference between the ion source and the MS. In addition a dry-
ing gas is used to break up clusters that form as the solvent evaporates [4].
ESI-MS was introduced by Yamashita and Fenn in 1984 [9, 10] based on the work of
Dole in 1968 [11] and since then has developed into a method of outstanding impor-
tance, particularly for new biochemical applications in the field of MS [12, 13, 14].
The liquid sample flows through a steel capillary tip, where a voltage of 3-6 kV is
applied, resulting in a charge enrichment at the liquid surface and the formation of
the Taylor cone, ultimately resulting in a jet of emitting droplets with a charge ex-
cess [15] (Fig. 1.2). Nebulising-/drying-gas and constant sample evaporation shrink
the radius r of the droplet at constant charge q until electrostatic repulsion reaches





with ε0 permittivity of vacuum. Equation 1 gives the conditions at which the charge
q becomes equal to the surface tension γ, holding the droplet together. At a par-
ticular r the droplet becomes unstable and a ’coulombic explosion’ releases smaller
droplets. Further solvent evaporation leads to ion generation via one of two possible
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mechanisms. The charge residue model (CRM) proposed by Dole et al. suggests
solvent evaporation until a single analyte ion emerges [11] (Fig. 1.2b). Per con-
tra, Iribarne and Thomson [17] proposed a mechanism coined the ion evaporation
model (IEM) were q and γ become so high, that direct ion emission becomes pos-




































































































































Figure 1.2: Schematic of involved processes during electrospray ionisation (a) (positive ionisation
mode). (b) The two mechanisms discussed for ESI (adapted from [18, 19]).
MALDI is used to analyse large molecules up to 300 kDa employing pulsed laser
techniques for ionisation [20]. Thereby the analyte is condensed in an ultraviolet
(UV) light absorbing organic matrix such as α-cyano-4-hydroxycinnamic acid or
trihydroxyacetophenone. The technique is often used for the analysis of synthetic
and natural polymers, proteins, and peptides because mainly singly charged ions
and few fragments are observed [4].
1.1.2 Mass Analysers
After ions are formed in the source region they are accelerated into the mass analyser
by an electric field and separated according their m/z values. The quadrupole mass
analyser (QMA) is the most common analyser used in MS comprising of multiples
of two perfectly parallel rods as first described by Paul and Steinwedel [21]. Ions
traveling through the QMA are subjected two potentials ±Φ0:
Φ0 = +(U − V cos ωt) and − Φ0 = −(U − V cos ωt) (2)
with ω the angular frequency, U the direct potential and V the amplitude of the RF





+ (au − 2qu cos 2ξ)u = 0 (3)
where u stands for either x or y, ξ is a dimensionless parameter (ξ = ωt/2), au is
the ion stability with respect to the DC component (U) and qu the ion stability for
the RF component (V ). So au and qu can be expressed as:
au = ax = −ay =
8zeU
mω2r20




As long as x and y remain less than r0, an ion can travel via the QMA and scan-
















Figure 1.3: Quadrupole mass analyser. Ions generated in the source region travel through two sets of
parallel rods before reaching the detector (adapted from [22]).
The time of flight (TOF) mass analyser separates ions in time as they traverse a
flight tube. In the drift tube the ions are accelerated to high velocities by a potential
Vs (Eq 5), flying the distance d (Eq 6) before reaching the detector. Mass to charge
ratios (Eq 7) are calculated from the time ions take to travel through the flight tube




mv2 = qv2 = zeVs (5)
















The concept of the first TOF analyser was described by Stephens [23] in 1946 and
in 1955 McLaren [24] published the design of a linear TOF-MS which became one
of the first commercial instruments available. A disadvantage of the linear TOF-MS
was its poor resolution, which improved dramatically with the invention of reflec-
tron TOF analysers [25]. The reflectron is usually defined by a series of grids and
ring electrodes, which create a retarding field acting as an ion mirror by reflecting
the ions back through the flight tube. The TOF anaylser has become a popular
tool largely due to its flexibility, low cost and theoretically no upper mass limit of
detection [4].
The quadrupole ion trap was first reported by Paul and Steinwedel in the 1960’ s
and has been refined to provide a very sensitive and relatively inexpensive MS by
Stafford et al. in 1984 [26, 27]. The sensitivity results from the efficiency of trap-
ping and analysing ions produced in the source with the drawback of higher signal
to noise (s/n) ratios, compared to other analysers. The quadrupole ion trap con-
sists of a ring- and two endcap-electrodes to which a combination of RF and DC
voltages are applied, creating an electric field trapping the ions in a potential en-
ergy well in the trap center. Mass spectra are acquired by scanning the RF and
DC fields so that ions of increasing m/z values are ejected through a hole in one
of the endcap-electrodes and strike the detector, followed by refilling the trap [4, 22].
Ion cyclotron resonance (ICR) MS offers high mass resolution and was first ap-
plied by Sommer [28]. The heart of the instrumentation is a superconducting magnet
trapping ions in a circular orbit with a particular cyclotron frequency ω. An ap-
plied RF-voltage allows resonance absorption and excites ions of a particular mass,
resulting in a larger orbit with a different ω. Measuring the changes in ω, the mass
can be calculated.
In 1974 Marshall and Comisarov [29] implemented fourier transformation (FT) to
the ICR technique. Thereby a short RF-pulse over a wide frequency range is ap-
plied to excite all trapped ions, producing a signal at the cyclotron frequency of each
m/z -value for the present ion. Transforming this signal, which is similar to a free
induction decay (FID) produced in an FT-NMR experiment, from the time domain
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to the frequency domain resulting in a mass spectrum [30].
1.1.3 Detectors
There are three different types of detectors found in state of the art MS equipment:
electron- and photo-multiplier and microchannel plates (MCP). In electron multipli-
ers (EM) detection of primary ions triggers the emission of secondary particles (ions,
electrons or neutrals), which are then responsible for amplification in a channeltron
(horn shaped device comprising a series of dynodes), resulting in a measurable cur-
rent. Electron multipliers are often found in quadrupole- and ion-trap instruments
[4] (Section 1.1.2).
Photomultipliers (PM) work on the same principles as EM with the difference that
the secondary particles collide with a phosphorescent screen, leading to photon emis-
sion and amplification in a photomultiplier tube.
The microchannel plate or array detector represents an array of thousands of in-
dividual EM fit on a plate enabling the detection of a large number of ions at the
same time. Due to its quick response time <1 ns it is often coupled to TOF-MS
instrumentation [4].
1.1.4 Liquid Chromatography ESI-Mass Spectrometry
Over the last few decades MS coupled separation techniques have become more
and more sophisticated and the development of ESI-MS (Section 1.1.1) prompted a
break through in these methods, allowing continuous ionisation/analysis (’on-line’
LC-MS). The first on-line LC-ESI-MS experiment was conducted in 1984 by Alexan-
drov and co-workers [31] and since then HPLC-ESI-MS has become one of the major
tools for separation coupled MS. Current development follows two major routes, (a)
the reduction of scale, using smaller columns for improving the detection limits and
(b) the reduction of time to satisfy the ever growing demands of high-throughput
analysis [22].
Miniaturisation of LC-columns from mm to low µm inner diameters (ID) re-
sults in dramatic flow rate reductions from mL/min to low nL/min utilising ’nano-
capillary-LC-systems’ in conjunction with nano-ESI sources. This capillary/nano-
scale HPLC-ESI-MS approach has had a massive impact on the amount of sample
that is needed for analysis, especially in the field of proteomics when coupled with
tandem mass spectrometry as reviewed by Heck et al. [32].
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Traditionally, LC was not viewed as a fast methodology, however, the time consum-
ing nature of chromatography has stimulated design of methods that improve the
speed of separations, aiming for the minimal separation efficiency still leading to
accurate results [33]. This is especially important for hydrogen deuterium exchange
(HDX; Section 1.3) LC-MS experiments, where short run times are necessary to
guarantee data accuracy. Increased flow rates and the use of capillary columns,
monolithic columns, open tubular columns and small diameter packed capillaries
further increase the speed of analysis [34]. Another approach to increase throughput
utilises multiple HPLC columns [35], autosamplers [36] or high flow rate ionisation
sources such as TurboIonSpray1.
In conclusion, there is no ’best’ methodology for a particular application rather
a plethora of options to choose from, compromising between sample requirements
and resources. Other liquid phase separation techniques such as capillary elec-
trophoresis, capillary electrochromatography and microchips, or gaseous phase ’gas
chromatography’ can further be utilised in conjunction with API sources as reviewed
in [37, 33, 38].
1.2 Protein Structure and Folding
Proteins are the major functional molecules enabling life on earth. They are in-
volved in almost every metabolic process within our bodies and play a key role in
the development of serious diseases, e.g. muscular dystrophy and Kreutzfeld-Jakob
disease, due to either mutations in their primary sequence or their structural prop-
erties may be impaired, resulting in a loss of physiological activity [39]. Many types
of cancers are attributed to mutations in ’guardian-proteins’ (Section 1.4.3) such as
p53, altering its structure and disabling apoptosis induction of malignant cells [40].
Therefore enzymes and receptors interacting with those proteins are usually drug
targets to restore function or destroy cancer.
After the human genome revolution [41, 42] the field of proteomics started sys-
tematically characterising proteins in different biological compartments and their
correlation with the available genomic data. The ultimate goal of protein science is
to be capable of de novo protein structure- and activity-prediction and gain insight
of how potential ligands will bind to an enzyme [43].
1Applied Biosystems - Foster City, USA
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1.2.1 Protein Building Blocks
Proteins are macromolecules translated in the ribosomes from messenger ribonucleic
acid (mRNA), transcripted from desoxyribonucleic acid (DNA) mainly comprising
20 ’natural’ occurring L-α-amino acids (aa; Appendix 8.1) along an unbranched
polypeptide chain linked by an amide bond between the α-carbonyl- of one residue
and an α-amino group of the next residue [44, 45]. This molecular arrangement infers
amphoteric properties so that each aa can exist in either a neutral or zwitterionic
state. In nature chirality is a major criterium for efficiency and during evolution,
for no obvious reason, the L-form was chosen over the D-form. The planar double
bond character of the amide bond rotationally restrains the polypeptide resulting
in two possible configurations, cis and trans, where the trans-form is intrinsically
energetically favored, probably due to lesser repulsion between non-bonded atoms.
All naturally occurring peptide bonds in proteins exhibit the trans conformation
with a few rare exceptions. If the following residue is proline, its cyclic side chain
diminishes the repulsion between atoms and the intrinsic stability of the cis isomer
is comparable to that of the trans isomer, however, still slightly favoring the trans
conformation of the peptidyl-prolyl-bond (Section 1.4.1) [46, 43].
1.2.2 Noncovalent Interactions
To maintain the three-dimensional structure of proteins and nucleic acids, or to
enable a molecule to bind specifically but transiently to another and form a complex,
several types of non-covalent interactions are essential. The energy released in the
formation of non-covalent bonds is 4-250 kJ/mol [47], less than the bond energies
of single covalent bonds (e.g. C-H, 418 kJ/mol) [48]. Hence these weak bonds are
often referred to as interactions, rather than bonds. Three fundamental non-covalent
interactions can be distinguished: electrostatic- and van der Waals interactions and
hydrogen bonding.
Electrostatic Interactions
Electrostatic interaction energies vary according to the nature of the charges and
the permittivity ε of the medium. For two ions q1, q2 with net charges the energy
V falls of with distance r as 1/εr (Coulomb potential Eq 8). The permittivity
ε (ε = εr · ε0) is also important, being about 80 in water and 2-4 in a protein.
Functional groups on individual amino acids show specific ε, which are influenced






Table 1.1 provides an overview of other charged/non-charged or polarised species
and their distance dependence along with typical energies of the interaction [47].
Table 1.1: Electrostatic interactions and distance dependence of potential energy
(adapted from [47]).




dipolea -dipolea 1/r3 2
dipolea /dipoleb -dipoleb 1/r6 0.6
London (dispersion) 1/r6 2
a permanent dipole.
b induced dipole.
Van der Waals Interactions
The basis of non-polar, hydrophobic van der Waals, or dispersion forces is that
the distribution of electronic charge around an atom changes with time creating
transient dipoles. The interaction of these induced-dipoles is described as dispersion-
or London-interaction and depends on the polarisibility α of the two molecules and











where I1 and I2 are the ionisation energies of the two molecules. Van der Waals
interactions are smaller compared to electrostatic binding energies (Table 1.1) but
when the surfaces of two large molecules come together a large number of atoms are
in van der Waals contact, and the net effect, summed over many atom pairs, can be
substantial [47, 43, 48].
Hydrogen Bonding
A particular important bond in biological systems is the hydrogen bond (H-bond).
The hydrogen atom is formally bonded covalently to one of two electronegative atoms
competing for the same proton, the donor. It also interacts favorably with the other,
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the acceptor. Usually it is bonded to one of the atoms with a normal covalent bond
length. The main component of the H-bond is an electrostatic interaction between
the dipole of the covalent bond and the partially positively charged hydrogen atom
and the partially negatively charged other atom. The small size and the substantial
charge attributed to positively polarisation, lead to H-bond formation [44, 48].
In enzymes hydrogen bonding often involves the carbonyl- and the amino-group of
the peptide backbone most often forming hydrogen bonds with bond lengths of 1.9-
2.0 Å.
The energy of H-bonds have been variously estimated to be between 12 and 38
kJ/mol. Bonds of this strength are of particular importance, since they are stable
enough to provide a significant binding contribution, but sufficiently weak to allow
rapid dissociation [44, 43].
1.2.3 Protein Structure
The three dimensional structure of a protein is determined by its genetically encoded
sequence [49] or its primary structure.
The polypeptide chains are found to be organised by hydrogen bonding of buried
carbonyl oxygen atoms and an amino group into α-helices and β-sheets. This organ-
isation is referred to as secondary structure. The α-helix was first described in
1951 by Linus Pauling and is an important structural element in biological macro-
molecules [50]. A carbonyl oxygen of residue n bonds with an amide bound hydrogen
atom of residue n+4 resulting in 3.6 aa’s in each turn of the cylindrical helix. About
one-third of aa-residues in proteins are organised in helical structures, often exhibit-
ing amphipathic character. One side has hydrophobic residues, allowing hydrophobic
interactions, one side has hydrophilic properties enabling interactions with water.
The second major element of structure are β-sheets, whereby the polypeptide chains
are either aligned parallel or antiparallel. Individual strands vary in length between
5-10 aa-residues. α-helices and β-sheets are connected by loop regions of various
lengths and irregular shape. Frequently recurring α and/or β substructures or folds
are collectively termed motifs or supersecondary structures. One simple example is
the β hairpin, comprising two antiparallel strands joined by a loop of three to five
residues [50, 43].
The arrangement in space of all the atoms in a single polypeptide chain or in cova-
lently linked chains is coined tertiary structure, whereas the overall organisation
of subunits in oligomeric proteins is termed quaternary structure [43, 48].
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Structure Elucidation Tools
Over the last few decades a set of biophysical methods has evolved which have
enabled the determination of the tertiary structure of proteins.
The single most important technique in the investigation of enzymes has been
x-ray diffraction crystallography, because it has provided the experimental ba-
sis of the present knowledge of the structure of proteins. X-rays are scattered when
they strike an electron in a crystal, creating a unique diffraction pattern, which af-
ter fourier transformation, yields the electron density of the crystal. The degree of
accuracy depends on the resolution, which can vary between 6.0-1.9 Å, the quality
and the size of the crystal. The time frame for solving a novel crystal structure is
from several months to years [43, 48].
As x-ray crystallography provides little information about the position of hy-
drogen atoms due to weak electron density of the H atom, neutron diffraction
circumvents this issue. However, it is a time consuming approach with the need for
special facilities [43, 48].
In recent years NMR has become one of the most important tools for protein
structure determination. The principle is based on calculating the overall protein
structure from short distance restrains (<5 Å) between natural abundance 1H atoms
in a one dimensional experiment. Per contra, multidimensional methods such as
nuclear overhauser effect- (NOE) or heteronuclear single quantum coherence (HSQC)
experiments with 13C- and 15N-labeled proteins provide further information for the
structure determination of larger proteins [51].
1.2.4 Protein Folding
The major driving force for protein folding seems to be the burying and clustering
of hydrophobic side chains (secondary structural elements) to minimise their con-
tact with water. Also weak interactions such as H-bonds and van der Waals forces
contribute to the process of protein folding [43, 48].
According to the first and second law of thermodynamics (Appendix 8.2), the total
energy in a system and its surrounding being constant, and the total entropy in-
creases of a system and its surrounding for spontaneous processes, the free energy
change ∆G must be negative for a reaction to be spontaneous [52]. As protein
folding can be assumed a spontaneous process under appropriate conditions, there
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has to be an increase in entropy in the system or its surrounding. Polar molecules
(aa-residues) in an aqueous phase interact with water molecules forming ionic or
hydrogen-bonding interactions (Section 1.2.2). Per contra, water molecules in con-
tact with non-polar, hydrophobic molecules (aa-residues) form a cage around it
resulting in a decreased entropy compared to free water. In the process of two
non-polar molecules (aa-residues) coming together more highly ordered water gets
released, increasing the entropy of the water. This phenomenon, termed the hy-
drophobic effect, helps to compensate for the entropy losses inherent in the folding
process [48].
In conclusion, protein folding is a complex procedure attributed to hydrophobicity,
non-covalent interactions and heat release during the folding reaction resulting in a
negative enthalpy change of the system, resulting in an overall negative free energy
[43, 48, 53].
The energy landscape theory describes how the energy of a protein system
changes with geometry of the individual residues [54]. The classical viewpoint estab-
lished by Levintal was that an unbiased search through the plethora of conformations
open for a denatured protein would take too long for a protein to fold, suggesting
the existence of pre-defined pathway offering choices [43]. For proteins with random
aa-sequences one would not assume such bias and expect the most stable structure
to be the least ’frustrated’ one [55]. The term frustration evolved from the spin-
glass system emphasising the inability of a system to reach its energetic ground state
[43]. Replacing and generalising the classical stepwise pathway with a series of in-
termediates, the energy landscape theory of protein folding involves the progressive
organisation of an ensemble of partially folded structures on a free energy surface
represented by a folding funnel (Fig. 1.4) [56]. The evolution of new techniques, e.g.
nuclear magnetic resonance (NMR) dynamic spectroscopy has enabled observation
of fast folding events supporting the basic validity of the theory [57].
The two axes of a two dimensional protein-energy landscape depict the energy-
entropy balance associated with competing physical processes and the ruggedness of
the funnel indicating frustration [58]. Local free energy minima represent transient
kinetic traps, whereas the native state lies at the bottom of the funnel. Frauenfelder
et al. emphasised that the physiologically active state is not just a lowest energy one
but more a variety of states differing at least in side-chain orientation [59, 60]. The

















Figure 1.4: Protein energy landscape. E represents free energy and Q the fraction of native-like
contacts, whereas entropy corresponds to the width of the folding funnel (adapted from [43]).
of native-like contacts. The width of the funnel represents the entropy (Fig. 1.4)
[58]. A quantitative statistical approach to free energy landscapes can be found in
[61].
1.2.5 Protein Stability
The stability of a protein is governed by the sum of its non-covalent interactions
such as packing of the hydrophobic side chains and hydrogen bonding (Section 1.2.4)
ranging from 20 to 63 kJ/mol [43]. Furthermore the interactions of individual water
molecules have to be considered. So the gross thermodynamic properties of a pro-
tein in the native and unfolded state are determined by enthalpy/entropy changes
in water and the protein in question (Section 1.2.4, Appendix 8.2).
Experimentally the free energy of protein folding is determined using thermal-
/solvent-denaturation methods such as differential scanning calorimetry (DSC) or
denaturation with a chaotropic agent. In the first instance the heat absorbance is
measured as the protein is slowly heated through its melting transition. Denaturing
agents such as urea or guanidinium hydrochloride (GDH) either solubilise all the
constituent parts of the protein, from the amide backbone to the side chains or di-
rectly interact with groups of the protein [62]. To a first approximation, the transfer
of protein backbone and side chains from water to the denaturant is proportional
to its concentration as shown by Tanford et al. [63, 64]. As the denatured state
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(D) is more exposed than the native state (N), it is preferentially stabilised by the
denaturant and ∆G can be determined:
∆GD−N = ∆G
H2O
D−N − mD−N [Denaturant] (10)
where m is a constant of proportionality named by Greene et al. [65] (−∂(∆GD−N)/
∂[Denaturant]) containing information pertinent to the protein. The m-value strongly
correlates with the surface exposure of the protein upon unfolding in a two-state
unfolding event [66]. Low m-values may indicate a protein does not become highly
unfolded during denaturation or the denaturation step occurs stepwise rather than
in a single cooperative step [66, 43]. This observation is important for interpretation
of findings in Chapters 3, 4 and 5.
1.2.6 Protein-Ligand Interactions
Over the last few decades a variety of methodologies have evolved to investigate
non-covalent enzyme substrate interactions.
Utilising low sample volumes and radioactively labeled ligands, equilibrium dial-
ysis with a semi permeable membrane directly yields concentrations of free and
bound ligand.
In equilibrium gel filtration assays a gel filtration column is primed with a
ligand, prior to application of the enzyme. As the protein travels through the col-
umn it drags any bound ligand with it at the same flow rate resulting in a ligand
peak in the position of the protein and a trough in the position normally occupied
by the smaller ligand. Ideally peak areas should be equal and proportional to the
bound ligand [67, 43].
Analytical ultracentrifugation is utilised to investigate larger sample vol-
umes (100-200 µL) measuring ultraviolet- (UV) absorbance in correlation with sed-
imentation. The higher molecular mass complex hereby sediments faster as free
protein/ligand resulting in a sharp UV-peak while migrating down the cell [68, 43].
Useful data from nucleic acid-protein interactions has been derived from filter
assays, where enzymes are immobilised on nitrocellulose filters and free ligands,
however, are not retained. In special cases this economical procedure provides use-
ful data for assaying binding [69, 43].
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Spectroscopic methods such as measuring the Trp-fluorescence of a protein and/or
a ligand are popular methods to observe protein-interactions. However, the concen-
tration of free ligand is not directly accessible and often titration experiments with
the ligand are performed. Fitting the fluorescence data yields the dissociation con-
stant at relatively low sample concentrations and volumes [43].
Isothermal titration calorimetry (ITC) is a method to directly measure the
specific heat change upon ligand binding under isothermal conditions. Depending on
the dissociation constant (Kd) of the system, different sample concentrations yield
information about binding stoichiometry, enthalpy and Kd [22, 43].
A recently developed methodology uses refractive indices to determine concen-
trations of proteins and/or ligands immobilised on a glass slide to calculate Kd’s from
concentration changes. Hence, light passes between two media with low and high
refractive indices on a conducting surface, inducing an electric field causing pho-
ton/plasmon energy conversion, when constructive interference occurs. This results
in a resonance effect, termed surface plasmon resonance (SPR). Nevertheless,
high accuracy data represents an immobilised state of a protein and care must be
taken comparing these results with other methods [22].
In the field of mass spectrometry a variety of techniques have emerged to
observe protein and protein-ligand interactions in the gaseous and aqueous phase
and to study structural properties of these biological systems. Since the first ob-
servations of non-covalent complexes in the gas phase by Ganem, Li and Henion
[70] a lot of work has been done on quantifying these properties, as reviewed in
[71, 72, 73, 74, 75]. The dialectic character of how well gas-phase properties reflect
those in solution have been demonstrated i.a. by Aplin et al. [76] and Robinson
and co-workers on the E. coli chaperonin groEL and tandem mass spectrometry [77],
exhibiting low and high grade of reproducibility for gas- and solution phase deter-
mined information. These findings triggered the evolvement of indirect methods to
observe protein-ligand interactions such as hydrogen-deuterium exchange methods
(Section 1.3), PLIMSTEX (Section 1.5) and SUPREX (Section 1.6).
Tandem mass spectrometry describes the process of multiple rounds of isolation
of a particular ionic species and dissociation followed by mass analysis and has been
widely employed for proteomic analysis. Dissociation is achieved via vibrational and
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electronic mediated processes. The former utilises i.a. neutral buffer gas molecules
as reactants for fragmentation and is referred to as collision induced dissociation
(CID) or collisionally activated dissociation (CAD) [78]. CID is perhaps the most
widely used fragmentation technique in the field of MS and has been well studied
over the years, as reviewed in [79].
Another vibrational dissociation technique is surface-induced dissociation (SID)
whereby collisions between gaseous ions and a surface increase the internal energy of
the ionic species, culminating in fragmentation as demonstrated by Wysocki, Futrell
and co-workers [80, 81].
Electronic mediated fragmentation processes such as electron capture dissociation
(ECD) were first described by Zubarev, Kelleher and McLafferty in 1998 [82], thereby
electron capture leads to charge reduction and electron mediated dissociation. Since
then, ECD is a well applied method for protein structure elucidation, probing protein
properties and nucleic acid sequencing as demonstrated by Breuker et al. [83, 84].
In the last 25 years ion mobility mass spectrometry (IM-MS) has become an
important analytical tool to study the shape of compounds and has recently been
applied to investigate biological systems. It is based on determining the mobility
of an analyte ion in an electric field and a buffer gas environment, resulting in
an averaged collisional cross section for the compound in question, as reviewed in
[85]. Over the years protein systems of all sizes have been investigated ranging from
small peptides by Bowers et al. [86] to moderate size proteins, such as cytochrome
C, haemoglobin and calmodulin probed by Barran and co-workers [87] and large
biological systems such as groEL, investigated by Robinson and Heck et al. [88, 89].
1.3 Hydrogen Deuterium Exchange
Since the detection of deuterium in 1932 by Urey and Brickedde [90], its exchange
with hydrogen has been the subject of intensive study. In 1933 Bonhöffer and Klar
showed that little hydrogen-deuterium exchange occurs in small organic molecules
in heavy water [91]. The pioneering work of Linderstrøm-Lang and Hvidt in the
mid 50’s established HDX as a central technique for studying proteins [92, 93].
While the majority of protein HDX experiments still employ high resolution NMR
to observe exchange kinetics [94] the ground breaking work of Katta and Chait
firstly demonstrated the great potential [95] of marrying HDX with MS and laid the
foundation for several MS based HDX methods [96, 97, 98, 99].
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1.3.1 HDX in Macromolecules
Proteins posses three different types of hydrogen atoms distinguished by their bind-
ing partner and their intrinsic rates of HD-exchange (Fig. 1.6) [100].
The hetero atom bound hydrogens of the side chains are coined type 1 hydrogen
atoms undergoing a fast reversible exchange under all buffer conditions [100] (Fig.
1.6a).
Amide bound hydrogen atoms of the protein backbone are referred to as type 2
hydrogens exhibiting solvent depending behaviour. Low pH and temperature con-
ditions slow down the exchange rate and these features are widely used in HDX
experiments [94].
The aliphatic and aromatic bound hydrogens are named type 3 hydrogen atoms
and show no exchange within the time of an usual HDX-MS experiment [91].
In choosing the right pH conditions the intrinsic rate of exchange (kint) of an
amide hydrogen can be lowered four orders of magnitude, whereas temperature
control adds another order of magnitude (Fig. 1.6).
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Figure 1.5: Types of hydrogens in an enzyme with: type 1 hydrogen atoms in blue, type 2 (red) and
type 3 (green; visualised with ChemDraw - CambridgeSoft - Cambridge, USA).
1.3.2 HDX Models
In enzymes global HDX depends on the nature of the hydrogen atom to be exchanged
and its rate constant for exchange. Type 2 hydrogens are nearly all involved in H-
bonding, either intramolecularly or with water. Also, amide protons are often less
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solvent accessible due to the folded state of a protein and therefore show reduced
exchange rates [98]. At physiological pH, HDX is base catalysed (Section 1.3.3),
however, at low pH acid catalysis (Section 1.3.3) plays an important role [101]. The
rate constant for hydrogen deuterium exchange kex for proteins with equilibrium
unfolding behaviour following a two state process (folded - unfolded) [102] HDX can










with P Hcl the protonated folded, P
H
op the protonated unfolded, P
D
op the unfolded
deuterated and P Dcl the deuterated folded species. kop and kcl being the rate constants
for the unfolding/refolding process and kint the intrinsic exchange rate for amide
HDX to occur. The overall HDX rate constant kex can be written as:
kex =
kopkint
kop + kcl + kint
(12)
When kint ≫ kcl and kint ≫ kop (termed EX1 kinetics) the exchange rate kex is
given by the unfolding rate constant kop:
kex = kop (13)
Per contra, under physiological conditions it is more common for kcl ≫ kop and





kop and kcl can be rewritten as the equilibrium constant for the unfolding reaction:
kex = Kopkint (15)
While only a few proteins show EX1 kinetics naturally, all proteins undergo EX2
kinetics under physiological conditions and exchange can be influenced towards the
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Figure 1.6: Amide bond exchange rates. (a) Rate constants and half lifes for amide HDX at different
pH and temperature settings (reproduced from: homepage Engen JR, http://www.hxms.neu.edu). (b)
Average exchange rates of amide- (black) and side chain bound hydrogen atoms [22, 94].
1.3.3 Mechanisms of Exchange
Hydrogen exchange at unprotected sites in a protein is pH dependent, both acid-
and base-catalysed mechanisms are important. The overall intrinsic exchange rate
(kint) is usually presented:
kint = kacid[H
+] + kbase[OH
−] + kH2O (16)
with kacid the acid-catalysed rate constant, kbase the base-catalysed rate constant and
kH2O the spontaneous rate constant in water. The absolute and relative values for
kint are aa-residue dependent and have been tabulated by Englander and co-workers
[107].
Base-catalysis occurs via the imidate anion caused by amide proton abstraction
of the base (Fig. 1.7). Acid-catalysis takes place by one of the two suggested
pathways. The first occurs via an ionic amide intermediate analogue to the basic-
catalysed pathway. The second, involves deuteron abstraction by the α-carbonyl



















































Figure 1.7: Proposed HDX mechanisms for acid- and base-catalysis. (a) Base-catalysed HDX mech-
anism via imidate anion. (b) First acid-catalysed mechanism via positive charged amide nitrogen. (c)
Second acid-catalysed mechanism via imidic acid mechanism (adapted from [94]).
1.4 Biological Systems
1.4.1 The Peptidyl-Prolyl cis-trans Isomerase Family
Since the discovery of cyclophilin A in 1984 by Handschumacher et al. and Hard-
ing et al. [108] as a binding partner to cyclosporin A (Kd 30 nM) resulting in an
immune suppression reaction, there has been keen interest in the immunophilin pro-
tein family. In 1989 another protein was identified binding the immunosuppressive
drug FK506 and named FK506-binding protein (FKBP) [109, 110]. In the same pe-
riod it was demonstrated that cyclophilins and peptidyl-prolyl-cis-trans isomerases
(PPIase) are species variants of the same protein [111, 112]. In 1994 a third mem-
ber of the PPIase family was discovered, the parvulins, which are in contrast to
CypA and FKBP, irreversibly inhibited by juglone, 5-hydroxy-1,4-naphthoquinone
[113, 114, 115].
Protein folding was initially thought to be a spontaneous process, transforming the
amino acid sequence in a well defined three-dimensional structure, suggesting all
information for proper folding is located in the primary sequence [49]. Refolding
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experiments of denatured globular single-domain proteins showed refolding events
occurring in a second to millisecond time scale. However, the cis-trans isomerisa-
tion of the peptidyl-prolyl bond is the rate limiting step in protein folding and takes
significantly more time [116]. During biosynthesis of proteins in the ribosomes the
trans isomer is most abundant, as it is in most native peptides. Nonetheless, both
isomers are accessible in the peptide backbone. The PPIases lower the energy bar-
rier of this rate limiting step and thereby accelerate protein folding [112]. However,
knockout experiments in E. coli [117] and A. calcoacet. [118] did not show any sig-
nificant phenotype in growth. Per contra, mutation experiments in Drosophila and
C. elegans showed severe effects on sight and fertility, respectively [119, 120]. Based
on these findings it was concluded that the immunophilins do not play a general
essential role in protein folding but rather may perform specific functions through
interactions with unique sets of restricted partner proteins that remain to be fully
identified.
The immunosuppressive actions exerted of CsA and FK506 have been numer-
ously reviewed [121, 122] and are visualised in Figure 1.8. During T cell activation
calmodulin (CaM) binds to the phosphatase calcineurin (CN) as a result of ele-
vated levels of intracellular Ca2+. The complex dephosphorylates the nuclear factor
of activated T cells (NF-AT), now able to cross the nuclear membrane. In the
nucleus dephosphorylated NF-AT acts as transcriptional activator for the early T-
cell-activation gene product interleukin-2 (IL-2). Binding of CsA to CypA alters the
structure of CsA, enabling binding to CN and therefore blocking the phosphatase
activity of the CN/CaM complex. Inhibition of the CN/CaM phosphatase activity






























Figure 1.8: Possible pathways associated with CypA-CsA and FKBP-FK506 complexation during
T cell activation. During T cell activation CaM binds to CN due to high Ca2+ levels resulting in
dephosphorylation of NF-AT. In the nucleus NF-AT acts as activator for IL-2 transcription (adapted
from [123]).
Cyclophilin A
The cyclophilins are ubiquitous proteins found in almost all cell types, i.a. bac-
teria, yeasts, fungi, plants and vertebrates. The CypA family is highly conserved
in structure and consists of CypA, B, C and D. Human CypA is a cytosolic 165
aa, 18 kDa protein comprising two α-helices and eight β-strands forming the hy-
drophobic core of the protein. Despite structural differences, FKBP and CypA
share a common domain involving residues Tyr48 and Phe53 in the hydrophobic
core, Tyr79 on the surface and Phe60 in the CsA binding pocket [124]. Intensive
x-ray crystallography and NMR structural studies by Wüthrich, Walkinshaw et al.
[125, 126, 127, 124, 128, 129, 130, 131, 132] identified residues Arg55, Ile57, Phe60,
Met61, Gln63, Gly72, Thr73, Ala101, Asn102, Ala103, Gln111, Phe113, Trp121,
Leu122, His126 being involved in CsA binding and therefore form a 15·20·10 Å
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binding pocket (Fig. 1.9). It has been shown that up to 5 water molecules are es-
sential for CsA binding [133, 134]. More recent calculations of Lazaridis et al. [135]
suggest the involvement of only 4 water molecules.
Lately, studies have shown the involvement of CypA in replication and infectivity
of the human immunodeficiency virus type 1 (HIV-1), which encodes i.a. the viral
protein R (Vpr) involved in the induction of G2 host cell cycle and the translocation
of the pre-integration complex of the incoming virus to the nucleus [136, 137]. The
N-terminus of this 96 aa enzyme comprises a highly conserved proline rich region,
from which two show a preference for the cis conformation of the imidic bond,
suggesting a regulation of the isomerisation of Vpr by the host PPIase. As a result
CypA is incorporated into HIV-1 virons by binding to Pro222 in the proline rich
region of the HIV-1 capsid protein. This specific interaction disables detection by
inhibitory host factors such as Ref-1, which facilitates the infection [138, 139, 140].
Cyclosporin A
The undecapeptide CsA (Fig. 1.10) binding to CypA is a cyclic peptide with a
mass of 1202.65 Da and a pronounced hydrophobic character, first isolated from
the fungus Tolypocladium inflatum. Since its discovery in the early 1980’s (Section
1.4.1) it has been used as an immunosuppressive drug to prevent graft rejection after
organ transplantation [108]. Side effects such as nephrotoxicity led to the search for
new metabolites [141] and the synthesis of new compounds.
Due to its hydrophobic character, CsA studies in different solvents showed a confor-
mational polymorphism of CsA [142]. In the complexed form with CypA all peptide
bonds are in the trans conformation and none of the intramolecular hydrogen bonds,
found in the free structure are present. Nonetheless, one hydrogen bond is formed
between the hydroxyl group of the Bmt-1 side chain and carbonyl oxygen of MeLeu-4
(Fig. 1.10). In the complex only residues 1, 2, 3, 9, 10 and 11 of CsA are in contact;
the remaining residues 4-8 protrude out of the CypA surface. This hydrophobic
protrusion is referred to as the ”effector loop”, which is implicated in the specific
interaction with CN. Conclusively, this explains the phenomenon that binding of a
CsA analogue was a requirement, but not sufficient, for immunosuppressive activity
[143, 144, 134].
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Figure 1.9: The CypA-CsA binding pocket with Arg55, Ile57, Phe60, Met61, Gln63, Gly72, Thr73,
Ala101, Asn102, Ala103, Gln111, Phe113, Trp121, Leu122, His126 residues involved in CsA binding.
Cyclosporin represented in grey (pdb file 1cwb visualised with pymol (DeLano Scientific LLC - Palo
Alto, USA)).
FKBP12
Members of the FKBP protein family range from 12 to 52 kDa. FKBP12 is a 107
aa small ubiquitous protein (˜12 kDa) with all seven proline residues in the trans
conformation [145]. It is a PPIase and induces immune suppression (Section 1.4.1,
Fig. 1.8) by binding to FK506 or rapamycin. Dissociation constants for the FKBP-
FK506 and FKBP-rapamycin complex have been determined to 0.4 nM and 0.2 nM,
respectively [146, 147, 148].
Its structure has been solved to atomic resolution, identifying residues Tyr82, Ile92,
Phe36, Phe99, Tyr26, Phe46, Phe48, Val55, Ile56 and Trp59 forming a hydrophobic
pocket, responsible for ligand binding [149, 150, 151, 152]. It was found that the vol-
ume of this binding pocket only accommodates a five-membered or a six-membered
ring [147] and in 1998 Denesyuk et al. identified the 6-membered pipecolinyl ring




The immunosuppressive drug FK506 is a 788 Da polyketide and mainly produced by
the bacterium Streptomyces tsukubaesis first discovered in a soil sample in Tsukuba,
Japan [154]. It is structurally related to rapamycin, 901.5 Da (Fig. 1.10), isolated
from Streptomyces hygroscopicus found on Easter Island in 1975. Both act as an
immunosuppressive drug and find wide medical application [155, 156]. To find less
toxic analogues a variety of compounds have been synthesised and investigated [157]

















































































Figure 1.10: Structures of immunophilin binding ligands. (a) The cis-trans isomerisation of the pro-
line imidic bond. (b) Cylosporin A, 1. 4R-4[(E)-2-butenyl]-4, N-dimethyl-L-threonine (MeBmt); 2.
L-α-aminobutyric acid (Abu); 3. sacrosine (Sar); 4. leucine (Leu); 5. valine (Val); 6. N-methylleucine
(meLeu); 7. alanine (Ala); 8. D-Ala; 9. MeLeu; 10. MeLeu; 11. N-methylvaline (MeVal). (c) Ra-
pamycin. (d) 5-Hydroxy-1,4-naphthoquinone (juglone). (e) FK506. Structures visualised with Chem-
Draw - CambridgeSoft - Cambridge, USA.
1.4.2 The GroEL/GroES E.coli Chaperon System
Molecular chaperones, or chaperonins were initially identified in bacteria, archaea
and eukaryotic cells as reviewed in [158, 159, 39]. Chaperonins seem to provide ki-
netic assistance in protein folding of newly translated or translocated polypeptides.
Although Anfinsen identified in 1973 that all steric information specifying the final
three-dimensional structure of a protein is contained in its primary sequence [49],
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there is an apparent disposition under certain conditions for many proteins to mis-
fold and aggregate irreversibly in vivo [160]. By preventing this from happening,
molecular chaperons facilitate the production of native state proteins under condi-
tions in which the native form would otherwise not be achieved [161]. Conclusively,
their actions increase the yield of properly folded proteins but rarely increase the
inherent rate of the folding reaction [162, 160].
The E.coli chaperon system groEL/groES is one of the most studied molecular
chaperon systems and is expressed from the groE operon of the bacterium, whereby
L stands for large and S for small. GroEL comprises 14 identical subunits with a
relative mass of ˜58 kDa each, which are arranged in two stacked heptameric toroids,
constituting a cylinder of 145 Å height, 135 Å diameter and a central inner channel
of 45 Å (Fig. 1.11). Each groEL protein is composed of three clearly defined do-
mains: apical (a), intermediate (i) and equatorial (e). The apical domain is formed
by aa residue 191-376 and provides the binding site for non-native proteins and the
co-chaperon groES. It has been found that the non-native protein target is bound at
the edge of the inner channel co-assisted by the end-surfaces of the groEL cylinder
containing hydrophobic clusters for extra fixation [163, 164, 165, 166, 167]. The
largest (equatorial) domain (aa residue 6-133 and 409-523) delivers the majority of
inter-subunit and inter-ring contacts and hosts the ATP/ADP binding site on the
upper part of the inner channel surface [168]. The intermediate domain contains
89 aa (134-190 and 377-408) and connects a- and e-domain providing large scale
conformational changes of the protein during ligand interactions [168, 164, 160]).
The co-chaperon groES contains seven identical ˜10 kDa subunits assembled in
one heptameric dome shaped ring 30 Å in height, 70-80 Å in diameter incorporating a
hole of 10 Å in diameter. In the presence of Mg-ATP/ADP, groES interacts with the
a- and i-domain of the groEL protein inducing large scale movements enabling the
formation of the large inner chamber (Anfinson’s cage) [164, 166, 160, 169, 170, 89].
The model for groEL/ES assisted productive folding includes several steps (Fig.
1.12). First, binding of non-native proteins to the a-domain of the preexisting
groEL/ES triggers a conformational change releasing groES. In the presence of ATP
groES binds once again to groEL forming the Anfinsen’s cage. Cooperative hydrol-
ysis of ATP by the cis ring of groEL enhances its affinity to groES resulting in
a conformational change in the a-domain releasing the non-native protein into the
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Anfinson’s cage for spontaneous folding in a state, isolated from external medium.
ATP binding to the opposite trans ring triggers cooperative hydrolysis and allosteric
conformational changes in the cis ring, dissociating groES and releasing the native
protein from the Anfinson’s cage [171, 172, 173, 174, 175]. In case one cycle is not
enough for the final folding of the protein, it reoccurs once again.
(a) (b)
(c) (d)
Figure 1.11: Protein structures of groEL/ES. (a) The groEL/groES complex. (b) A single groEL toroid
with apical- (blue), equatorial- (red) and intermediate- (green) domain. (c) Top view into the groEL
cavity. (d) Top view of the 10 subunit-groES protein (pdb file 1oel visualised with pymol (DeLano
Scientific LLC - Palo Alto, USA).
Over time, it has been shown that groEL/ES also chaperones protein folding in
proteins too big for the inner cavity and the groES-lid, as shown for the mitochon-
drial aconitase [176], a 82 kDa protein and maltodextrin glucosidase [177] with 62
kDa. Studies on rhodanese and cyclophilin without the groEL ligands K+, Mg2+,
ADP, ATP and the co-chaperonin groES revealed protein folding attributes solely
contributed to groEL [178, 179, 162]. The findings of the groEL-CypA interaction
will be further discussed in Chapter 5. GroEL has been well investigated in the field














Figure 1.12: GroEL/ES folding mechanism. With U standing for the unfolded protein and N repre-
senting the native folded protein (adapted from [162]).
Conclusively , after almost 40 years of investigation a basic mechanism of the
groEL/ES chaperonin activity has been established. However, there is still discussion
about alternative mechanisms as reviewed by Marchenkov [162].
1.4.3 AGr2
Anterior gradient 2, also known as gob-4 [180] or hAG-2 [181] is a 175 aa, ˜20 kDa
protein found to play a key role in cancer development and survival [182].
It is the human orthologue of the Xenopus laevis AGr2 protein, XAG-2. In the
frog embryo it has a putative role in ectodermal patterning and is regulated by a
number of fundamental embryonic molecules like noggin and chordin [183]. XAG-2
is secreted and induces cement gland differentiation and expression of neural mark-
ers. The role of AGr2 in humans is uncertain. Liu et al. suggested that AGr2 in
humans is secreted as well [184]. Others proposed, based on basic local alignment
search tool (BLAST) analysis [185], that AGr2 represents a novel member of the
protein disulfide isomerase family, involved in protein maturation in the endoplas-
matic reticulum (ER) [186, 187].
Hupp and co-workers found, that the over expression of AGr2 attenuates the activa-
tion of p53 in UV-damaged cancer cells, suggesting AGr2 acting as a survival factor
through p53 inhibition [188]. Experiments conducted in rat mammary tumor cells
over expressing AGr2 demonstrated enhanced adhesion to substrate and increased
metastatic potential [184]. The profiling of expressed genes of circulating tumor
cells in peripheral blood from metastatic cancers such as colorectal and pancreatic
cancers illustrated the presence of AGr2 [182, 189]. Furthermore, it has been shown
to be expressed in breast [190, 181, 191], prostate [192], fibrolamellar carcinoma
[193] and lung cancers [194], although its role in these diseases remains unclear.
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Hupp et al. demonstrated a universal up-regulation of the AGr2 expression in Bar-
rett’s epithelium or Barrett’s oesophagus [195, 196], morphological intermediates
also referred to as metaplasia and dysplasia in the development of an oesophageal
adenocarcinoma [188]. Whang and co-workers found AGr2 acting as an oncogene
by promoting tumor growth, cell migration and cellular transformation in the same
type of human cancer [197].
So far there is little known about the structure of AGr2 as no crystal or NMR-
structures have been determined, yet.
1.4.4 The Complement System and Factor H
The complement system is part of the innate immune system responsible for recog-
nition and elimination of damaged and modified self structures, as well as foreign
invading microbes [198] and was first described by Ehrlich and Bordet in the 1890’s
[199].
The Complement System
Individual complement components act in a cascade type manner (Fig. 1.13a) and
are linked together to form an important immune surveillance system. The classical
pathway activation is triggered by immune antigen-antibody complexes, whereas the
lectin pathway is activated by carbohydrate complexes on microbial surfaces [200].
Per contra, the alternative pathway is constantly activated at a low level caused by
spontaneous conformational changes of the complement component 3 (C3). This
’tick over’ activation initiates a powerful amplification cycle, generating multiple
C3b, cleavage products of C3, by the C3 convertase C3bBb which further triggers
immune response, by releasing anaphylatoxins (e.g. C3a and C5a) and formation
of the membrane attack complex. The latter is responsible for cell lysis, whereas
anaphylatoxins lead to inflammation reactions (Fig. 1.13a), ultimately leading to
elimination and safe removal of a foreign or modified particle. The activation cascade
is controlled by proteins belonging to the regulators of complement activation (RCA)
family, i.a. factor H (fH), complement regulator 1 (CR1) and the membrane control
protein (MCP) [201, 202, 203].
Factor H
Factor H is a single peptide chain plasma glycoprotein of ˜155 kDa in mass. It
was first discovered by Nilsson and Müller-Eberhard in 1965 as β1H globulin and
is abundant in the blood plasma at concentrations of several hundred µg/mL [204].
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Inhibition of complement activation by fH occurs on the level of the C3 convertase
by preventing and inhibiting formation of the C3 convertase, enhancement of dis-
sociation of a performed convertase (decay-accelerating activity) and acting as a
co-factor for the C3b cleaving serine protease factor 1 [198, 205, 205].
It has been shown that sequence modifications and gene truncations can be as-
sociated with several, quite different diseases [202]. FH mutations and sequence
variations are directly linked to renal diseases such as haemolytic uraemic syn-
drome (HUS) [206, 207], dense deposit disease (DDD) [208] or membranoprolif-
erative glomerulonephratitis (MPGN) [209] or retinal diseases such as age related
macular degeneration (AMD) [210, 211].
FH is composed of of 20 complement control proteins modules (CCP) that re-
semble beads on a flexible string in the transmission electron microscope [212, 213].
The N-terminal four CCPs (module 1-4) encompass the region capable of co-factor
and decay accelerating activity as well as binding to C3b [214, 215, 216, 217]. A sec-
ond principal binding site lies within the C-terminal pair of CCP’s 19-20 [218, 219].
It has been shown that at least two sites on fH (i.e. CCP 7 and 20) interact with
heparin and other poly anions [220, 221, 222, 223, 224, 225, 226, 227]. Furthermore,






















Figure 1.13: Complement mechanism and protein structure of factor H CCP modules 19-20. (a)
Complement mechanism (adapted from [198]). (b) NMR protein structure of fH CCP module 19-20
(pdb file 2bzm visualised with pymol (DeLano Scientific LLC - Palo Alto, USA)).
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1.5 PLIMSTEX
A methodology employing solution phase HDX to quantify protein ligand interac-
tions with the sensitivity and specificity of MS was developed by Gross and co-
workers in 2003 and named PLIMSTEX (protein-ligand interactions in solution by
MS, titration and HD exchange) [1]. For affinity quantification the method requires
a change to occur in HDX during titration. The PLIMSTEX method is based on
reactivity similar to footprinting experiments [228], but it is also analogous to titra-
tion monitoring by spectroscopic methods. It relies on spectral position shifts (∆mi)
rather than spectral absorbances.
Figure 1.14 visualises the individual steps involved in a PLIMSTEX experiment.
The protein of question is first equilibrated with different concentrations of the lig-
and in a non-deuterating environment, before HDX is initiated with a deuterated
buffer. After reaching near steady state conditions HDX is quenched by lowering
the temperature to 0 ◦C and the pH to 2.5. The solution is loaded on a guard
column for desalting and back exchange of the T1 deuterons of the side chains of
the immobilised protein. Elution with an organic gradient into the MS for analysis
reveals the deuterium uptake due to HDX of T2 hydrogens, reflecting the protein’s
state prior quenching.





































Figure 1.14: The PLIMSTEX protocol. (a) Methodology of a PLIMSTEX experiment. (b) The
resulting PLIMSTEX curve (images modified from [229]).
The quenching and desalting process causes the ligands to dissociate and be
washed of the column, liberating the protein for which the number of solvent acces-
sible amide deuteriums can be determined by MS. A plot of the mass difference of
the deuterated and the non-deuterated enzyme vs. the total ligand concentration
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results in the PLIMSTEX curve (Fig. 1.14b). ∆mfree describes the deuterium level
of the apo protein, ∆mcomplex of the holo protein and ∆ms is the difference between
∆mfree and ∆mcomplex describing the change in ∆mi upon ligand binding from a 1:1
to a 1:n protein-ligand ratio. This change describes the degree of protection due to
ligand binding and thereby induced changes in protein conformation. PLIMSTEX
curves are sensitive to the total protein concentration and do not yield reliable K
values when the protein is titrated at concentrations higher than ˜100 times the Kd.
Nevertheless, when the concentration is too high, ’sharp-break’ curves (Fig. 1.15a
are obtained and can be used for stoichometric evaluation of the protein-ligand
complex [229]. For a 1:1 protein-ligand system Equation 54 (page 188) is applica-
ble (derivation in Appendix 9.8). However, for 1:n protein-ligand systems a more














































Figure 1.15: Sharp-break PLIMSTEX and SIMSTEX curves. (a) Sharp-break PLIMSTEX curve for
a model protein-ligand system (image modified from [229]). (b) SIMSTEX curves for an aggregating
model protein (adapted from [232]).
1.5.1 SIMSTEX
In 2006 Gross et al. adapted PLIMSTEX to determine solution phase self-association
equilibrium constants of insulin analogues [232]. SIMSTEX stands for self-association
interactions using MS, self-titration and HD exchange. It first requires the deter-
mination of the deuterium uptake of the monomeric protein species at steady state
equilibrium as a function of the total protein concentration (Fig. 1.15b). The pro-
cess for calculating the affinity constants from the SIMSTEX curves starts with the
PLIMSTEX modeling procedure [230]. However, the equations for the oligomer so-
lution concentrations were modified to accommodate self-association as described
in [233] yielding affinity constants for different stages of oligomerisation. A detailed
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derivation of the SIMSTEX equations along with the results for insulin analogues
can be found in [232].
1.6 SUPREX
Another method utilising HDX-MS to probe protein-ligand behavior is SUPREX.
The ’stability of unpurified proteins from rates of H/D exhange’ technique was
first reported by Fitzgerald and coworkers [2] in 2000 and since then has become
well applied. The approach is based on measuring the stability (i.e. the standard
free energy of protein folding (∆Gf) of a protein or a protein-ligand system by
denaturation with a chemical denaturant utilising the reactions of globally protected
amide protons during HDX. Generally ∆Gf reflects the stability of a protein in its
’native’ conformation and therefore differs in miss-folded proteins or protein-ligand
complexes. In the first instance, a miss-folded protein is generally less stable than
it’s ’native’ conformation [234] whereas ligand-binding has a stabilising effect [235].
Once ∆Gf values have been determined, Kd and m-values can be calculated for the
protein-ligand complex [236, 237]. SUPREX is an alternative way to circumvent
time consuming spectroscopic based methods like fluorescence or circular dichroism
(CD) [238] with the advantage of using 1-2 orders of magnitude less sample [239].
The fact that no highly purified protein samples were needed and that the process
was automated with MALDI or LC-ESI-MS analysis make it a versatile method
to investigate biological systems and properties (e.g. in vivo protein studies [240],
multimeric proteins [241], protein-DNA complexes [242] and multi-domain proteins
[243]) in a high-throughput fashion [244, 245].
1.6.1 The SUPREX Protocol
The SUPREX technique relies on measuring the mass increase (∆m), due to the
HDX reaction of globally protected amide protons of an enzyme or an enzyme-
substrate system due to denaturation and deuteration of the protein in various
concentrations of a chemical denaturant (e.g. urea or guanidinium hydrochloride).
Therefore the protein in question is incubated for different time periods at different
concentrations of the chemical denaturant in the deuterated buffer. The denaturant
destabilises the protein’s structure, which has the effect of increasing the rate of
global HDX and increasing the rate of deuterium incorporation into the protein.
After quenching with 2 M HCl, the solution is loaded on a guard column, washed
with non-deuterated buffer to back exchange T1 deuterons followed by elution with
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an organic gradient into the MS (process described for developed LC-ESI-MS, Fig.
1.16c). Ultimately, ∆m is detected via MS analysis and plotting the different ∆m
values at different concentrations of the denaturant yields the SUPREX curve (Fig.












Where ∆M0 represents ∆m before global exchange, a is the amplitude of the curve
in Da, [Denaturant] is the molar concentration of the chemical denaturant and b is
a parameter that describes the steepness of the transition [237]. At this point it
should be noted that the C
1/2
SUPREX values are not midpoints of denaturing curves
in the classical way where C
1/2
den depends on the protein stability and the m-value
of the protein [2, 241]. In SUPREX the midpoint is not only a function of this
parameters but also depends on the time of exchange t and the average intrinsic
exchange rate of an amide proton 〈kint〉 in Equation 18. The values for 〈kint〉 can
either be estimated by averaging the values for all the backbone amide hydrogens
as shown by Englander, Bai and coworkers [107, 246], or the simple relationship
〈kint〉 = 10

















SUPREX values have been determined according to Equation 61 (Appendix
9.14) plotting −RTln(〈kint〉t/0.693 − 1) vs. C
1/2
SUPREX followed by linear square fit
analysis yields ∆Gf at a 0 M concentration of the denaturant as the intercept with
the ordinate and the m value as the slope of (Fig. 1.16b). In 1975 Schellman re-
ported a way to calculate dissociation constants of protein-ligand complexes from



































































Figure 1.16: SUPREX methodology and curves for a model protein. (a) Theoretical SUPREX curve
for an apo model protein (black), holo protein (magenta) at a single incubation time and resulting in a
stabilisation of the complex. (b) Evaluation of SUPREX, free energy of protein folding vs. C
1/2
SUPREX
(images a and b modified from [2]). (c) SUPREX methodology modified for LC-ESI-MS usage.
1.6.2 Precision and Accuracy
The precision of SUPREX under well defined two-state unfolding and EX2 exchange
conditions is mainly dependent on the precision of the C
1/2
SUPREX-value. SUPREX
experiments with various proteins (i.a. β-trypsin) showed an average standard de-
viation of ˜10 %. The accuracy under the same conditions with the same set of
proteins was within 46 % of ∆Gf values previously reported by NMR, CD, fluores-
cence and calorimetry [247].
SUPREX was developed to gain information about the standard free energy of
protein folding. Therefore EX2 exchange conditions (Section 1.3) and two-state
unfolding are necessary to guarantee the accuracy of the SUPREX approach. To in-
vestigate SUPREX accuracy under non-EX2/unknown conditions, unfolding studies
with ubiquitin [248, 249] have been performed. Thereby good agreement for ∆Gf
values were obtained as long as experiments were performed at lower pH conditions
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(to favor EX2 conditions) and H/D exchange times to yield C
1/2
SUPREX at lower de-
naturant concentrations (i.e., less than 2 M). Non-linearity of acquired SUPREX
data and large deviations in the correlation coefficient in the non-linear least-squares
analysis might indicate non-two-state, non-EX2 or EXX exchange behavior (Section
1.3).
1.6.3 Single Point SUPREX and SPROX
To increase throughput of SUPREX enabling more efficient screening, a single point
SUPREX approach has been devised [244]. For quantitative analysis of protein-
ligand behaviour a SUPREX curve has to be recorded (Fig. 1.16). However, this
process would be more time and sample consuming than a single point SUPREX
experiment. Therefore a SUPREX experiment at a wisely chosen single denatu-
rant concentration and time would be sufficient. It would of course be necessary
to perform a full SUPREX experiment to investigate the protein in question’s ther-
modynamic properties. Fitzgerald and coworkers presented in 2004 and 2008 the
feasibility of the MALDI single point SUPREX approach on protein-S and CypA
[244, 245].
Based on SUPREX a methodology of chemical modification combined with MALDI-
/LC-MS was presented by Fitzgerald and coworkers in 2008, termed stability of
proteins from rates of oxidation (SPROX). It is, like SUPREX, based on measuring
the thermodynamic properties of an enzyme-substrate system, however, utilising
oxidation rates of globally protected sites in a protein instead of HDX. One advan-
tage of SPROX is the irreversibility of the oxidation compared to HDX. However,
it is limited to the number of globally protected methionine residues providing only
a relatively low resolution probe for studying conformational changes in proteins.
Despite this, various protein-ligand systems have been investigated, i.a. CypA,
ubiquitin, ribonuclease A and bovine carbonic anhydrase II [250] (Table 3.1, Section
3).
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2 Experimental and Method Development
2.1 Bacterial Work
To increase the amount of DNA for protein expression mini- and maxi-preparations
were performed. Therefore the E. coli strains OrigamiTM B (DE3) pLysS (Novagen
- Darmstadt, Germany), XL1-Blue Quick Change (Stratagene - La Jolla, USA) and
Top 10 (Invitrogen - Paisley, UK) were used. For protein expression chemical com-
petent E. coli hosts BL 21TM and BL 21 StarTM (Novagen - Darmstadt, Germany)
were used.
2.1.1 Preparation of Electrocompetent Cells
E. coli is unlike other bacteria, such as Bacillus subtilis, not able to incorporate
foreign DNA. Therefore it is important to make E. coli competent to transform a
reasonable amount of foreign DNA. Hence, a 15 mL centrifuge tube containing 6 mL
of LB-medium (Section 2.1.6) was inoculated with a single colony of E. coli from
a 1.5 % agar plate and incubated at 225 rpm at 37 ◦C (Stuart Orbital Incubator
SI50 - Bibby Scientific - Staffordshire, UK) overnight. Then a 2 L Erlenmeyer flask
with 500 mL pre-warmed LB-medium was inoculated with 25 mL of the overnight
culture and further incubated until an OD600 value of 0.4. The cell growth was
stopped by transferring the flask in an ice-bath for 15-30 min. The cultures were
then transferred to pre-cooled centrifuge bottles and centrifuged for 15 min at 4 ◦C
at 2500 rpm (1000 xg - Sorvall RC26 plus - Waltham, USA). The supernatant was
discarded and the cell-pellet was washed once with 250 mL ice-cold H2Odd water
and once with 10 % glycerol to remove the buffer salts. After centrifugation the
cell pellet was dissolved in ice-cold 2x YT-medium (Section 2.1.6) and diluted to an
OD600 of 1.0 (ca. 2.5 x 108 cells). To make sure that during the electroporation no
arcing occurs, 40 µL of the cell solution was transferred to an ice-cold electroporation
cuvette and an electrical pulse was applied (5 ms, 12.5 kV/cm). After ensuring that
the conductivity is sufficiently low, the cell solution was dispensed in 40 µL aliquots
in a micro centrifuge tube, shock frozen in liquid nitrogen and stored at -80 ◦C.
2.1.2 Chemical Transformation of Recombinant DNA
To transform plasmid DNA into chemically competent E. coli a slightly modified
protocol of Hanahan [251] was used. A single micro centrifuge tube with chemically
competent cells was thawed on ice followed by the addition of 5-10 ng of DNA. After
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30 min incubation on ice a heat shock was applied by putting the cells for 45 s in a 42
◦C water bath (SUB14 - Grant - Shepreth, UK) followed by another 5 min incubation
on ice. Then 1 mL of pre-warmed SOC medium (Sigma-Aldrich - Derset, UK) was
added and the suspension was incubated for 1 h at 37 ◦C and gentle rotations
(Stuart Orbital Incubator SI50 - Bibby Scientific - Staffordshire, UK). Then 50,
100 and 150 µL were streaked out on an pre-warmed LB-agar ampicilin plate (100µg/mL; Section 2.1.6) and incubated overnight at 37 ◦C.
2.1.3 Transformation of Recombinant DNA via Electroporation
To transform recombinant DNA into electro competent bacteria cells the following
procedure was applied. A micro centrifuge tube containing 40 µL of electro compe-
tent cells was thawed on ice. After transferring the cells into an ice-cold electropo-
ration cuvette 25 ng of DNA in a volume of 1-5 µL were added and incubated for 60
s. Then an electrical pulse of 25 µF capacitance, 2.5 kV and 200 Ω resistance was
applied (Gene Pulser II, Pulse Controller plus and Capacitance Extender plus - Bio
Rad - Hercules, USA) to the cuvette followed by the addition of 1 mL of pre-warmed
SOC-medium (Sigma-Aldrich - Derset, UK). The cells were then transferred into a
1.5 mL micro centrifuge tube and incubated with gentle rotation for 1 h at 225 rpm
and 37 ◦C (Stuart Orbital Incubator SI50 - Bibby Scientific - Staffordshire, UK),
streaked out on a pre-warmed LB-agar ampicilin plate (100 µg/mL) and incubated
overnight at 37 ◦C.
2.1.4 Isolation of Plasmid DNA (Minipreparation)
For the isolation of small amounts of DNA up to 20 µg the QIAgen spin plasmid
DNA-kit was used (QIAgen - Crawley, UK). Therefore the DNA of question was
transformed into E. coli as described above (Section 2.1.3, 2.1.2). A 15 mL centrifuge
tube containing 5 mL of 2x YT/LB media was inoculated with a single colony from
the overnight culture and incubated overnight at 37 ◦C and 225 rpm (Stuart Orbital
Incubator SI50 - Bibby Scientific - Staffordshire, UK). The cells of the overnight
culture were spun for 15 min at room temperature (RT) at ˜4300 rpm (˜4000 xg -
Sorvall RC26 plus - Waltham, USA) and the supernatant was discarded. The cell
pellet was re-suspended in 250 µL buffer P1 and then transferred in a 1.5 mL micro
centrifuge tube. Then 250 µL of cell lysis buffer P2 were added and incubated for 5
min at room temperature (RT). After the incubation 350 µL of ice cold N3 buffer
were added to neutralise the basic cell lysis and inverted 5 times before incubating for
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5 min on ice. Another centrifugation step for 10 min at RT at 14000 rpm (˜10000
xg - Eppendorf 5515C - Hamburg, Germany) the supernatant was applied to a
QIAprep-spin column (QIAgen - Crawley, UK) sitting in a 2 mL micro centrifuge
tube and spun for 1 min at RT at 14000 rpm (˜10000 xg - Eppendorf 5515C -
Hamburg, Germany). The flow through was discarded and the column was washed
once with 750 µL of PE buffer. After spinning for another minute the flow through
was discarded again and an additional spinning step was applied to get rid of excess
buffer. The plasmid-DNA was eluted by adding 50 µL Tris/HCl buffer (2.5 mM, pH
7.5) on to the column and incubation for 2 minutes, followed by placing the column
in a micro centrifuge tube and centrifugation for 1 min at RT at 14000 rpm (˜10000
xg - Eppendorf 5515C - Hamburg, Germany). DNA was stored at -20 ◦C.
2.1.5 Isolation of Plasmid DNA (Maxipreparation)
For isolation of larger amounts of DNA up to 1500 µg the Jet Star DNA purifica-
tion kit was used (Genomed - Löhne, Germany). Therefore the DNA of interest
was transformed into appropriate E. coli (Section 2.1.3, 2.1.2) and colonies of in-
terest were picked from a LB-carbenicillin/ampicilin (Sigma-Aldrich - Derset, UK)
plate (100 µg/mL) and transferred into a 5 mL carbenicillin/ampicilin (100 µg/mL)
containing 2x YT pre-culture. After 4-5 h of incubation at 37 ◦C and 225 rpm
(Stuart Orbital Incubator SI50 - Bibby Scientific - Staffordshire, UK) a 200 mL
LB-carbenicillin/ampicilin (100 µg/mL) containing 1 L Erlenmeyer flask was inocu-
lated with 50-200 µL of the pre-culture depending on the cell growth and incubated
overnight at 37 ◦C and 225 rpm (Stuart Orbital Incubator SI50 - Bibby Scientific -
Staffordshire, UK). At first a maxi-column was equilibrated with 30 mL of E4 Buffer.
The overnight culture was transferred in a 250 mL centrifuge bottle and spun for 15
min at 37 ◦C and 6000 rpm (˜4000 xg - Sorvall RC26 plus - Waltham, USA) and the
supernatant discarded. The E. coli cell pellet was re-dissolved in 10 mL E1 buffer
and transferred to a 50 mL centrifuge tube. Then cell lysis was induced by adding 10
mL of E2 buffer and gently inverted. After 5 min of incubation lysis was stopped by
adding E3 neutralisation buffer and gently inverting before incubating for another
5 min. The cell debris was spun down for 30 min at 37 ◦C and 10000 rpm (˜10000
xg - Sorvall RC26 plus - Waltham, USA) and the supernatant was filtered through
a paper filter (Whatman - GE Healthcare - Chalfont St Giles, UK) and applied to
the equilibrated maxi-column. The column was emptied by gravity flow and washed
once with 60 mL of E5 buffer. The plasmid DNA was eluted from the column into
a 30 mL centrifuge tube by applying 15 mL E6 elution buffer and precipitated by
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the addition of 10.5 mL of 2-propanol (Fisher Scientific - Loughborough, UK) and
incubation for 2 h at -20 ◦C. After centrifugation for 30 min at 4 ◦C and 10000 rpm
(˜10000 xg - Sorvall RC26 plus - Waltham, USA) the DNA pellet was washed with
1 mL 70 % ethanol (Fisher Scientific - Loughborough, UK). After centrifugation for
10 min at 4 ◦C and 10000 rpm (˜10000 xg - Sorvall RC26 plus - Waltham, USA)
the supernatant was discarded and the DNA pellet was air-dried for 15 min before
dissolving in 1 mL 2.5 mM Tris/HCl pH 7.0 and storage at -20 ◦C.
2.1.6 Buffers and Media
LB-Medium
For LB-medium 10 g trypton (Oxoid - Basingstoke, UK), 10 g sodium chloride
(Fisher Scientific - Loughborough, UK) and 5 g yeast extract (Bacto - Liverpool,
Australia) were dissolved in 1 L H2Odd. The pH was adjusted to 7.3 by using 1
M and 10 M sodium hydroxide (Sigma-Aldrich - Derset, UK). The medium was
autoclaved (Boxer 200/150L - Hertfordshire, UK) and stored at 4 ◦C.
2x YT-Medium
16 g trypton (Oxoid - Basingstoke, UK), 10 g sodium chloride (Fisher Scientific
- Loughborough, UK) and 5 g yeast extract (Bacto - Liverpool, Australia) were
dissolved in 1 L H2Odd. The pH was adjusted to 7.0 by using 1 M and 10 M
sodium hydroxide (Sigma-Aldrich - Derset, UK). The medium was autoclaved (Boxer
200/150L - Hertfordshire, UK) and stored at 4 ◦C.
Ampicilin/Carbenicillin Containing LB-Agar-Plates
In the first instance 1 L of LB-medium was prepared (Section 2.1.6) and 1.5 % (w/v)
of agar was added followed by autoclaving (Boxer 200/150L - Hertfordshire, UK)
the medium. The still hot medium was allowed to cool down to ˜40
◦C at RT, then
1 mL of an ampicilin/carbenicilin (Sigma-Aldrich - Derset, UK) stock solution (100µL/µL) was added to 1 L medium to achieve a final concentration of 100 µg/mL.
After mixing the solution was poured in sterile petri dishes. The cold plates were
stored at 4 ◦C in the dark.
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2.2 Protein Expression and Purification
Various proteins were expressed and appropriate purification procedures applied.
2.2.1 Cyclophilin A Expression and Purification
For the expression of CypA in E. coli the psw3-003 vector containing the CypA gene
[252] (kindly donated by Prof. M Walkinshaw) was chemically transformed (Section
2.1.2) in BL 21 StarTM (Novagen - Darmstadt, Germany) cells. Then a starter
culture was incubated overnight in 15 mL 2x YT containing 100 µg/mL ampicilin
(Sigma-Aldrich - Derset, UK) at 37 ◦C and 225 rpm (Stuart Orbital Incubator
SI50 - Bibby Scientific - Staffordshire, UK). Four 2 L Erlenmeyer flasks containing
1 L 2x TY (100 µg/mL ampicilin) each were inoculated with 2 mL of the starter
culture and incubated at 225 rpm (Stuart Orbital Incubator SI50 - Bibby Scientific
- Staffordshire, UK) and 37 ◦C (Model G 25 - New Brunswick Scientific - Edison,
USA). The OD600 was checked every hour until ˜0.6 was reached. Then 1 mL of a 1 M
isopropyl β-D-1-thiogalactopyranoside (IPTG) (VWR - West Chester, USA) stock
solution was added and incubated for another 3 h. After stopping the cell growth on
ice, the suspension was transferred to four 1 L centrifuge bottles and centrifuged for
15 min at 4 ◦C at ˜3000 xg (Sorvall RC26 plus - Waltham, USA). After decanting
the supernatant the cells were washed once with 100 µL ice cold lysis buffer and
centrifuged at 4 ◦C at ˜3000 xg (Sorvall RC26 plus - Waltham, USA). The cell
pellet was then re-suspended in 10 % (w/v) ice cold lysis buffer containing an excess
of protease inhibitor cocktail (Sigma-Aldrich - Derset, UK) and sonicated on ice for 6
x 30 s bursts (Soniprep 150 - MSE - London, UK), with 30 s cooling in between. The
cell lysate was subjected to centrifugation for 2 h at 4 ◦C at ˜20000 xg (Sorvall RC26
plus - Waltham, USA) and the supernatant was exhaustively dialysed overnight
against 50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma-
Aldrich - Derset, UK), 1 mM dithiothreitol (DTT, Acros Organics - Geel, Belgium),
2.5 mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich - Derset, UK), 1
mM NaN3 (Sigma-Aldrich - Derset, UK), 100 µM phenylmethylsulphonyl fluoride
(PMSF,MP Biomedicals - Cambridge, UK), 100 µM Benzamidine (Sigma-Aldrich
- Derset, UK); pH 6.8. Then the solution was filtered through a 0.2 µm filter
(Satorius - Göttingen, Germany) and applied to an SP-sepharose column (XK 26 -
GE Healthcare - Chalfont St Giles, UK) pre-equilibrated in 50 mM HEPES (Sigma-
Aldrich - Derset, UK), 1 mM DTT (Acros Organics - Geel, Belgium), 2.5 mM
EDTA (Sigma-Aldrich - Derset, UK), 1 mM NaN3 (Sigma-Aldrich - Derset, UK);
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pH 6.8. Proteins were eluted with a 0-400 mM NaCl gradient (Fig. 2.1a, b) using
the same buffer over 200 mL and then analysed via SDS-PAGE (Section 2.2.3, Fig.
2.1c). Fractions containing CypA, eluting between 160 mM and 250 mM NaCl, were
pooled and concentrated to ˜1 mL. After filtering through a 0.2 µm filter (Satorius
- Göttingen, Germany) the solution was loaded onto a XK 16/Sephacryl-200 HR
gel filtration column (GE Healthcare - Chalfont St Giles, UK), pre-equilibrated in
25 mM Tris (Sigma-Aldrich - Derset, UK) and 1 mM NaN3. CypA was eluted ˜90
% pure as judged by SDS-PAGE (Fig. 2.2). The protein was concentrated to a
concentration of ˜500 µM and stored on ice at 4 ◦C for 6 to 8 weeks at most.
























































Figure 2.1: Cation exchange chromatography for cyclophilin A. (a) Overview of cation exchange
chromatogram with UV trace (black) and percentage of elution buffer (blue). (b) Enlargement of peak
II with fractions collected. (c) 12.5 % SDS-PAGE gel of collected fractions. Chromatograms visualised
with Origin - Microcal, USA; gel images enhanced with Fireworks - Adobe, USA.
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Figure 2.2: Gel filtration chromatography for cyclophilin A. (a) Overview of gel filtration elution profile.
(b) Enlargement of peak III with fractions collected. (c) 10 % SDS-PAGE gel of collected fractions.
Chromatograms visualised with Origin - Microcal, USA; gel images enhanced with Fireworks - Adobe,
USA.
Further CypA expressions were carried out by Dr. John White in the fermen-
tation suite in the Edinburgh Protein Interaction Centre (EPIC). Therefore freshly
transformed psw3-003 [252] in BL 21 StarTM (Novagen - Darmstadt, Germany) was
grown up in a 10 L fermenter (BioFlo4500s - New Brunswick - Edison USA) to the
appropriate OD600, protein over expression was induced and cells were harvested as
described above. The cell pellet was stored at -20 ◦C until further purification.
2 EXPERIMENTAL AND METHOD DEVELOPMENT 44
2.2.2 GroEL Expression and Purification
GroEL was expressed from a pET11a (Novagen - Darmstadt, Germany) expression
vector containing the groEL coding frame according to a modified protocol from
[160]. Initially the expression vector (kindly donated by Dr. D Campopiano, orig-
inated from [160]) was multiplied by maxi preparation (Section 2.1.5). A starter
culture was incubated overnight in 15 mL LB-medium containing 100 µg/mL ampi-
cilin (Sigma-Aldrich - Derset, UK) at 37 ◦C and 225 rpm (Stuart Orbital Incubator
SI50 - Bibby Scientific - Staffordshire, UK). Then four 2 L Erlenmeyer flasks con-
taining 1 L LB-medium (100 µg/mL ampicilin) each, were inoculated with 2 mL of
the starter culture and incubated at 225 rpm (Stuart Orbital Incubator SI50 - Bibby
Scientific - Staffordshire, UK) and 37 ◦C (Model G 25 - New Brunswick Scientific -
Edison, USA). The OD600 was checked until ˜1.0 was reached, followed by induction
with 1 M IPTG for 3 h and harvesting of the cells (Section 2.2.1). The cell pellet
was then re-suspended in 10 % (w/v) ice cold buffer A (50 mM Tris-HCl, 10 mM
MgCl2, 1 mM DTT, 0.5 mM KCl, 1 mM EDTA, 0.05 % NaN3 and 50 µg/mL PMSF,
[pH 7.5]). Cell lysis was performed at 21 kPa and 4 ◦C utilising a cell disruptor (TS
Series - Constant Systems - Daventry, UK). After centrifugation for 70 min at 4 ◦C
and ˜50000 xg (Sorvall RC26 plus - Waltham, USA) the supernatant was filtered
(0.2 µm; Satorius - Göttingen, Germany) and loaded onto a HiPrepTM DEAE FF
column (GE Healthcare - Chalfont St Giles, UK), pre-equilibrated in buffer A. Pro-
teins were eluted with a 0-500 mM NaCl gradient using buffer A over 200 mL and
then analysed via SDS-PAGE (Fig. 2.3). Fractions containing groEL were pooled
and concentrated to ˜1 mL and applied onto a HiPrep
TM 16/60 S300 HR gel fil-
tration column (GE Healthcare - Chalfont St Giles, UK) using 50 mM Tris-HCl,
0.05 % NaN3, [pH 7.5]. Fractions containing groEL eluted close to the void volume
of the column (Fig. 2.4), were collected and applied on a MonoQ 5/50 GL anion
exchange column (GE Healthcare - Chalfont St Giles, UK). After elution over 200
mL with a 0-500 mM NaCl gradient using buffer A, fractions containing groEL were
analysed via SDS-PAGE (Fig. 2.5) and concentrated to ˜200 µL. Protein samples
for imminent use were kept at 4 ◦C. For long term storage groEL was frozen in N2,(l)
in buffer A and kept at -80 ◦C.
2 EXPERIMENTAL AND METHOD DEVELOPMENT 45














































Figure 2.3: Weak anion exchange chromatography for groEL. (a) Overview of weak anion exchange
chromatogram with UV trace (black) and percentage of elution buffer (blue). (b) Enlargement of peak
II with fractions collected. (c) 7.5 % SDS-PAGE gel of collected fractions. Chromatograms visualised
with Origin - Microcal, USA; gel images enhanced with Fireworks - Adobe, USA.
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Figure 2.4: Gel filtration chromatography for groEL. (a) Overview of gel filtration elution profile.
(b) Enlargement of peak I with fractions collected. (c) 7.5 % SDS-PAGE gel of collected fractions.
Chromatograms visualised with Origin - Microcal, USA; gel images enhanced with Fireworks - Adobe,
USA.
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Figure 2.5: Strong anion exchange chromatography for groEL. (a) Overview of strong anion exchange
chromatogram with UV trace (black) and percentage of elution buffer (blue). (b) Enlargement of peaks
II, III and IV with fractions collected. (c) 7.5 % SDS-PAGE gel of collected fractions. Chromatograms
visualised with Origin - Microcal, USA; gel images enhanced with Fireworks - Adobe, USA.
2.2.3 SDS-PAGE
To estimate molecular weights and purity of proteins sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) was performed. Therefore self cast (Ta-
ble 2.1) or precast SDS-PAGE gels (Bio Rad - Hercules, USA) were used.
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Table 2.1: Self cast SDS-PAGE gels with different percentages of acrylamide for
different protein sizes.
Chemical 7.5 % 10 % 12.5 % 15.0 % 18.0 %
(V/mL)
1.5 M Tris-HCl buffer, pH 8.8a 5.00 5.00 5.00 5.00 5.00
30 % Acrylamidea 5.00 6.70 8.30 10.00 12.00
H2Odd
b 10.00 8.30 6.70 5.00 3.00
APS (25 % w/v)c 0.06 0.06 0.06 0.06 0.06
TEMEDa 0.03 0.03 0.03 0.03 0.03
a Bio Rad - Hercules, USA.
b Satorius - Göttingen, Germany.
c Sigma-Aldrich - Derset, UK.
For all SDS-PAGE running gels at different acrylamide concentrations 5 % stack-
ing gels were used (2.5 mL 1.5 M Tris-HCl buffer, pH 8.8; 1.25 mL 30 % acry-
lamide; 5.83 mL H2O; 60 µL ammonium persulfate (APS, 25 % w/v); 60 µL tetram-
ethylethylenediamine (TEMED). SDS-PAGE gels were mounted in the electrophore-
sis cell (Mini-protean tetra cell - Bio Rad - Hercules, USA), filled with Tris-glycine
electrophoresis buffer (prepared from 10 x Tris/Glycine/SDS buffer (Bio Rad - Her-
cules, USA)). Then 12 µL protein sample were mixed with 12 µL 2x SDS sample
buffer (Bio Rad - Hercules, USA) and heated for 3 min at 95 ◦C (Dry Block Heater
HBS-130 - Anachem - Bedfordshire, UK)). After cooling down the samples were
loaded on the appropriate SDS-PAGE gel together with a molecular weight ladder
(Precision Plus Protein StandartTM - Bio Rad - Hercules, USA). The power supply
(Power Pac basic - Bio Rad - Hercules, USA) was connected and a voltage of 10
V/cm was applied. The gel was run until the blue marker front reached the bottom
of the gel (˜50 min). After staining the gel for 1 h in coomassie brilliant blue (Sigma-
Aldrich - Derset, UK) with gentle rotation (The belly dancer - Sorvall - Waltham,
USA) the gel was destained by soaking in 10 % acetic acid, 10 % methanol and 80 %
water for 1 h with gentle rotation (The belly dancer - Sorvall - Waltham, USA).
2.2.4 Bradford Assay
To determine protein concentrations after purification a Bradford assay was con-
ducted [253]. Therefore 2 mL of Bradford dye reagent concentrate (Bio Rad - Her-
cules, USA) were diluted in 8 mL H2Odd in a 15 mL centrifuge tube and incubated
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for 10 minutes. The solution was aliquoted in 1.5 mL micro centrifuge tubes at 1 mL
each. Then the standard samples for the calibration curve were prepared at different
concentrations by adding different amounts of bovine serum albumin (BSA; Sigma-
Aldrich - Derset, UK) to the aliquoted Bradford reagent and further incubation for
10 min. For the micro Bradford assay the amount of BSA was between 0 and 10µg. 1 µL of the unknown protein sample was diluted in 9 µL H2Odd and 1 to 10 µL
were added to the aliquoted Bradford reagent each. The absorbance was read at 595
nm using a UV/VIS Biophotometer (Biophotometer 600 - Eppendorf - Hamburg,
Germany). Plotting the readouts on the calibration curve (Appendix 9.1 for CypA)
and considering the dilution factor, the protein concentration was calculated.
2.3 Reagents and General Sample Preparation
All buffer solutions were prepared using high purity water from a Satorius - Arrium
611 UV water purification unit (Satorius - Göttingen, Germany) delivering double
distilled grade, 0.2 µm sterile filtered (H2Odd). The buffer salts were weighed out
using either a Mettler - Toledo PB 1501, Mettler - Toledo AB 204 or a Mettler
AC 100 (Mettler-Toledo - Leicester, UK) to an accuracy of ± 0.1 g and ± 0.0001
g respectively. The pH adjustments were performed using a Jenway 3305 (Bibby
Scientific - Staffordshire, UK) with a range of concentrations between 0.1-10 M of
NaOH and HCl. Solvents for HPLC analysis met analytical HPLC grade and were
0.2 µm sterile filtered prior usage.
2.3.1 Protein Sample Preparation
Protein standards such as myoglobin and insulin were purchased from Sigma-Aldrich
(Derset, UK). However, AGr2 and fH19-20 protein samples were kindly donated by
Dr. H. Florance, Ms. J. Nicholson and Dr. A. Herbert, respectively. Unless stated
otherwise proteins of interest were dissolved/diluted in 10 mM NH4OAc (Fisher
Scientific - Loughborough, UK) at different concentrations prior analysis.
2.3.2 Ligand Preparation
Ligands for direct infusion, HDX-labeling, PLIMSTEX and SUPREX experiments
were sourced and diluted/dissolved according to Table 2.2.
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Table 2.2: Preparation and origin of ligands.
Ligand System Solvent Source
CsA a CypA 36.88 % MeOH in H2O Prof. M. Walkinshaw
KM184 b CypA 36.88 % MeOH in H2O Prof. M. Walkinshaw
ES1234 b CypA 36.88 % MeOH in H2O Prof. M. Walkinshaw
FK506b FKBP12 MeOH Ms. E. Blackburn
Rapamycinb FKBP12 MeOH Ms. E. Blackburn
PTTIYY-Pen b AGr2 H2O Ms. J. Nicholson
PATIAA-Penb AGr2 H2O Ms. J. Nicholson
Fondaparinuxb fH19-20 H2O Dr. A. Herbert
a fresh prepared with every batch of fresh CypA (6-8 weeks).
b imminent use after preparation (1-2 weeks).
2.3.3 MS-Sample Introduction
Generating protein ions in the gas phase for direct infusion, HDX labeling, PLIMS-
TEX and SUPREX experiments was achieved using electrospray (Section 2.3.3) and
nano-electrospray ionisation (Section 2.3.3).
Electrospray
ESI (Section 1.1.1) was performed using a set of gas tight syringes (Gasthigt 1725-
1750 - Hamilton - Bonaduz, Switzerland) containing 250 µL-500 µL of sample,
mounted on a syringe pump (Harvard apparatus - Kent, UK) connected to the
ESI-probe. Flow rates varied between 10 µL/min-40 µL/min.
Nano-Electrospray
Nano-ESI (Section 1.1.1) was carried out with in house pulled glass tips of different
taper shapes and diameters using borosilicate capillaries (0.12 x 10.16 cm; World
Precision Instruments Inc. - Savasota, USA; P97 - Sutter Instrument co. - Novato,
USA). 20 µL of sample were loaded into the capillary, platinum wire (99.99 % purity;
Sigma-Aldrich - Derset, UK) inserted and mounted onto the nESI probe.
2.3.4 Direct Infusion
For direct infusion (DI) ESI(Section 2.3.3) or nano-ESI (Section 2.3.3) experiments
under native like conditions the purified protein sample of interest was diluted into
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10 mM NH4OAc (Fisher Scientific - Loughborough, UK), pH 6.88. Under dena-
turing conditions 5 % of formic acid (FA, Fisher Scientific - Loughborough, UK)
was added to the sample. For direct infusion analysis of AGr2 and fH19-20 buffer
exchange/dialysis (Section 2.4.1) was performed prior to the experiment. For high-
throughput DI the automated SUPREX HPLC setup (Section 2.7.3) was used with
a sample pick up of 65 µL, loading onto a 50 µL sample loop and transferred to the
MS.
2.3.5 HDX Labeling Experiments
HDX experiments were conducted with deuterated 10 mM d -NH4OAc. Therefore
NH4OAc (Fisher Scientific - Loughborough, UK) was dissolved in D2O (Sigma-
Aldrich - Derset, UK). The pH corrections for d -buffers of 0.4 according to [254]
were applied, where appropriate.
For HDX labeling experiments the apo protein of interest was diluted into d -NH4OAc
and incubated for a particular time period. In the presence of ligand the same
procedure was applied after incubation with the ligand for 20 min. Mass increase
vs. time was analysed via various HPLC-MS setups (Section 2.6.2, 2.6.3, 2.7.3). For
the latter, an automated sample pick up of 65 µL, loading onto guard column/sample
loop (DI) and washing for 8 min at 0 ◦C was carried out (Section 2.6.4). The detailed
LC method program is described in Appendix 9.5.
2.4 General Experimental Procedures
2.4.1 Buffer Exchange/Dialysis
Proteins for DI-MS-analysis or as part of a protein purification step were dial-
ysed/buffer exchanged using appropriate dialysis tubing according to sample volume
or desalting columns. For volumes <1 mL dialysis tubing with a diameter of ˜2 cm
was used. Samples <100 µL were dialysed using disposable ’Dispo-Biodialyzer’.
All used dialysis equipment had a molecular weight cut off of 10 kDa and was pur-
chased from Sigma-Aldrich - Derset, UK. Protein samples were exhaustively dialysed
overnight against 4 L of 10 mM NH4OAc, 1 mM NaN3 (Fisher Scientific - Loughbor-
ough, UK), pH 6.8 for 24 h at 4 ◦C, exchanging buffer every 3 h at gentle rotations.
For desalting a PD10 column (Amersham Biosciences - Little Chalfont, UK) was
equilibrated with 2.5 mL 10 mM NH4OAc (Fisher Scientific - Loughborough, UK),
the protein sample applied in 2.5 mL volume and the flow through discarded. Elu-
tion with 3.5 mL 10 mM NH4OAc (Fisher Scientific - Loughborough, UK) into a
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micro centrifuge tube was often followed by sample concentration via viva-spin con-




For accurate mass measurements the Micromass Platform II was calibrated every
3 months. Therefore a calibration mixture containing NaCsI (2mg/mL NaI, 0.05
mg/mL CsI in 1:1 2-propanol, H2Odd) was sprayed via DI-ESI at 5 µL/min and the
automatic calibration routine started. The calibration was verified by comparison of
the NaCsI reference peak list with the mass spectrum just acquired. Once deviations
were within a particular threshold the calibration was accepted and applied.
QTOF Ultima/ QTOF 2
To guarantee mass accuracy the Micromass ”QTOF Ultima” and ”QTOF 2” were
calibrated on a weekly basis. Therefore NaCsI (2mg/mL NaI, 0.05 mg/mL CsI in
1:1 2-propanol, H2Odd) was injected via nano-ESI and a spectrum recorded over ˜50
scans using the ’uncal’-calibration file. The ’calibrate from file’-option was used to
calibrate the quadrupole- and TOF-analysers after manually checking the correct
peak assignment. To test the accuracy of the calibration a protein standard was
investigated and the calibration procedure repeated, if necessary.
2.4.3 Instrumental Parameters
Depending on mass spectrometric instrumentation, different tuning parameters were
used.
The Platform II (Micromass - Manchester, UK) was operated throughout in
positive ionisation mode at a capillary voltage of 3.5 kV, a cone voltage of 50 V, a
source temperature of 85 ◦C and a multiplier setting of 650 arbitrary units.
The QTOF-2 and -Ultima were used at capillary voltages of 3.5 kV for ESI and
0.8-1.8 kV for nESI, a cone voltage between 30-60V and a source temperature of
˜90
◦C. The MCP settings were 2000 V and 2400 V on the QTOF-2 and -Ultima,
respectively.
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2.5 General Data Processing
After mass spectrometric data has been collected in DI-, HDX-labeling, PLIMSTEX-
and SUPREX experiments it was deconvoluted using particular software depending
on the instrument used. Most of the data was produced using Micromass (UK)
instrumentation. Nevertheless, some manual SUPREX work (Section 3.6) was car-
ried out with a LCQ classic (Thermo Corporation, UK) requiring different data
processing.
MassLynx
Utilising Micromass mass spectrometers (Platform II, QTOF-2 and QTOF-Ultima)
MassLynx versions 3.5-4.1 have been used. Post acquisition the individual spectrum
was smoothed with 2-6 Da peak width and 10-20 smoothing steps using a Savitzky
Golay algorithm after combining over the acquired DI- (Appendix 9.2) or HPLC
chromatogram (Appendix 9.3). The baseline subtraction was performed with a 5th
order polynomial for signals less than 40 % of the maximum intensity. The peaks
were centered with 4 channels at the minimum peak width at half height at 80
% centroid top of the peak (Fig. 3.1, Chapter 3.2). To determine the mass from
a spectrum two adjacent peaks were manually selected and the transform option
within the MassLynx software was employed for deconvolution. Some of the CypA
PLIMSTEX data (Section 3.4) was deconvoluted manually due to high s/n-ratio and
low signal intensities. Therefore the spectrum was processed as described above, but
the centered spectrum list was exported to Microsoft Excel XP to identify adjacent
peaks, before calculating the mass (Eq 19) for each charge state and averaging.
mass = (m/z · cs) − cs (19)
With m/z the mass to charge ratio and cs the individual charge state.
Xcalibur
Data acquired with with a LCQ classic (Thermo Corporation, UK) was processed
using the instrument software Xcalibur 2.0. Spectra were smoothed using the 15
points gaussian smoothing routine and centered. The m/z values were manually
transferred to Microsoft Excel XP and the average mass calculated as described
above.
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2.6 PLIMSTEX Method Development
2.6.1 PLIMSTEX Buffers and Sample Preparation
According to the PLIMSTEX protocol (Section 1.5) the deuteration buffer was pre-
pared as for the HDX labeling experiment (Section 2.3.5) and ligands prepared as
described previously (Section 2.3.2).
HPLC buffer for priming and loading the C4 guard column was denoted as
washing buffer (WB; 97 % H2O, 3 % acetonitrile, [pH 2.5]). For elution of the
protein from the guard column elution buffer (EB, 96 % acetonitrile, 4 % H2O, [pH
2.5]) was used.
For the first PLIMSTEX experiments (Section 2.6.2) and for the manual PLIM-
STEX approach (Section 2.6.3), 2 µL of the protein in question was incubated with
2 µL of ligand at different concentrations, ranging from a 0-20 fold excess of ligand.
After 20 min incubation 96 µL of 10 mM d -NH4OAc (Fisher Scientific - Loughbor-
ough, UK) were added to initiate HDX. The total sample volume was 100 µL with
a total protein concentration of 2 µM-4 µM.
The automated PLIMSTEX approach (Section 2.6.4) utilised the same protein-
ligand concentrations and ratios. However, the total sample volume was shrunk
to 70 µL. Thereby 2 µL protein (122 µM stock) and 1 µL of ligand at different
concentrations (Section 2.3.2) were placed in a 250 µL, 12x32 mm autosampler vial
each and sealed with a snap cap (magenta, Fig. 2.6a). Final ligand concentrations
reached from 0-20 equivalents of the total protein concentration. 3 mL of 10 mM
d -NH4OAc (Fisher Scientific - Loughborough, UK) were filled in a 22.5x45 mm
headspace vial and crimped with a 20 mm headspace cap and placed in a 48 well
plate (orange, Fig. 2.6a).
2 EXPERIMENTAL AND METHOD DEVELOPMENT 55
A A












Figure 2.6: PLIMSTEX and SUPREX 48 well plate sample array. (a) Nine protein PLIMSTEX samples
(magenta) and nine ligand samples (violet). Orange, 10 mM d-NH4OAc. (b) Nine apo protein SUPREX
samples, cyan. Blue, nine different denaturing concentrations in 10 mM d-NH4OAc. Green, 10-20 fold
excess of ligand.
2.6.2 The Beginning; First Steps
The development of the HPLC front end for the PLIMSTEX (Section 1.5) approach
was first undertaken. Therefore the sample was placed in a 250 µL gas tight syringe
(Gasthigt 1725-1750 - Hamilton - Bonaduz, Switzerland) mounted on a syringe
pump (Harvard apparatus - Kent, UK; Fig. 2.7). The needle was connected to
1/16 peekTM tubing with 0.005 in inner diameter (ID) via a 0.010 in 10-32 ZDV
peekTM union. Between sample and MS a C4 guard column (Optimize Technologies
- Oregon City, USA) was placed into the sample line, packed in ice in a polystyrene
box. If not otherwise stated all HPLC accessories were purchased from Anachem -
Luton, UK.
To perform a PLIMSTEX experiment the syringe was filled with 200 µL washing
buffer and attached to the sample line, priming the column at a flow rate of 10 µL-
30 µL. Flow through was collected in a separate container. Then 100 µL of sample
(Section 2.6.1) was quenched after a 90 min of incubation by adding 2 µ L of 2 M HCl
and lowering the temperature by placing the sample on ice. After loading the sample
onto the syringe and connecting to the C4 guard column, injection was started and
the time closely monitored with a stop watch. This was important to guarantee
the best possible reproducibility. The flow through was discarded and the protein
loaded/washed on the column. After 4 min of washing the buffer in the syringe was
changed to elution buffer and the protein was eluted after connecting the HPLC
tubing to the Platform II. The data acquired was mass deconvoluted (Section 2.5)







10-32 Peek UnionHamilton 1700, 250 Lµ
2) Loading deuterated protein
3) Washing
4) Elution
Figure 2.7: First developed PLIMSTEX setup. Showing a syringe pump with gas-thight syringe
connected to a C4 guard column, sitting on ice in a polystyrene box, connected to the mass spectrometer.
(1) C4 column was primed with washing buffer. (2) Sample applied to the syringe and loaded onto
guard column. (3) Washing step. (4) Elution into Platform II for mass analysis.
and further analysed according to the PLIMSTEX routine (Section 2.6.5).
First HDX Labeling Experiment
Before PLIMSTEX experiments were performed with the CypA-CsA system the
setup developed was tested by carrying out HDX labeling experiments with apo
CypA. Therefore a 4 µM CypA sample in 100 µL was prepared (Section 2.3.5)
and subjected to the PLIMSTEX routine (Section 2.6.2) at a flow rate of 30 µL.
The washing time, which was crucial for the back exchange, was held constant at
4 min. Each incubation time was repeated at least twice. However, not every
experiment resulted in a mass. Figure 2.8 shows the deuterium uptake of CypA vs.
time, indicating findings were not reproducible for short incubation times. This was
mainly attributed to errors made in timing the experiment, handling the individual
steps and due to flow rate issues caused by leakages of the syringe. This was due
to machine fatigue as a result of the chosen flow rate in conjunction with the back
pressure generated by the HPLC tubing and the guard column. The inaccuracy of
the apo CypA results emphasised the necessity of a better flow rate management,
which led to the development of a more sophisticated HPLC front-end (Section
2.6.3).
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Figure 2.8: First HPLC HDX labeling experiment with developed setup and apo CypA. Error bars
represent standard deviation of at least two independent experiments.
2.6.3 The Manual Approach
To circumvent the flow rate issue a set of HPLC pumps (PU980 - Jasco - Essex,
UK) was used to deliver a constant flow, adjusted to 30 µL/min for washing and
elution buffer. Figure 2.9 provides an overview of the total setup. For diversion of
the flow paths 3 Rheodyne valves (7725, 7000 - IDEX Health & Science - Wertheim-
Mondfeld, Germany) were mounted on a metal plate and connected with low ID 1/16
peekTM tubing (ID 0.005 in)2. The metal plate holding the valves was positioned
on a polystyrene box filled with ice, immersing the valves in ice to guarantee a sam-
ple temperature close to 0 ◦C. To further assist low temperature conditions stainless
steel (ss) loops were bend and installed between HPLC pumps and Rheodyne valves,
buried in ice. For sample injection a 100 µL ss sample loop was employed in con-
junction with a C4 guard column (Optimize Technologies - Oregon City, USA) for
protein ’trapping’ (Fig. 2.9a). PLIMSTEX (Section 2.6.1) or HDX labeling sam-
ples (Section 2.3.5) were quenched precisely as in Section 2.6.2 and loaded onto the
sample loop with a 250 µL gasthight syringe via the needle port of valve I in the
load position (blue ports connected), while valve II remained in the inject position
(magenta ports connected) to allow flow over the guard column and valve III in the
load position (blue ports connected) going to waste. After loading, the sample valve
I was switched to the inject position allowing washing buffer to empty the sample
loop and loading the quenched protein sample onto the guard column. The mo-
ment the switch was turned for loading/washing the sample onto the column, time
acquisition was started and the protein was washed with non-deuterated buffer for
2thanks to Dr. H. Husi for advise on general HPLC questions.
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as close to 4 min as possible. Then mass acquisition was started and valves II and
III were switched to the load and inject position, respectively. Elution buffer now
ran over the C4 column eluting the protein into the MS, followed by data analysis
(Section 2.5, 2.6.5).
HPLC pump: elution buffer


























Figure 2.9: Manual PLIMSTEX and SUPREX setup. (a) Flow path schematic of wash/elution buffer.
(b) Image of the HPLC switches on top of the polystyrene ice box.
Flow Rates
To get an idea about the error associated with the uncertainty of the flow rates,
both wash and elution buffer flow rates were determined and recorded for every
experimental day. Therefor an empty 250 µL gasthight syringe was connected to
port 2 of valve III (Fig. 2.9). Using a stop watch the elapsed time was measured
until the syringe was filled with buffer and the average flow rate calculated. Figure
2.10a shows the flow rate deviation from the set value of 30 µL/min for wash and
elution buffer. Deviations for the washing buffer are relatively small and within
a range of ±2 µL/min. However, for the elution buffer discrepancies are larger,
compared to the wash buffer, within a range of ±10 µL/min. This might be due to
the solvent properties of the elution buffer in context with a lower backpressure of
the system relative to the washing buffer.
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Figure 2.10: Flow rates for manual PLIMSTEX and SUPREX. (a) Deviations from 30 µL/min shown
for washing (black) and elution buffer (red) for manual PLIMSTEX. (b) Deviations from 100 µL/min
and 30 µL/min for washing (black) and elution buffer (red) for manual SUPREX experiment.
HDX Labeling Experiment with the Manual Setup
The manual setup was tested repeating the same HDX labling experiment as with
the first PLIMSTEX setup (Section 2.6.2). As Figure 2.11a visualises the repro-
ducibility is much better than in the previous experiment and more data points
could be collected.



























Figure 2.11: CypA HPLC-HDX labling experiment and back exchange optimisation. (a) HDX labeling
experiment with the manual PLIMSTEX setup. (b) Back exchange optimisation for CypA.
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Back Exchange Optimisation
To minimise the experimental error on PLIMSTEX data it was necessary to get
an idea of the back exchange profile of the utilised system. Therefore CypA was
incubated in 10 mM d -NH4OAc (Fisher Scientific - Loughborough, UK) at a con-
centration of 4 µM for 120 min before quenching (Section 2.6.2) and loading 100 µL
of the sample onto the ’manual setup’ (Fig. 2.9). Loading/washing the sample for
different time periods yielded the different changes in mass of CypA due to back
exchange of type 1 and type 2 deuterium atoms (Section 1.3). Figure 2.11b shows
the change in the mass difference between undeuterated and deuterated CypA de-
pending on the washing time on the guard column. The rapid decrease at short
washing times is due to the back exchange of the fast exchanging type 1 deuterons,
whereas the plateau for times longer than 400 s represents the slower back exchange
of the amide bound T2 deuterons. A compromise between a too low deuterium level
and big fluctuations in the T1 back exchange region was a washing time of ˜6-9 min.
Further manual PLIMSTEX experiments were carried out at this very washing time.
CypA-CsA PLIMSTEX
After optimising the washing step a PLIMSTEX experiment (Section 2.6.3) with
the CypA-CsA system was conducted. An example mass spectrum for CypA-CsA
PLIMSTEX experiments is visualised in Appendix 9.4. Figure 2.12 shows the PLIM-
STEX curve for the system (quantitative discussion of manual CypA-CsA PLIM-
STEX data in Chapter 3.4). Two sets of experiments were run and the standard
deviation was plotted as error bars. The errors are within a reasonable threshold,
finally emphasising the usefulness of the developed PLIMSTEX HPLC-front end.
However, as all steps within the developed protocol (Section 2.6.3) were manually
timed and executed there was still room for improvement of reproducibility and
increasing the throughput.
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Figure 2.12: Manual CypA-CsA PLIMSTEX curve. Error bars represent standard deviation of two
independent runs.
2.6.4 The Automated Method
As the manual acquisition of PLIMSTEX experiments limited throughput and ac-
curacy, a fully automated approach was developed.
Hardware
A software controlled HPLC system was employed comprising a Dionex Ultimate
3000 quaternary analytical pump (Dionex - Sunnyvale, USA) with a flow accuracy of± 0.1 % accuracy for better flow rate management. Sample handling was taken care
of by a Famos Micro Autosampler (Dionex - Sunnyvale, USA), which was further
equipped with a 100 µL syringe (Dionex - Sunnyvale, USA) to accelerate handling
of larger sample volumes. The standard 2.4 µL sample needle was replaced with
a self built 15 µL one (Fig. 2.13a). Fused glass capillary tubing (SGE Europe
Ltd - Kiln Farm Milton Keynes, UK) was glued into grey 1/16 peekTM tubing
(Anachem - Bedfordshire, UK) using a two component epoxy adhesive (Araldite -
Huntsman Advanced Materials - Cambridge, UK) and dried/hardened for ˜ 7 days.
A stopper was placed at a particular position to guarantee exact sample needle
height. All measures are visualised in Figure 2.13a. Individual HPLC components
were connected with fused glass capillary tubing of different diameters (PLIMSTEX:
50 µm, SUPREX: 75 µm) and lengths to keep the tubing dead volume as low as
possible. The methodology was identical for the preparation of the autosampler
needles (Fig. 2.13b). It was necessary to adapt tubing inner diameters (ID) to the
flow rate of the individual HDX experiment (PLIMSTEX or SUPREX) to guarantee
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Figure 2.13: Autosampler tubing. (a) In house made 15 µL needle for Famos Micro Autosampler. (b)
Fused glass capillary tubing in different lengths and ID’s.
For sample injection different sized sample loops were prepared. Utilising 0.02
in 1/16 peekTM tubing in the lengths of 14.8, 24.7, 29.6 and 49.34 cm sample loops
of 30, 50, 60 and 100 µL were built.
The main issue of any automation attempt was the low temperature needed for
the quenching of the HDX reaction. To circumvent this issue a device was required,
which was able to hold a reasonable amount of ice for at least 24 h. A ss box
was built3 matching the dimensions to fit a polystyrene box. HPLC connections
were established via two 0.020 in 10-32 ZDV ss unions (Anachem - Luton, UK),
silver soldered into the ss box according to Figure 2.14. A C4 guard column was
attached from the inside of the box and connected with 50 µm ID fused glass capillary
tubing at the inside and the outside. Now water tight, the ss box was put into the
polystyrene box and filled with a water/ice mixture for better heat transmission.
Figure 2.15 provides an overview of the automated PLIMSTEX setup.
Methodology
For automated PLIMSTEX experiments, samples were prepared according to Sec-
3Mr. D. Paden, University of Edinburgh
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Figure 2.14: HPLC ice box. (a) Front view with dimensions of the ice box. (b) Top view, with column
assembly.
tion 2.6.1, put in a 48 well plate according Figure 2.6a and positioned in the au-
tosampler. The LC method program (Appendix 9.7) used for PLIMSTEX involved: ligand addition (1 µL) to protein sample (1 µL; Fig. 2.6a) waiting block of 20 min pick up of 66 µL 10 mM d -NH4OAc from headspace vial and dispense into
individual sample vial waiting block for 90 min to allow HDX sample pick up of 65 µL, loading onto guard column and washing for 8 min
(Section 2.6.4) sample elution into MS.
At this point it is important to emphasise the lack of an explicit pH quenching
step due to the time it would take to perform this. However, due to the pH of the
washing buffer the sample was instead quenched ’online’ while been loaded/washed.
Duration of an individual experiment was ˜105 min, allowing ˜14 samples being
investigated within 24 h. Data analysis was performed as described in Section 2.5
and 2.6.5.



















70 µL PLIMSTEX sample
15 µL AS needle
50 sample loopµL
100 µL AS syringe
ss box
ICE / WATER
Figure 2.15: Automated PLIMSTEX overview with software controlled HPLC pump, autosampler, ice
box and mass spectrometer.
Automated Back Exchange Optimisation
Before PLIMSTEX experiments were conducted, the time for loading/washing the
quenched protein sample was optimised. Horse heart myoglobin (HHM; Section
2.7.6) was used as a standard due to easy and cheap accessibility. A 1 mL HHM
sample was prepared (Section 2.3.1) in 10 mM d -NH4OAc at a concentration of
4 µM and incubated for 120 min. Then 65 µL d -HHM sample were loaded via
the autosampler on the sample loop and loaded onto the column, where different
washing times were applied. Figure 2.16a illustrates the different retention times
of the sample due to different washing times. The associated changes in mass are
visualised in Fig. 2.16b. In comparison with the back exchange experiment of the
manual setup (Fig. 2.11), data shows a more linear decrease of the protein deuterium
level in time, indicating T2 deuterons already back exchanging. Due to the fact that
one HPLC pump serves two buffers (wash/elution) the shortest retention time was
shown to be 7 min. Meaning, directly after sample injection the flow path was
changed to the elution buffer, taking 7 min for elution to occur. To compromise
between run duration and deuterium level of the protein a washing time of 1 min,
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resulting in a retention time of 8 min was chosen for further automated PLIMSTEX
experiments.
































Figure 2.16: Back exchange optimisation for the automated PLIMSTEX setup using HHM. (a) MS
chromatogram for HHM elution with retention times between 7-14 min. (b) Associated mass shifts of
HHM due to different retention times.
2.6.5 PLIMSTEX Data Processing
The experimental PLIMSTEX data was processed (Section 2.5) and plotted in a
PLIMSTEX curve (Fig. 1.14a) before modeling the data according [1], [230] and
[229]. Therefore a methodology has been developed by Dr. Phillip Camp (University
of Edinburgh) to model 1:1 binding behaviour by using equation 54 (Appendix 9.8)
in conjunction with Microcal - Origin 7.5 to fit and plot experimental PLIMSTEX
data, yielding values for ∆mfree, ∆mcomplex, and K the mass difference due to
deuterium uptake of the free protein, the fully complexed protein and the affinity
constant, respectively. A further detailed derivation can be found in Appendix 9.8.
2.6.6 PLIMSTEX Optimisation
Due to the self-assembly capabilities of insulin, the new developed automated PLIM-
STEX setup was tested with recombinant (r) human insulin.
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Insulin
Insulin is 51 aa protein (Section 9.9) with a mass of 5808 Da. It is a hetero dimer
[255] consisting of an α- and β-subunit with 21 and 30 amino acids covalently con-
nected via two disulfide bonds (Fig. 2.17a). It is produced in the pancreas as
a monomer to regulate blood glucose levels and self-associates in solution. How-
ever, storage takes place in the pancreas as a hexamer [256]. Dissociation into the
monomeric active form is needed for absorption into the blood stream [232, 257].
Recombinant human insulin is widely used for type 1 diabetes. Therefore it’s struc-
tural form plays an important role in terms of bioavailability and duration of action.
Hereby one hypothesis is that the higher the tendency of an insulin to self-associate,
the longer it takes to act [258].
(a) (b)
Figure 2.17: Human insulin structure. (a) Heterodimer (pdb file 1a7f). (b) Phenol stabilised hexamer
(pdb file 1ai0 visualised with pymol (DeLano Scientific LLC - Palo Alto, USA)).
Gross et al. investigated the self-assembly properties of r-human, porcine, bovine
and lispro insulin and other insulin mutants utilising an adaptation of PLIMSTEX,
termed SIMSTEX (Section 1.5.1). Equilibrium constants for the oligomerisation of
the various insulin analogs have been reported [232]. These findings demonstrate
the presence of the dimeric, tetrameric and hexameric insulin form in solution and
the existence of a trimeric and pentameric form in the gas phase.
Insulin PLIMSTEX
The insulin SIMSTEX experiment (Section 2.6.6) was carried out with DI mass
spectrometry. As a proof of principle and to optimise the automated PLIMSTEX
setup self-association LC-experiments were carried out. At first a HDX labeling ex-
periment (Section 2.3.5) with the automated setup (Section 2.7.3) was performed to
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gain information about exchange kinetics and deuterium levels of r-human insulin.
Figure 2.18a shows the HDX labeling curve at a fixed concentration of 40 µM. In
conjunction with a 30 µL/min for wash/elution buffer the maximum deuterium in-
corporation could be determined to be ˜28 amide deuterons, compared to the total
number of 50 exchangeable hydrogens, meaning 22 amide protons were shielded
due to protein structure and therefore showed no exchange. However, some degree
of back exchange also contributed to this finding as the back exchange experiments
with HHM (Section 2.6.4) indicated. Nevertheless, as PLIMSTEX experiments were
performed under identical experimental conditions using the automated HPLC front-
end (Section 2.6.4), back exchange was not further investigated but considered as
constant.
For low sample concentrations of insulin the high s/n ratio and the low signal in-
tensities were problematic. Figure 2.18b illustrates the increasing signal intensity
of the chromatogram with increasing insulin concentration, taken from the elution
peak maximum.
Insulin PLIMSTEX experiments (Section 2.6.4) clearly emphasise the applica-
bility of the developed setup, as the resulting PLIMSTEX curve (Fig. 2.18c) showed
the expected trend.
2.7 SUPREX Method Development
In 2000 SUPREX was initially designed for MALDI-MS analysis [2]. So it was
necessary to adapt the method for ESI-LC-MS application. As it turned out the
previously developed PLIMSTEX setup was applicable for SUPREX as well.
2.7.1 SUPREX Buffers and Sample Preparation
SUPREX experiments were performed according to the SUPREX protocol (Section
1.6.1). Therefore a series of SUPREX-buffers with different denaturing concentra-
tions were prepared from urea and guanidinium hydrochloride stock solutions (Table
2.3) and 10 mM d -NH4OAc (Fisher Scientific - Loughborough, UK). Stock solutions
were prepared according to [259] by dissolving 1.103 g of urea in 1 mL of 10 mM
d -NH4OAc (Fisher Scientific - Loughborough, UK) to yield a 10 M stock. For guani-
dinium hydrochloride 1.816 g/mL resulted in a 8 M stock solution. Concentrations
were verified using an Abbe-refractometer (Carl Zeiss - Jena, Germany) at RT and
10 mM d -NH4OAc (Fisher Scientific - Loughborough, UK) as blank. Refractive
indices were transformed into concentrations using equation 20 for urea and 21 for
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Figure 2.18: Insulin HDX overview. (a) Deuterium uptake vs. time. (b) Elution chromatogram
intensity with respect to insulin concentration. (c) Insulin PLIMSTEX curve. Error bars represent
standard deviation of two independent runs.
guanidinium hydrochloride [259].
[c] = 117.66(∆N) + 29.753(∆N)2 + 185.56(∆N)3 (20)
[c] = 57.147(∆N) + 38.68(∆N)2 − 91.60(∆N)3 (21)
With [c] concentration in molL−1 and ∆N the difference in the refractive index
between the denaturant solution and d -buffer at the sodium D-line.
For the manual SUPREX approach (Section 2.7.2) 1 µL of the apo protein in
question was added to a micro centrifuge tube followed by the addition of 96 µL of
the SUPREX-buffer at a particular GDH concentration, resulting in a 4 µM total
protein concentration. After incubation between 10-420 min the HDX reaction was
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quenched by adding 2 µL of 2 M HCl (Fisher Scientific - Loughborough, UK). The
same procedure was applied for the holo protein apart an additional 20 min waiting
period prior SUPREX-buffer addition due to complex formation.
For the automated SUPREX approach (Section 2.7.3) the final protein concen-
tration was between 4 µM-5 µM, depending on the protein ligand system, and the
final volume was 70 µL. Therefore 4 µL protein (60 µM stock) was placed in a 250µL, 12x32 mm autosampler vial and sealed with a snap cap. The SUPREX-buffers
were pipetted and sealed in identical vials according to their concentration. Where
a holo experiment was performed n+1 volume equivalents of ligand were filled in an
additional vial at concentrations between 10-20 fold excess to the apo protein (Fig.
2.6b).
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Table 2.3: Guanidinium hydrochloride and urea stock solutions for
SUPREX. Volumes to prepare 1 mL of SUPREX buffer.
cdenaturat VGDHstocka VNH4OAc Vureastockb
VNH4OAc
molL−1 mL mL mL mL
0.00 0.00 1000.00 0.00 1000.00
0.25 38.75 961.25 25.23 974.77
0.30 46.50 953.50 30.28 960.32
0.50 77.50 922.50 50.46 949.54
0.60 93.00 907.00 60.50 939.50
0.75 116.25 883.75 75.70 924.30
1.00 155.00 845.00 100.93 899.07
1.25 193.75 806.25 126.16 873.84
1.50 232.50 767.50 151.39 848.61
1.75 271.25 728.75 176.62 823.38
2.00 310.01 689.99 201.86 798.14
2.25 348.76 651.24 227.09 772.91
2.50 387.51 612.49 252.32 747.68
2.75 426.26 573.74 277.55 722.45
3.00 465.01 534.99 302.79 697.21
3.25 503.76 496.24 328.02 671.98
3.50 542.51 457.49 353.25 646.75
3.75 581.26 418.74 378.48 621.52
4.00 620.01 379.99 403.71 596.29
4.25 658.76 341.24 428.95 571.05
4.50 697.51 302.49 454.18 545.82
4.75 736.26 263.74 479.41 520.59
5.00 775.01 224.99 504.64 495.36
5.25 813.76 186.24 529.87 470.13
5.50 852.51 147.49 555.11 444.89
5.75 891.27 108.73 580.34 419.66
6.00 930.02 69.98 605.57 394.43












a prepared from 6.45 M guanidinium hydrochloride stock.
b prepared from 9.91 M urea stock M.
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2.7.2 Manual SUPREX
For manual SUPREX experiments the previously developed manual PLIMSTEX
setup (Section 2.6.3) was used. For desalting purposes it was necessary to increase
the WB flow rate and time dramatically. Therefore a flow rate of 100 µL/min for
the WB was used, whereas the EB flow rate remained the same at 30 µL/min. For
error estimation flow rates were determined every experimental day and recorded
(Section 2.6.3, Fig. 2.10b). The quenched samples (Section 2.7.1) were loaded onto
the manual HPLC-setup (Fig. 2.9), washed/loaded with the appropriate buffer for
8 min, followed by elution into the mass spectrometer (precisely as in Section 2.6.3)
and mass analysis (Section 2.5, 2.7.5).
2.7.3 Automated SUPREX
Hardware
The developed automated PLIMSTEX setup in Section 2.6.4 was, again, a good
starting point for automated SUPREX experiments in a more high throughput fash-
ion. As Fig. 2.15 illustrates, there is just one flow path to the MS, meaning all de-
salting solvent of a SUPREX sample goes into the instrument, limiting the number
of possible SUPREX experiments to ˜6 on the Platform II (Micromass - Manchester,
UK) due to contamination. Finally, having the opportunity to use a ’Famos Switchos
Unit’ (Dionex - Sunnyvale, USA) with two software controlled 10-port valves and
HPLC pump, circumvented this issue. It also reduced the time between switching
from washing to elution buffer from ˜8 min to <1 min, increasing LC efficiency and
throughput. Individual HPLC components were connected with in house prepared
75 µm ID fused glass capillary (Section 2.6.4) due to the higher washing flow rate
of 160 µL/min, increasing the back pressure significantly. Figure 2.19 visualises the
overall setup.
Software
The one remaining bottle neck was the chromelion software, only allowing one
sample to be investigated at a time. Meaning, during long HDX incubation times the
system would sit idle, wasting resources. The only option to get round this problem
was to program each LC step individually, designing a unique sample list with
continuous sample mixing and analysis for each incubation time. A basic LC method
for a SUPREX experiment consists of 4 blocks: ligand addition, ligand incubation,
buffer addition and LC analysis. According to sample preparation (Section 2.7.1)
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Switchos Unit Autosampler Pump Unit
Figure 2.19: Automated SUPREX overview with software controlled HPLC pump unit, autosampler,
switchos system, ice box and mass spectrometer.
the individual block durations were illustrated in Table 2.4. Every LC step was
timed three times and average values taken.
Table 2.4: Duration of LC method programmes for SUPREX.
Event Duration Average Duration/Reaction time
Ligand addition a 02 min 47 s
02 min 56 s 02 min 56 s
02 min 57 s
Waiting block b 01 min 00 s 01 min 23 s
02 min 00 s 02 min 23 s
03 min 00 s 03 min 23 s
Buffer addition c 02 min 54 s
02 min 52 s 02 min 52 s
02 min 52 s
LC run d 13 min 01 s
13 min 02 s 13 min 01 s
13 min 01 s
a time it took to add ligand to apo protein sample.
b duration of waiting block.
c time it took to add d -buffer to holo protein sample.
d duration of LC analysis.
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Having determined the duration of each individual LC step, sample lists for apo
and holo SUPREX experiments were prepared. For HDX incubation times <60 min
it was more efficient to utilise the individual genuine LC method program precisely
as described in Section 2.6.4. However, for incubation times >60 min the prepared
apo and holo sample lists at least doubled throughput efficiency due to less idle
time of the system. Detailed sample lists for 10 and 18 samples for even and odd
incubation times can be found in Appendix 9.10, 9.11 and 9.12.
Methodology
SUPREX samples were prepared according to Section 2.7 for apo and holo protein
experiments and placed into a 48-well plate (Fig. 2.6b). According to Section
2.7.3 samples for HDX incubation times <60 min were carried out with a single LC
method program involving: (ligand addition of 4 µL to apo protein sample) (waiting block for 20 min to allow protein ligand incubation) pick up of 66 µL (62 µL) 10 mM d -NH4OAc containing different concentrations
of the chemical denaturant and dispense into individual sample vial waiting block for various SUPREX times to allow HDX sample pick up of 65 µL, loading onto guard column and washing for 8 min
(Section 2.6.4) sample elution into mass spectrometer.
Steps in brackets designate a holo SUPREX experiment. For incubation times >60
min the same procedure in terms of sample volumes and incubation times was ap-
plied. However, the sample lists were manually designed (Section 2.7.3) for each
individual incubation time to reduce idle time of the system as much as possible
Appendix 9.10, 9.11 and 9.12. This two approaches allowed a throughput of 33 apo
SUPREX samples and 21 holo SUPREX samples within a 24 h period.
2.7.4 Temperature Dependent Automated SUPREX
All PLIMSTEX and SUPREX experiments were carried out at constant 22 ◦C in an
air conditioned lab and are referred to as RT. However, investigation of temperature
dependent SUPREX experiments needed precise temperature control. Therefore a
2 EXPERIMENTAL AND METHOD DEVELOPMENT 74
48-well plate containing heating and cooling channels was designed. On the basis
of a standard 48-well plate for the Famos Micro Autosampler (Dionex - Sunnyvale,
USA) a replicate was made4 from aluminium comprising channels for a secondary
heating/cooling device (Fig. 2.20). Mains water was used to heat/cool the sample
tray in conjunction with a copper spiral immersed in a water bath (JB12 - Grant -
Shepreth, UK) connected via plastic tubing (5 mm ID, Nalgene - Thermo Corpo-
ration, UK). For low temperature measurements the copper coil was put in an ice
box. Two temperatures, different from 22 ◦C, were investigated. Adjusting the the
water bath temperature to 85 ◦C at a flow rate of ˜ 500 mL/min resulted in a 50
◦C sample temperature, measured with a glycerol sample and a thermometer. For
the low temperature experiment at the same flow rate a sample temperature of 15
◦C could be observed. Temperature dependent SUPREX experiments were carried
out as those previously described in Sections 2.7.1, 2.7.3 and 2.7.3.
A








Figure 2.20: Heated 48-well sample tray for SUPREX experiments.
2.7.5 SUPREX Data Processing
Post acquisition, SUPREX mass spectra (illustrated on apo CypA in Appendix
9.13) were processed as described in Section 2.5 and the change in mass shift due
to deuteration and denaturation was plotted versus the concentration of the chem-
ical denaturant, utilising Microcal - Origin 7.5. Data fitting with equation 17 was
carried out as described in Section 1.6.1. ∆Gf ’s were determined using equation 61
(Appendix 9.14) and plotting −RTln(〈kint〉t/0.693− 1) vs. C
1/2
SUPREX. 〈kint〉 values
were calculated according to Bai et al. [107] employing SPHERE, a server program
for HDX rate estimation5. Dissociation constants were extracted from changes in
∆Gf for the apo and holo systems according to equation 63 (Appendix 9.14).
4Mr. D. Paden, University of Edinburgh
5http://www.fccc.edu/research/labs/roder/sphere/sphere.html
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2.7.6 SUPREX Optimisation
Before wasting valuable protein resources on the automated SUPREX methodology
developed, myoglobin was investigated as a protein standard.
Myoglobin
Myoglobin is a 153 aa protein (Appendix 9.15) responsible for oxygen storage in
muscle tissue in a non-cooperative way, compared to haemoglobin and the oxygen
transport chain. A proximal histidine-bound iron protoporphyrin IX allows oxygen
uptake, whereas a distal histidine prevents carbon monoxide from binding [48]. Fig-
ure 2.21 illustrates the eight α-helices in the secondary structure of HHM with the
heme group in the hydrophobic core. The mass of apo and holo HHM is 16951 Da
and 17567 Da, respectively. Due to its easy accessibility it has been widely used
as a protein standard not only in the field of mass spectrometry and its properties
have been well characterised over the years as shown inter alia by Feng et al. in
1993 [260] and Konermann et al. in 2000 [261].
Figure 2.21: X-ray cristal structure of azide stabilised horse heart myoglobin (pdb file 1azi visualised
with pymol (DeLano Scientific LLC - Palo Alto, USA)).
Myoglobin SUPREX Results
Automated SUPREX experiments were conducted and evaluated according to Sec-
tion 2.7.1, 2.7.3 and 2.7.5. Table 2.5 summarises the C
1/2
SUPREX values for horse heart
myoglobin at different incubation times. Figure 2.22a illustrates the change of the
SUPREX midpoints with different incubation times. Due to clarity only 10, 60, 120
and 180 min incubation are shown. SUPREX curves at each individual incubation
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time can be found in Appendix 9.16. The average intrinsic exchange rate 〈kint〉t
was calculated with SPHERE to 4.53 s−1 at 22 ◦C. All SUPREX inflexion points
gathered at different guanidinium hydrochloride concentrations were plotted versus
∆Gf . Figure 2.22b gives an overview of the free energy of protein folding vs. de-
naturant concentration. ∆Gf for myoglobin at a 0 M denaturant concentration was
determined to be -26.90 ±1.05 kJmol−1. The m-value was calculated to 5.40 ±1.63
kJmol−1M−1.
Fitzgerald and coworkers [262] reported thermodynamic properties for horse skeletal
muscle myoglobin by conventional denaturing experiments and MALDI-SUPREX.
∆Gf was determined to -24.27 ±0.84 kJmol−1 with an associated m-value of 22.60±0.84 kJmol−1M−1. However, no thermodynamic parameters different than the
C
1/2
SUPREX values could be extracted from graphs via MALDI-SUPREX due to the
non-linearity of the ∆Gf vs. denaturant concentration plots as reported by Pace and
Vanderburg in 1975 [263]. This might indicate a non-two state folding behaviour
due to the population of partially unfolded intermediates.
However, Ahmad et al. observed linear unfolding behaviour and determined ∆Gf
and m-values for horse heart myoglobin to -22.43 ±0.42 kJmol−1 and 18.58 ±0.42
kJmol−1M−1 at a pH of 5.88 utilising conventional spectroscopic denaturing exper-
iments [264].
In conclusion, SUPREX data acquired with the automated ESI-LC SUPREX
setup showed good reproducibility as Figure 2.22a emphasises and is within a 10-
15 % range to conventional unfolding data for HHM. The effect of different solvents
in the denaturing buffer affecting ∆Gf and m-values also contributes to the dif-
ference in reported values [262, 263, 264]. However, the non-two state behaviour
reported with MALDI-SUPREX [262] and spectroscopic methods [263] could not be
confirmed suggesting that sample preparation and analysis also have an effect on
the nature of protein unfolding.
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Figure 2.22: SUPREX curves for HHM and free energy vs. denaturant concentration plots. (a)
Incubation times of 10 (black), 60 (red), 120 (blue) and 180 min (magenta). Error bars represent
standard deviation of 2 runs. (b) Free energy vs. denaturant concentration plot for HHM. Error bars
represent C
1/2
SUPREX error due to least-square analysis.
Table 2.5: Horse heart myoglobin SUPREX re-














a visualised in Fig. 2.22 and Appendix 9.16.
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3 SUPREX and PLIMSTEX of the Immunophilins
In this Chapter the HPLC front ends developed for high throughput ESI-PLIMSTEX
and SUPREX are tested with enzymes of the PPIase protein family. CypA and
FKBP12 were investigated with potentially binding ligands (Section 2.3.2) and com-
pared to data derived from other techniques.
3.1 Introduction
Mass spectrometry screening applications play an important role in drug discovery
and multiple methodologies have been elaborated to reflect gas phase behaviour of
protein-ligand systems via DI-ESI [265, 266, 267, 19]. In contrast, PLIMSTEX and
SUPREX have the potential to deliver solution phase information based on HDX
reverse phase LC-MS with ESI-MS or MALDI-MS. In the last six years several
enzyme-substrate systems have been investigated, including CypA/CsA as illus-
trated in Table 3.1.
Since Gross et al. established PLIMSTEX in 2003 [1] five enzyme/substrate
systems have been investigated as visualised in Table 3.1. Those PLIMSTEX deter-
mined Ka’s and Kd’s are within a factor of two for reported proteins-ligand systems.
Fitzgerald and co-workers utilised MALDI-SUPREX in 2004 [268] to determine
free energies of protein folding and dissociation constants of CsA with purified CypA
and CypA extracted from lung tumor tissue. ∆∆Gf values of -19.66 ± 3.35 kJ/mol
and Kd’s of 77 ± 17 nM and -17.57 ± 4.2 kJ/mol and 32 ± 20 nM have been de-
termined for the purified and extracted CypA, respectively. Reported dissociation
constants are in the range of Kd’s determined with other techniques (Table 3.2). In
2008 SPROX (Section 1.6.3) was utilised to investigate CypA/CsA resulting in a Kd
of 86 nM [269]. Single point MALDI-SUPREX screening of a 880 member library
of potential CypA binding ligands did not detect any new ligands, however, CsA
could be identified as a positive hit at a throughput of 3 min per ligand [245].
Exchange rates for aa-residues in CypA have been measured by NMR and cal-
culated by Shi and co-workers [270], resulting in three different classes of exchange
speed, exhibiting fast, moderate and slow exchange. The CypA/CsA system was
investigated to further characterise newly synthesised PPIase ligands (Section 2.3.2)
with the new devised LC-ESI-SUPREX setup in a high-throughput fashion to gain
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solution phase binding data. After in silico screening approaches Walkinshaw et
al. discovered dimedone analogues to bind to CypA [141]. Synthesised compounds
showed Kd’s between 11.2-170 µM with KM184 being the most potent candidate
(Table 3.2). Table 3.2 provides an overview of PPIase ligand dissociation constants,
for ligands investigated in this thesis, derived with different techniques (Section
1.2.6). DI-ESI-MS data was acquired with automated MS equipment utilising ESI
and nano-ESI (NanoMateTM) MS techniques by Florance [19] (Table 3.2). It is note-
worthy, that dimedone analogue ES1234 is referred to as compound 5 in [141] and
KM5 in [19].
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Table 3.1: Proteins investigated with different mass spectrometry solution phase HDX methods.
Protein Method Year Reference
PLIMSTEX
intestinal fatty acid binding protein (IFABP), ESI 2003 [1]
Ras-GDPa , calomdulin (CaM)
CaM ESI 2003 [231]
IFABP, CaM ESI 2003 [230]
recombinant human insulin (rh-insulin) ESI 2004 [229]
human telomeric binding factor 2 (hTRF2) ESI 2008 [271]
SIMSTEX
rh-insulin, insulin analogues ESI 2006 [232]
SUPREX
maltose binding protein, monomeric λ repressor MALDI 2000 [2]
ribonuclease A (RNaseA) - bovine pancreas MALDI 2001 [239]
monomeric λ repressor (in vivo) MALDI 2001 [240]
GCN4p1 dimer, coil-VaLd trimer, 4-OT hexamer, MALDI 2002 [241]
TrpR dimer, ArcR dimer, (DOA20)ArcR dimerb
protein G, S-protein, TrpR, MALDI 2002 [236]
abelson tyrosine kinase SH3 domain-S-Protein MALDI 2003 [237]
CopG, equine cytochrome C, β-lactoglobulin A, MALDI 2003 [247]
protein L, β-trypsin, ubiquitin, lysozymec
CopG, ArcR MALDI 2003 [242]
S-protein MALDI 2003 [244]
unpurified/purified cyclophilin A MALDI 2004 [268]
membrane bound lytic transglycosylase B (MltB) MALDI 2004 [272]
ferric binding protein (FbpA) MALDI 2004 [273]
ubiquitin MALDI 2005 [274]
molybdopterin (MPT) MALDI 2005 [275]
MltB MALDI 2006 [276]
α-lactalbumin, cytochrome C, IFABP, MALDI 2006 [262]
horse skeletal muscle myoglobin
ubiquitin MALDI 2006 [248]
protein kinase C Θ (PKCΘ) ESI 2006 [277]
sortase A (SrtA) MALDI 2007 [278]
CaM, BCAII, RmlB, Bcl-xL
d MALDI 2007 [279]
CaM, Fyn-constructe , human serum transferin MALDI 2007 [243]
CaM MALDI 2007 [238]
ferric binding protein (FbpA) MALDI 2008 [280, 281]
cyclophilin A (CypA) MALDI 2008 [245]
SPROX
ubiquitin, RNaseA, CypA, BCAII MALDI/ESI 2008 [269]
a Ras-GDP: GDP-bound human p21H−ras protein.
b with 4-OT: 4-oxolatocrotonate tautomerase, TrpR: Trp repressor, ArcR: Arc repressor and Arc
mutant DOA20.
c β-lactoglobulin A, β-trypsin and ubiquitin from bovine, hen egg lysozyme.
d BCAII: bovine carbonic anhydrase II, RmlB: d-TDP-D -glucose 4,6-dehydratase, Bcl-xL:
pro-apoptotic factor Bcl-xL.
e Fyn-construct: a linked SH3- and SH2-domain.
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3.1.1 The Dissociation Constant
The affinity constant Ka of an enzyme/substrate system measures the affinity, pro-
tein and ligand have to each other. It is usually determined by measuring the free
ligand concentration (e.g. equilibrium dialysis (Section 1.2.6)). According to the
law of mass action, assuming an equilibrated state, Ka will remain constant under




PL and; Ka =
[PL]
[P ] · [L]
(22)














If the free ligand concentration [L] is less than the Kd there is little association, as
binding conditions favor excess of ligand [235]. In contrast, if Kd and [L] are equal
half of the protein is complexed (eq. 23) [19].
3.2 Direct Infusion
Each freshly expressed CypA batch (Section 2.2.1) was tested for binding with a
freshly prepared CsA stock solution (Section 2.3.2) via DI-ESI (Section 2.3.4) under
native like conditions with a two fold excess of ligand at a total protein concentration
of ˜40 µM, acquired on a QTOF-Ultima. Figure 3.1a visualises the apo protein
spectrum for CypA showing a charge state distribution from 7+ to 24+, resulting
in a deconvoluted mass of 18144 Da, however, according to the CypA sequence
(Appendix 10.1) a theoretical mass of 18012 Da should be expected. The mass
difference of 132 Da suggests an additional N-terminal methionine residue of CypA
attributable to the E. coli expression system. The mass spectrum of the CypA-CsA
complex (Fig. 3.1) demonstrates the same charge state distribution as the apo CypA
spectrum plus additional CypA-CsA complex peaks of charge states 7+, 8+ and 9+.
Deconvolution results in a mass of 19346 Da for the complex, which agrees well as
the sum of individual CypA and CsA. Unbound CsA is present in a 2+ charge state
at a m/z value of 601. DI-ESI-MS findings for CypA-CsA emphasise the strong



































Table 3.2: Comparison of dissociation constants of the investigated immunophilins with different biophysical and biological methods.












CsA Fig. 1.10 1202.61 38.5 ± 10.4 nMa 26 ± 9 nM b 11.4 ± 3.9 nMc 6.3 ± 3.8 nMb











412.5 189 ± 43 µMe 36 µMb 12.2 ± 9.2 µMb 190 ± 60 µMf







O 373.44 271.97 µMe ˜50 µMf 19.5 ± 5 µMf 27.3 ± 9.2 µMf
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Figure 3.1: Direct infusion spectrum CypA-CsA. (a) CypA sprayed under native like conditions from 10
mM NH4OAc exhibiting charge states from 7+ to 24+. (b) CypA-CsA complex spectrum under native
like conditions from 10 mM NH4OAc with uncomplexed CypA (black squares), CypA-CsA complex
peaks at charge states 7+, 8+ and 9+ (black filled circle) and excess ligand at charge state 2+ (black
circles).
Before PLIMSTEX and SUPREX experiments with potential immunophilin lig-
ands KM184 and ES1234 were conducted, DI-ESI-MS studies were employed for
compound characterisation. The KM184 ligand was sprayed from pure methanol
containing 5 % FA, resulting in singly charged analyte ions with a deconvoluted
mass of 413 Da, showing good agreement with the theoretical mass of 412.5 Da
(Fig. 3.2a). CypA-KM184 complex was investigated under native like conditions
displaying free protein signals at charge state 8+ and 2269.9 m/z, complexed KM184
at 2321.7 m/z and charge state 8+ and CypA complexed with a KM184 fragment
at m/z of 2306.5 and charge state 8+ (Fig. 3.2b). Masses are calculated to 18151.7,
18444.0 and 18565.7 Da for apo and complexed CypA, verifying the correct mass of
CypA-KM184 at m/z 2321.7 and yielding a fragment mass of 292.3 Da. Fragmen-
tation/degradation can either occur by cleavage by CypA or degradation caused by
storage at 4 ◦C, the latter being the most likely explanation. The fact the degrada-
tion product does not appear in the DI-ESI-MS spectrum of the ligand (Fig. 3.2a),
suggests poor ionisation properties of the fragment.
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Figure 3.2: DI-ESI spectrum of CypA-KM184. (a) KM184 sprayed from pure methanol containing
5 % FA with a mass of 412.5 Da. (b) CypA-KM184 complex (red) and CypA-KM184-fragment complex
(black) sprayed under native like conditions from 10 mM NH4OAc.
DI-ESI-MS for ES1234 sprayed from pure methanol containing 5 % FA reveals
singly charged ligand containing one sodium ion at m/z 395.7 (Fig. 3.3a). Two
singly charged fragmentation/degradation products of ES1234 are identified at m/z
287.7 and 230.8 showing binding to CypA at m/z 2306.51 and 2299.00 in Figure 3.3b.
Florance and Yang et al. [19, 141] confirmed a CypA-ES1234 interaction with Kd’s
between 19 and 272 µM utilising DI-ESI-MS, SPR and fluorescence methodologies
(Table 3.2).
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Figure 3.3: DI-ESI spectrum of CypA-ES1234. (a) ES1234 sprayed from pure methanol containing 5
% FA with a mass of 373.44 Da. Peak at 396.44 m/z corresponds to charge state 1+ of ES1234 with
one sodium ion. Ligand fragments/degradation products F2/F1 at 233.73 and 292.45 m/z shown in
red and blue, respectively. (b) CypA complexed with ES1234 fragments F2 (233.73 Da) and F1 (292.45
Da) sprayed under native like conditions from 10 mM NH4OAc.
Rapamycin was sprayed from pure methanol containing 5 % FA exhibiting a
series of species at the 2+ charge state comprising free ligand (460.5 m/z ), ligand
plus one sodium (469.7 m/z ) and ligand with two sodium ions (476.4 m/z ; Fig. 3.4).
Singly charged rapamycin containing one sodium atom at an m/z value of 913.19
shows good agreement with the expected theoretical average mass of 914.17 (Table
3.2). A native like spectrum of the FKBP-rapamycin complex comprises charge
state distributions for free and complexed protein ranging from 7+ to 21+ and 7+
to 10+, respectively. Deconvolution yields masses for apo FKBP12 of 13275.05 Da
and FKBP12-rapamycin 14190.38 Da resulting in a mass of 915.33 Da for rapamycin,
exhibiting good agreement with the free ligand studies (Fig. 3.4).
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Figure 3.4: DI-ESI spectrum of FKBP12-rapamycin. (a) Rapamycin sprayed from pure methanol
containing 5 % FA with a mass of 914.17 Da. Peak at 936 m/z corresponds to charge state 1+ of
rapamycin with one sodium ion. Charge state 2+ for rapamycin comprising 0, 1 and 2 sodium ions
shown in blue, red and green respectively. (b) Two overlaid spectra of apo FKBP12 (black squares) and
FKBP12-rapamycin complex (red circles) with uncomplexed rapamycin (blue triangle) sprayed under
native like conditions from 10 mM NH4OAc.
3.3 Labeling Experiments
Protein-ligand systems investigated were subjected to HDX labeling experiments to
ascertain amide HDX properties. Samples were prepared as described in Section
2.3.5 at a final enzyme concentration of 5 µM in conjunction with the automated
SUPREX setup (Section 2.7.3).
According to the sequence of CypA (Appendix 10.1) the total number of hydrogens
within the protein are 1245 considering one additional methionine, comprising 125
T1, 160 T2 and 952 T3 hydrogen atoms. In Figure 3.5 apo CypA exhibits the lowest
exchange rate and deuterium level, with about 275 min to reach a HDX equilibrium
at ˜43 T2 hydrogens. These 43 T2 protons represent 27 % of all available backbone
amide protons remaining after back exchange and protection, enabling qualitative
comparisons to ligand exposed CypA.
As all immunophilin ligands were dissolved in 36.88 % MeOH/water, which was
the lowest methanol concentration still guaranteeing complete solvation of the com-
pound, the final MeOH ratio for protein-ligand incubation was 18 % and for the
protein-ligand complex in the deuterated buffer 2.3 %. The curve representing CypA
in a total methanol ratio of 2.3 % MeOH exhibits the highest exchange rate and deu-
terium level, reaching HDX equilibrium after 451 min. This indicates partial alcohol
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denaturation of CypA in the presence of methanol. All investigated CypA-ligand
complexes display lower exchange rates and deuterium levels, due to interaction with
CypA. Surprisingly ES1234 demonstrates the lowest exchange rate and deuterium
level of the three ligands, however close to CsA, displaying a HDX equilibrium after
395 min. This indicates a strong interaction with CypA similar to CsA with a Kd of
30-300 nM. Deuterium levels of CypA-CsA reach HDX equilibrium after 457 min.
KM184 exhibits an exchange rate and deuterium level close to apo CypA in 2.3 %
MeOH, suggesting a weaker interaction compared to CsA and ES1234 with CypA.
HDX equilibrium is reached after approximately 457 min.














Figure 3.5: Automated CypA HDX labeling. Deuterium uptake versus time for apo CypA (black
squares), apo CypA in 2.3 % MeOH (red squares), CypA-CsA in 2.3 % MeOH (blue triangle), CypA-
ES1234 in 2.3 % MeOH (green diamond) and CypA-KM184 in 2.3 % MeOH (magenta star).
To get an idea about exchange rates and deuterium levels in the presence of the
chemical denaturant guanidinium hydrochloride, mass increase over time of CypA
complexed with ES1234 at one molar GDH was measured. Figure 3.6 illustrates the
HDX profile of CypA-ES1234 at 1 M GDH. The exchange rate and deuterium level
is almost twice as much as for the apo enzyme. In comparison with CypA-ES1234
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without GDH present, the deuterium level is already higher after 28 min, indicating
denaturation.















 t / s
Figure 3.6: Automated CypA HDX labeling. Deuterium uptake versus time for apo CypA (black
squares), apo CypA in 2.3 % MeOH (red squares), CypA-CsA in 2.3 % MeOH (blue triangle), CypA-
ES1234 in 2.3 % MeOH (green diamond), CypA-KM184 in 2.3 % MeOH (magenta star) and CypA-
ES1234 in 2.3 % MeOH in 1 M GDH (orange triangle).
3.4 PLIMSTEX - Manual
Manually executed PLIMSTEX experiments employed the devised manual HPLC
front end (Section 2.6.3) in conjunction with the Platform II MS. Sample prepara-
tion and procedure was undertaken as described in Section 2.6.1 and 2.6.3.
Back exchange and washing time optimisation (Section 2.6.3) resulted in a load-
ing/washing time of 6-9 minutes, with the latter taken for all manual immunophilin-
ligand PLIMSTEX experiments to guarantee the best possible accuracy.
Apo CypA subjected to the PLIMSTEX procedure shows a ∆mfree value of 37.32± 0.33 Da resulting in a mass of 18181 Da for deuterated CypA without any ligand
present. Titrating the ligand to the enzyme up to a 20-fold excess of ligand induces
a conformational change or a change in stability of the protein and therefore shows
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a decrease in deuterium uptake or an increase in protection due to the presence of
the ligand. Employing the PLIMSTEX fitting procedure (Section 2.6.5, Appendix
9.8) values for ∆mcomplex and ∆ms are determined to 29.69 ± 0.25 Da and 7.60 Da,
resulting in a Ka of 3.12 · 10
6 ± 1.24 · 106 M−1 and a Kd of 321 ± 128 nM (Fig.
3.7).














Figure 3.7: Manual CypA-CsA PLIMSTEX data, with ∆mfree 37.32 ± 0.33 Da, ∆mcomplex 29.69± 0.25 Da, ∆ms 7.60 Da, Ka 3.12 · 106 ± 1.24 · 106 M−1 and a Kd of 321 ± 128 nM. Error bars
represent standard deviation from five independent experiments.
Under identical conditions the KM184 ligand was titrated to CypA resulting in
∆mfree value of 33.35 ± 0.08 Da, ∆mcomplex 31.54 ± 0.06 and ∆ms 1.81 Da, resulting
in a Ka value of 8.20 · 10
6 ± 4.84 · 106 M−1 and a Kd of 121 ± 71 nM (Fig. 3.8).
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Figure 3.8: Manual CypA-KM184 PLIMSTEX data, with ∆mfree 33.35 ± 0.08 Da, ∆mcomplex 31.54± 0.06 Da, ∆ms 1.81 Da, Ka 8.20 · 106 ± 4.84 · 106 M−1 and a Kd of 121 ± 71 nM. Error bars
represent standard deviation from four independent experiments.
FKBP12-rapamycin PLIMSTEX experiments yield a deuterated mass of 13311.74
Da resulting in a ∆mfree value of 35.05 ± 0.08 Da. ∆mcomplex and ∆ms values are
determined to 28.00 ± 0.05 Da and 7.05 Da culminating in Ka/Kd value of 4.89 ·
1010 ± 4.83 · 106 M−1 and 0.02 nM, respectively (Fig. 3.9).
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Figure 3.9: Manual FKBP12-Rapamycin PLIMSTEX data, with ∆mfree 35.05 ± 0.08 Da, ∆mcomplex
28.00 ± 0.05 Da, ∆ms 7.05 Da, Ka 4.89 · 1010 ± 4.83 · 106 M−1 and a Kd of 0.02 nM. Error bars
represent standard deviation from five independent experiments.
The PLIMSTEX Kd value of 321 nM for CypA-CsA is within one order of magni-
tude to values reported in the literature (Table 3.2). For KM184 the PLIMSTEX
curve (Fig. 3.8) shows a steeper decrease of the deuterium level of CypA suggesting
a ’stronger’ interaction compared to CsA, which is reflected by the Kd of 121 nM
being within two orders of magnitude from values previously reported (Table 3.2).
However, a ∆ms of 1.8 Da indicates no increased protection upon ligand presence
and with values being within the margin of experimental error no quantitative in-
formation can be gained. Data for FKBP12-rapamycin indicates an even ’stronger’
interaction as CypA-CsA as the PLIMSTEX curve shows a very rapid decrease of
the deuterium level, which is not well represented by the PLIMSTEX fitting proce-
dure (Fig. 3.9). Nevertheless, a calculated Kd of 0.02, which is within two orders
magnitude from Kd’s reported previously (Table 3.2), emphasises the strong inter-
action.
Manually timed and executed PLIMSTEX experiments yield a throughput ef-
ficiency of ˜20 min per experiment after a particular incubation time, which was
determined to 80 min with regards to showing different deuterium levels for apo
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and holo protein, after 20 min incubation of protein and ligand, resulting in a total
number of ˜14 experiments per day.
As PLIMSTEX relies on conformational changes or a stability change of the pro-
tein in presence of the ligand, this change has to be reflected by amide protection,
otherwise PLIMSTEX would not be applicable. On that account knowledge of the
enzyme-substrate system in question is vital for PLIMSTEX data extraction, as a
priori screening of unknown protein-ligand systems does not yield any useful data.
The success of the method, furthermore, depends on the degree of amide protection
due to the presence of the ligand, id est the larger the protection the more reli-
able data can be extracted. Systems investigated by Gross et al. (Table 3.1) showed
∆ms values between 12 and 30 Da. Per contra, the investigated immunophilin-ligand
systems showed ∆ms values between 1.8 and 7.6 Da complicating data analysis, es-
pecially for the CypA-KM184 system with ∆ms being 1.81, which is clearly within
the error margin of the experiment (Fig. 3.8).
Nevertheless, if some knowledge of the system of interest is present, PLIMSTEX
might deliver qualitative information comparing different ligands, provided suffi-
cient protection due to the presence of the ligand occurs.
3.5 PLIMSTEX - Automated
3.5.1 Bulk Incubation
Increased throughput potential was achieved with the developed HPLC-front end
(Section 2.6.4). To get a first impression about applicability of the automated ap-
proach, PLIMSTEX was performed after bulk incubation of the protein with lig-
and in the PLIMSTEX buffer. Deviating from the standard PLIMSTEX sample
preparation protocol (Section 2.6.1), n+1 sets of PLIMSTEX samples for n sets of
experiments were prepared in one sample vial and incubated for two hours to reach
near steady state HDX equilibrium (Section 3.3) and subjected analysis. One set
of samples describes 11 different ligand-protein ratios (0-20). Thereby one set of
samples was investigated from low to high ligand-protein rations and vice versa, be-
fore analysing the next set of identical samples. This approach resulted in different
incubation times over a 24 h period, however, improved the throughput by a factor
of three from 14 experiments per day to 44.
CypA-CsA PLIMSTEX data acquired with this approach does not exhibit the ex-
pected trend as with increasing ligand concentration the protection of amide hydro-
gen atoms decreases. In theory a PLIMSTEX curve occurs for each set of samples
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with only slight differences in ∆m due to not reaching steady state conditions. Ac-
quired data, however, shows decreased protection with an increasing CsA ratio,
indicating denaturation of CypA by CsA over time, as samples were prepared at a
time t0 and from then on further incubated until analysis (Fig. 3.10a). The effect of
not reaching exact steady state HDX conditions is acceptable within ± 5 Da (Fig.
3.10a), which agrees well with the HDX labeling experiments conducted on CypA-
CsA (Section 3.3). This effect was partially counteracted by reversing the order of
sample analysis from high to low substrate-enzyme ratios (Fig. 3.10b). A different
batch of CypA and freshly prepared CsA stock solutions still resulted in the same
findings (Fig. 3.10c, d).
































































Figure 3.10: Automated PLIMSTEX CypA-CsA bulk incubation. (a) Data acquired from low to high
ligand/protein ratios. (b) Data acquired from high to low ligand/protein ratios. (c) Data acquired from
low to high ligand/protein ratios using fresh protein and ligand stocks. (d) Data acquired from high to
low ligand/protein ratios using fresh protein and ligand stocks. Error bars represent standard deviation
of three independent (a, c) and four independent experiments (b, d).
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For FKBP12 and rapamycin the same automated experiment was conducted, cul-
minating in controversial PLIMSTEX data.
As Figure 3.11 illustrates, the protection of amide protons increases with increasing
ligand-protein ratios, not considering 0 and 0.5 ratios. Fitting PLIMSTEX data,
neglecting FKBP12-rapamycin ratios 0, 0.5 and 7, a Kd value of 74.77 ± 7.85 nM
is calculated, with ∆mfree 79.73 ± 2.07, ∆mcomplex 35.59 ± 0.05 and Ka 1.34 · 107± 0.14 · 107 M−1. The Kd is within one order of magnitude to values previously
reported (Table 3.2) and within three orders of magnitude to manually determined
PLIMSTEX Kd. Presented data represents averaged data of two individual sets of
experiments each executed from low to high ligand-protein ratio and vice versa with
standard deviation as error bars.
On the contrary FKBP12-rapamycin data exhibits the same trend as CypA-CsA
data and only the larger ∆ms value of ˜8 Da facilitates the PLIMSTEX fit.
The automated PLIMSTEX approach with bulk incubation of CypA, CsA and
PLIMSTEX buffer demonstrates the denaturing capabilities of CsA impeding Kd
calculations. For the FKBP12-rapamycin system a dissociation constant of 74.77± 7.85 nM is calculated, in contrast to the manually determined PLIMSTEX Kd of
0.02 nM.
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Figure 3.11: Automated FKBP12-rapamycin PLIMSTEX data. Error bars represent standard deviation
from four independent experiments. Ligand/protein rations 0, 0.5 and 6 are not included in data fitting.
3.5.2 Individual Incubation
For the CypA-CsA system individually executed automated PLIMSTEX experi-
ments were performed according to the PLIMSTEX protocol in Section 2.6.1 guar-
anteeing constant protein-ligand incubation times (20 min) and HDX PLIMSTEX
buffer incubation (80 min) to circumvent denaturing issues with CsA and guarantee-
ing equal non-steady state conditions. Four independent sets of runs were performed
and analysed. Figure 3.12 visualises individual PLIMSTEX data. Curve fitting re-
sults in values for ∆mfree of 52.11 ± 0.32 Da, ∆mcomplex of 47.43 ± 0.08 Da, ∆ms
of 4.63 Da, Ka 1.27 · 10
6 ± 0.26 · 106 M−1 and a Kd of 789.4 ± 164.2 nM, whereby
ligand-protein ratios 10 and 20 are neglected, 6, 12 and 17 are accounted for 80
% and 0 is weighted for 5 %. The dissociation constant of 789.4 nM is within the
same order of magnitude as the manually determined PLIMSTEX Kd and within
one order of magnitude to values reported previously (Table 3.2), however, it is
questionable as the ∆ms of 4.63 Da is within the margin of the experimental error
(Fig. 3.12).
By executing each PLIMSTEX experiment individually, throughput decreases to 12
samples in a 24 h period due to software restrictions in the utilised HPLC control
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software, disabling usage of system idle time during HDX incubation periods. Never-
theless, automated sample handling and timing should eliminate manually executed
and timed errors.
















Figure 3.12: Single automated CypA-CsA PLIMSTEX data. Error bars represent standard deviation
from four independent experiments. Ligand/protein rations 10 and 20 are not included in data fitting.
Ratios 6, 12 and 17 are subjected a weighted fitting procedure and are accounted for 80 %. The starting
ratio 0 is weighted to gain ∆mfree of 52 Da, resulting in a 5 % weighting.
3.6 Cyclophilin A Manual SUPREX
Data in this Section (3.6) was acquired by L. Baillie in fulfilment with her masters
degree at the University of Edinburgh and is reproduced with her kind permission.
The developed manual HPLC front end (Section 2.6.3) was utilised in conjunc-
tion with the manual SUPREX procedure (Section 2.7.1). The intrinsic exchange
rate 〈kint〉 was calculated to be 5.59 s
−1 at 22 ◦C (Section 2.7.5). Sample concen-
trations throughout were 2 µM for CypA and 4 µM for CsA and ES1234 and GDH
was used a denaturant.
SUPREX C1/2 values are determined to be 2.20, 1.94, 1.51 and 1.50 M (Table
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3.3 and Section 2.7.5) for apo CypA resulting in a ∆Gf value of -28.91 kJmol
−1
and an m-value of 2.43 kJmol−1M−1 (Fig. 3.13a, d). For the CypA-CsA complex
midpoints of the SUPREX curve are at 2.76, 2.42, 1.75 and 1.92 M (Table 3.3) with
an associated ∆Gf value of -30.84 kJmol
−1 and a stabilisation of -1.92 kJmol−1 with
a m value of 2.72 kJmol−1M−1, ultimately resulting in a Kd of 3.3 µM (Fig. 3.13b,
d). The inflexion points of the CypA-ES1234 SUPREX curves are determined to
be 2.42, 2.50, 1.50 and 1.99 M (Table 3.3), impeding calculation of thermodynamic
properties (Fig. 3.13d). Manual SUPREX CypA data is visualised in Table 3.3 and
all SUPREX curves at different incubation times are displayed in Appendix 10.3.
SUPREX buffer conditions were chosen to favor EX2 exchange behaviour and
two state unfolding behaviour was assumed, as no intermediate species was detected
with the instrumentation used. As Figure 3.13 illustrates cyclophilin A is stabilised
by the presence of cyclosporin A. For 10, 40 and 60 min incubation C
1/2
SUPREX values
are shifted by 0.56, 0.48 and 0.42 M to higher denaturant concentrations. The pre-
transition baseline for the 10 and 40 min incubation of CypA complexed with CsA is
lower compared to the free protein indicating increased protection of backbone pro-
tons in the complex. In contrast, for the 60 min incubation the pretransition baseline
is higher as in the free protein, suggesting denaturation of CypA by CsA over time
as concluded in the HDX labeling- (Section 3.3) and bulk incubated PLIMSTEX
experiment (Section 3.5.1). Also the decreasing stabilisation over time corroborates
this finding.
The calculated Kd of 3.3 µM is within two orders of magnitudes of values presented
earlier (Table 3.2) and within one order of magnitude to manual and automated
PLIMSTEX results implying that PLIMSTEX better represents protein-ligand prop-
erties. SUPREX offers more potential for accuracy, as the change in mass measured
upon denaturation is much bigger than ∆ms upon protection/shielding in a PLIM-
STEX experiment. The four SUPREX data points for all CypA-ligand complexes
are not well represented by the linear curve fit (Fig. 3.13), therefore more data
points should be acquired to get more precise thermodynamic data of CypA and its
ligands, as the automated SUPREX approach will provide (Section 3.7).
CypA in complex with ES1234 exhibits a slightly weaker stabilisation by 0.22, 0.56
and 0 M for the incubation times 10, 40 and 60 min (Table 3.3). The pre-transition
baseline is lower for the 10 min incubation time and the same for 40 and 60 min,
suggesting a less denaturating effect on CypA compared to CsA. The four acquired
C
1/2
SUPREX values were not subjected to a linear fitting routine as results would have
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been questionable.
Manually timed and executed SUPREX experiments demonstrate similar through-
put rates as manual PLIMSTEX experiments with ˜14 runs per day.














































































Figure 3.13: Manual CypA-CsA SUPREX data.(a) Apo CypA incubation at 10 (black), 40 (red) and
60 min (blue) with C
1/2
SUPREX values of 2.20, 1.94 and 1.51 M. (b) CypA-CsA SUPREX incubation at
10 (black), 40 (red) and 60 min (blue) with C
1/2
SUPREX values of 2.76, 2.42 and 1.75 M. (c) CypA-
ES1234 with 10 (black), 60 (blue) and 120 min (green) incubation with C
1/2
SUPREX values of 2.42,
2.50 and 1.75 M. (d) Free energy vs. denaturant concentration plot for CypA (red) CypA-CsA (black)
and CypA-ES1234 (blue), resulting in ∆Gf values of -28.91 and -30.84 kJmol
−1 and m values of 2.43
and 2.72 kJmol−1M−1 for apo CypA and CypA-CsA, respectively. ∆∆Gf for the CypA-CsA complex
is -1.92 kJmol−1, resulting in a Kd of 3.3 µM. All error bars represent standard deviation of 2 runs.
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Table 3.3: Manual CypA SUPREX results.





10 2.20 2.76 2.42
40 1.94 2.42 2.50
60 1.51 1.75 1.50
120 1.50 1.92 1.99
∆Gf/kJmol
−1 -28.91 -30.84 N/A
∆∆Gf/kJmol
−1 -1.92 N/A
m/kJmol−1M−1 2.43 2.72 N/A
Kd/µM 3.3 N/A
a visualised in Fig. 3.13 and Appendix 10.3, 10.4 and 10.5.
3.7 SUPREX - Automated
After the automated method for ESI-SUPREX was devised (Section 2.7.3) and
exchange- and back exchange behaviour was optimised with HHM (Section 2.7.6),
CypA was further investigated with potential binding ligands. An automated SUPREX
approach with self created/timed sample lists doubled the throughput to 33 apo and
21 holo samples in a 24 h period.
3.7.1 Apo Cyclophilin A
Apo CypA was subjected the automated SUPREX methodology (Section 2.7.3) and
C
1/2
SUPREX values for incubation times 10, 15, 30, 45, 60, 90, 120, 150, 180 and 420 min
are determined (Table 3.4). Figure 3.14a illustrates 10 and 60 min incubation and
the induced shift to lower denaturation concentrations at increased exposure. The
complete set of SUPREX curves is displayed in Appendix 10.6. The deuterium level
pre-transition is ˜25 Da and post-transition ˜55 Da, resulting in a 30 Da increase
in mass upon denaturation. Due to different flow rate settings and washing times,
deuterium levels are lower in the automated approach, compared to the manual
approach (Section 3.6), however, the deuterium uptake upon deuteration is similar,
indicating identical pre- and post-transition CypA species. Plotting C
1/2
SUPREX vs.
∆Gf with 〈kint〉 being 5.59 s
−1 at 22 ◦C, for all further CypA SUPREX experiments,
results in a free energy of protein folding of -32.43 ± 1.88 kJmol−1 (Fig. 3.14b). The
abscissa related errors in Figure 3.14b represent the standard error associated with
the non-linear curve fitting procedure of C
1/2
SUPREX values, whereas the ∆Gf associ-
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ated error reflects the standard error of the linear fit. The m value is calculated to
12.38 ± 3.01 kJmol−1M−1.
In comparison ESI-SUPREX ∆Gf values are within those obtained by MALDI-
SUPREX and SPROX by Fitzgerald et al. for purified apo CypA -47.28 ± 2.93
kJmol−1 and unpurified apo CypA -39.33 ± 0.84 kJmol−1 [268] and -19.25 ± 1.67
kJmol−1 [269] for apo CypA. Differences in ∆Gf values might be the result of com-
paring different protein species in different environments, as purified and unpurified
CypA samples show ∆Gf differences of 7.95 kJmol
−1, mainly attributed to the pro-
tein mix of the unpurified sample. Different buffer conditions also affect relative
protein stability and in this thesis solely 10 mM NH4OAc was utilised, however,
Fitzgerald and co-workers solely employed 20 mM sodium phosphate. SUPREX de-
rived ∆Gf and m values are not meaningful in themselves, however, relative changes
in ∆Gf are used to calculate comparative dissociation constants.
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Figure 3.14: Automated apo CypA SUPREX data. (a) SUPREX curves at 10 and 60 min incubation
with C
1/2
SUPREX values 1.00 and 0.55 M respectively. Error bars represent standard deviation from two
independent experiments. (b) Free energy of protein folding vs. C
1/2
SUPREX . ∆Gf is determined to
-32.43 ± 1.88 kJmol−1 and m to 12.38 ± 3.01 kJmol−1M−1. Error bars represent standard error from
fitting SUPREX curves.
3.7.2 Cyclophilin A-2.3 % MeOH
All immunophilin ligands were dissolved in 36.88 % methanol, resulting in a fi-
nal methanol ratio of 18 % for the enzyme-substrate incubation and 2.3 % for
the protein-ligand system in the HDX/SUPREX/PLIMSTEX-buffer. Therefore
thermodynamic properties of apo CypA were determined under these very con-
ditions. Methodology and sample preparation did not deviate from previous de-
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scriptions (Section 2.7.3), with 2.3 % MeOH/10 mM NH4OAc without any ligand.
All SUPREX curves for apo CypA in 2.3 % MeOH are illustrated in Appendix 10.7.
∆Gf values determined for apo CypA in the presence of 2.3 % MeOH indicate a
stabilisation as C
1/2
SUPREX values are shifted to higher denaturant concentrations by
0.27, 0.39, 0.34 and 0.34 M for incubation times 10, 30, 60 and 120 min, respectively
(Fig. 3.15a and Table 3.4). The pre-transition baseline illustrates an increased
deuterium level by about 10 Da for 30 min incubation, or a decreased protection of
amide protons suggesting alcohol denaturation of CypA in the presence of methanol.
HDX labeling experiments (Section 3.3) support this findings (Fig. 3.5). The post-
transition baseline also shows elevated deuterium levels for all incubation times but
10 min.
The free energy of protein folding is calculated to be -38.74 ± 5.06 kJmol−1 resulting
in a stabilisation of -6.32 ± 5.40 kJmol−1 and a m value of 14.14 ± 4.60 kJmol−1M−1.
The increased m value in the 2.3 % MeOH containing CypA apo sample compared
to the pure buffer indicates an increased surface exposure of the protein, further
confirming a more unfolded state of CypA with a different C
1/2
SUPREX value.
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Figure 3.15: Automated CypA-2.3 % MeOH SUPREX data. (a) SUPREX curves at 30 min incubation
for apo CypA (black) and CypA-2.3 % MeOH (green) with C
1/2
SUPREX values 0.63 and 1.03 M respec-
tively. Error bars represent standard deviation from two independent experiments. (b) Free energy of
protein folding vs. C
1/2
SUPREX . ∆Gf is determined to -32.43 ± 1.88 kJmol−1 and m to 12.38 ± 3.01
kJmol−1M−1 for apo CypA (black) and -38.74 ± 5.06 kJmol−1 and m to 14.14 ± 4.60 kJmol−1M−1
for CypA-2.3 % MeOH (green). Error bars represent standard error from fitting SUPREX curves.
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3.7.3 Cyclophilin A-Cyclosporin A
Thermodynamic parameters for CypA-CsA are determined according to Table 3.4
for incubation times from 10 to 420 min. SUPREX curves for 10 min incubation can
be found in Figure 3.16, whereas the complete set of curves is visualised in Appendix
10.8.
The free energy of protein folding is determined to be -44.48± 4.35 kJmol−1 resulting
in a stabilisation of -12.05 ± 4.73 kJmol−1, compared to apo CypA. Figure 3.16a
emphasises the strength of the CypA-CsA interaction as for the 10 min incubation
the stabilisation is 1.57 M (Table 3.4). Average shifts of C
1/2
SUPREX values are between
1.57 and 2.39 M. The m value is calculated to 7.11 ± 1.63 kJmol−1M−1, exhibiting
less surface exposure of CypA in complex with CsA during the unfolding process
compared to the free protein (Section 3.7.1). The dissociation constant is determined
to 596.7 ± 234.7 nM.
The deuterium level of the pre-transition baseline is similar for all CypA and CypA-
CsA curves, however, the post-transition baseline is slightly lower for the CypA-CsA
complex compared to the free protein, indicating a more compact structure of CypA
in the complex. The lower m value of 7.11 ± 1.63 kJmol−1M−1, compared to the
free CypA, further indicates less solvent exposure due to a more compact state.
The longest incubation time investigated is 180 min in the presence of CsA, beyond
that incubation time no CypA could be detected due to degradation.
The Kd of 596.7 ± 234.7 nM determined is within the same order of magnitude as
manual and automated PLIMSTEX experiments and shows better accuracy than
manual SUPREX (Section 3.6) as a comparison of Figure 3.13d and 3.16b illustrates.
Reported values for ∆Gf and ∆∆Gf by Fitzgerald and co-workers are -64.85 ± 2.93
and -58.99 ± 3.34 kJmol−1 and -17.57 ± 4.2 and -19.66 ± 3.35 kJmol−1, for purified
and unpurified CypA, respectively [268] and thereby 1.5 times larger than ESI-
SUPREX values. As different buffer conditions explain the discrepancy of absolute
∆Gf values, however, resulting ∆∆Gf values are within the error associated with the
SUPREX approach as emphasised by reported values and uncertainties culminating
in the differences in reported dissociation constants.
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Figure 3.16: Automated CypA-CsA SUPREX data. (a) SUPREX curves at 10 min incubation for apo
CypA (black) and CypA-CsA (red) with C
1/2
SUPREX values 1.00 and 2.57 M respectively. Error bars
represent standard deviation from two independent experiments. (b) Free energy of protein folding vs.
C
1/2
SUPREX . ∆Gf is determined to -32.43 ± 1.88 kJmol−1 and m to 12.38 ± 3.01 kJmol−1M−1 for
apo CypA and -44.48 ± 4.35 kJmol−1 and m to 7.11 ± 1.63 kJmol−1M−1 for CypA-CsA (red). Error
bars represent standard error from fitting SUPREX curves.
3.7.4 Cyclophilin A-KM184
Automated SUPREX curves for CypA-KM184 at 30 min incubation time are illus-
trated in Figure 3.17a, whereas the complete set of curves is illustrated in Appendix
10.9.
∆Gf is determined to -35.52 ± 1.46 kJmol−1 with a stabilisation of -3.10 ± 2.38
kJmol−1 compared to uncomplexed CypA (Fig. 3.17b). The m value is determined
to 10.25 ± 1.34 kJmol−1M−1, culminating in a Kd of 32.4 ± 24.9 µM. The C1/2SUPREX
values exhibit smaller shifts to higher denaturant concentrations, compared to free
CypA indicating a weaker interaction between CypA and KM184, relatively, in com-
parison with the CypA-CsA system (Table 3.4). This is assisted by the m value,
as this is smaller as for the uncomplexed protein, but higher as in the CypA-CsA
complex. The Kd of 32.4 ± 24.9 µM is within the margin of error of the SPR and
fluorescence determined Kd’s and within one order of magnitude to in vivo and DI-
ESI-MS values.
Deuterium levels of the pre-transition baseline demonstrate higher deuterium up-
take of the KM184 complexed CypA, suggesting a more unfolded conformation be-
fore denaturation. In contrast, the post-transition baseline reveals a more compact
conformation, as deuterium levels are lower than in the apo protein.
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Figure 3.17: Automated CypA-KM184 SUPREX data. (a) SUPREX curves at 30 min incubation for
apo CypA (black) and CypA-KM184 (magenta) with C
1/2
SUPREX values 0.63 and 1.18 M respectively.
Error bars represent standard deviation from two independent experiments. (b) Free energy of pro-
tein folding vs. C
1/2
SUPREX . ∆Gf is determined to -32.43 ± 1.88 kJmol−1 and m to 12.38 ± 3.01
kJmol−1M−1 for apo CypA (black) and -35.52 ± 1.46 kJmol−1 and m to 10.25 ± 1.34 kJmol−1M−1
for CypA-KM184 (magenta). Error bars represent standard error from fitting SUPREX curves.
3.7.5 Cyclophilin A-ES1234
SUPREX data for CypA in complex with ES1234 is shown for 30 min incubation in
Figure 3.18b, all other incubation times are displayed in Appendix 10.10.
Individually C
1/2
SUPREX values show stabilisation from 0.21 to 0.55 M to higher guani-
dinium hydrochloride concentrations over an incubation time from 10 to 90 min.
However, absolute changes of C
1/2
SUPREX are not as big as observed with other im-
munophilin ligands, resulting in little change of the C
1/2
SUPREX values over time. This
dramatically affects ∆Gf , calculated to be -47.86 ± 10.84 kJmol−1 and a resulting
stabilisation of -15.44 ± 11.00 kJmol−1. The calculated Kd of 149.9 ± 106.8 nM
is the lowest, determined for the immunophilin ligands and is even lower than the
CypA-CsA Kd, in contrast with biological assays and DI-ESI-MS (Table 3.4). Where
Kd’s between 19.5 and 270 µM have been reported, differing between two to three
orders of magnitude. Figure 3.18b shows the steepest slope for the ∆Gf -fit of the
investigated immunophilin ligands, resulting in a high m value of 22.51 ± 10.04
kJmol−1M−1, suggesting either higher exposure of CypA upon unfolding compared
to other CypA-ligands or non-two state unfolding of CypA in the presence of ES1234
or observed ligand fragments (Fig. 3.3).
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Deuterium levels of the pre-transition baseline are comparable with those of the un-
complexed cyclophilin, whereas the posttransition baseline shows similar levels up to
30 min incubation and then decreasing levels, similar to those of the CypA-CsA com-
plex. This phenomenon and the fact of lower ∆C
1/2
SUPREX compared to CsA, suggests
a non-two state unfolding behaviour of CypA in the presence of the ES1234 ligand.
Labeling experiments of CypA with the immunophilin ligands (Section 3.3) further
supports the findings as deuterium levels of CypA-ES1234 are lower, compared to
CypA-CsA which suggests less surface exposure prior to denaturation.
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Figure 3.18: Automated CypA-ES1234 SUPREX data. (a) SUPREX curves at 30 min incubation for
apo CypA (black) and CypA-ES1234 (blue) with C
1/2
SUPREX values 0.63 and 1.03 M respectively. Error
bars represent standard deviation from two independent experiments. (b) Free energy of protein folding
vs. C
1/2
SUPREX . ∆Gf is determined to -32.43 ± 1.88 kJmol−1 and m to 12.38 ± 3.01 kJmol−1M−1 for
apo CypA (black) and -47.86± 10.84 kJmol−1 and m to 22.51 ± 10.04 kJmol−1M−1 for CypA-ES1234
(magenta). Error bars represent standard error from fitting SUPREX curves.
3.8 Denaturant Effect on HD-Exchange Behavior
The SUPREX experiments conducted with CypA and ligands show a decrease in the
deuterium level at high concentrations with the chemical denaturant guanidinium
hydrochloride. Tanford et al. [64] proposed that interactions of the denaturant with
the protein are more favorable than interactions of the protein with water. There-
fore a decrease in HDX with increasing GDH concentration would agree with these
findings. Myers and co-workers demonstrated that GDH is twice as effective as urea
in denaturation experiments [66], therefore a denaturing experiment of CypA with


































Table 3.4: Automated CypA SUPREX results (values in brackets denote shift in C
1/2
SUPREX due to stabilisation compared to apo CypA).




10 1.00 1.27 (0.27) 2.57 (1.57) 1.32 (0.32) 1.21 (0.21)
15 0.68 2.39 (1.71) 1.31 (0.63) 1.06 (0.38)
30 0.63 1.02 (0.39) 3.02 (2.39) 1.17 (0.54) 1.03 (0.40)
45 0.54 2.68 (2.14) 1.16 (0.62) 1.09 (0.55)
60 0.55 0.89 (0.34) 2.64 (2.09) 1.04 (0.49) 1.03 (0.48) 2.64
90 0.48 1.01 (0.53) 1.03 (0.55)
120 0.60 0.94 (0.34) 2.53 (1.93) 0.78 (0.18)
150 0.51
180 0.44 2.39 (1.95) 0.70 (0.26)
420 0.62
∆Gf/kJmol
−1 -32.43 ± 1.88 -38.74 ± 5.06 -44.48 ± 4.35 -35.52 ± 1.46 -47.86 ± 10.84
∆∆Gf/kJmol
−1 -6.32 ± 5.40 -12.05 ± 4.73 -3.10 ± 2.38 -15.44 ± 11.00
m/kJmol−1M−1 12.38 ± 3.01 14.14 ± 4.60 7.11 ± 1.63 10.25 ± 1.34 22.51 ± 10.04
Kd 596.7 ± 234.7 nM 32.4 ± 24.9 µM 149.9 ± 106.8 nM
a visualised in Section 3.7.1 Fig. 3.14 and Appendix 10.6.
b visualised in Section 3.7.2 Fig. 3.15 and Appendix 10.7.
c visualised in Section 3.7.3 Fig. 3.16 and Appendix 10.8.
d visualised in Section 3.7.4 Fig. 3.17 and Appendix 10.9.
e visualised in Section 3.7.5 Fig. 3.18 and Appendix 10.10.
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The conducted SUPREX experiment with the automated setup (Section 2.7.3) of
apo CypA denatured with urea is visualised in Figure 3.19. Deuterium uptake vs.
denaturant concentration was measured for urea concentrations between 0 and 8 M
at a single incubation time of 60 min. Evaluation reveals a C
1/2
SUPREX value of 2.64
(Table 3.4), shifted by 2.09 M to higher denaturant concentrations compared to apo
CypA denaturation with GDH.
Interestingly, the deuterium level of the pre-transition baseline is slightly higher
in the urea denaturation with 33 Da, compared to 25 Da in the GDH SUPREX
experiment, resulting in a difference of ˜8 deuterons (Fig. 3.19), under identical
experimental conditions. The same trend is observed for the post-transition baseline,
being 55 Da for GDH- and 70 Da for urea-denaturation, culminating in a difference
of 15 Da. The change in protection upon unfolding is similar, with 30 Da and 35 Da
for GDH and urea, respectively, suggesting pre- and post-denatured CypA species
are identical in both denaturation experiments.
This comparison emphasises the higher denaturation efficiency of GDH over urea at
the expense of lower deuterium levels due to a stronger interaction of denaturant
molecules with the protein, reducing HDX rates and efficiency.
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Figure 3.19: Automated CypA SUPREX with urea. (a) SUPREX curve for 60 min incubation of
apo CypA with GDH denaturation. C
1/2
SUPREX is 0.55 M, error bars represent standard deviation from
two independent runs. (b) SUPREX curve for apo CypA urea denaturation at 60 min incubation with
C
1/2
SUPREX 2.89 M. Data represents a single experiment.
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3.9 Conclusion
In conclusion, apo masses for all the undeuterated immunophilin proteins used have
been determined as well as free ligand masses, showing good agreement with the-
oretical calculated average masses. DI-ESI-MS experiments confirm ligand binding
for cyclosporin A, KM184 and rapamycin as well as the activity of the self purified
cyclophilin A. Under the same conditions DI-data of cyclophilin with the ES1234
ligand does not exhibit any intact protein-ligand complex, rather CypA complexed
with fragments/degraded ligand with masses of 287.7 and 230.81 Da, respectively.
Intact ES1234 is observed sprayed from solely methanol containing 5 % FA identi-
fying the intact ligand as the major component in the sample. The reason for this
discrepancy is not clear.
Hydrogen deuterium labeling experiments emphasise the partially denaturating
effect of methanol present at final concentrations of 18 % for protein-ligand incu-
bation and 2.3 % for incubation with the deuterated buffer. Despite this, all im-
munophillin ligands investigated display more protection of amide protons compared
to the apo CypA sample in 2.3 % MeOH. Thereby CsA and ES1234 show similar ex-
change rates and ES1234 slightly lower deuterium levels, suggesting a similar, if not
stronger, binding potential to CypA. The investigation of KM184 exhibits a similar
exchange pattern as the apo CypA in 2.3 % MeOH, indicating a weaker interaction
compared to CsA and ES1234 upon fewer protection. Adding the chemical denat-
urant to the CypA-ES1234 complex reveals hydrogen deuterium exchange patterns
for the denaturation process, demonstrating an additional deuterium incorporation
or deprotection of 30-40 deuterium atoms.
Manually timed and executed PLIMSTEX experiments exhibit a qualitative na-
ture of acquired data, with Kd’s within one to two orders of magnitude of the values
previously reported. Important for reliable PLIMSTEX data is that investigated
protein-ligand systems show a sufficient degree of protection of amide protons in
the presence of the ligand. Unfortunately the immunophilins investigated show
little protection upon ligand binding complicating PLIMSTEX data analysis. Nev-
ertheless, with extensive knowledge of the enzyme-substrate system in question and
tedious setup optimisation a qualitative trend of relative ligand affinity is demon-
strated.
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The automated PLIMSTEX application with bulk incubation of CypA, CsA and
PLIMSTEX buffer does not provide reliable PLIMSTEX data on grounds of different
incubation times for each individual sample. Incubation at near steady state HDX
conditions exhibits accountable deviations in deuterium levels of the protein. Per
contra, the denaturing properties of CsA prohibit bulk incubation as steady state
HDX occurs within a couple of hours and the data acquired would represent a ques-
tionable native state of the protein. The low ∆ms value of CypA also contributes to
this finding, whereas a higher ∆ms value found for FKBP12-rapamycin culminates
in a determinable Kd. Bulk incubation shows three times higher throughput rates
compared to the manual approach and therefore would be favorable.
Individually incubated automated PLIMSTEX experiments circumvent non equi-
librium HDX states and denaturing issues at the expense of decreased throughput
rates. Denaturation of CypA by CsA still occurrs, however, it is put into perspec-
tive by identical incubation times. Throughput rates decreased to 12 samples in a
24 h period, however, guaranteeing constant sample handling and incubation times.
Once more, automated PLIMSTEX emphasises how little protection of the amide
protons is attributed to CypA upon ligand binding, resulting in a Kd in the same
order of magnitude as the manually determined, and within one order of magnitude
to values previously reported (Table 3.2).
Manual SUPREX results clearly indicate a stabilisation of CypA by binding to
CsA for all incubation times. However, relative stabilisation decreases from low to
high incubation times emphasising the denaturing character of CsA over time, as
bulk incubated PLIMSTEX experiments suggest. This is further supported by com-
paring the pretransition baseline of apo and CsA complexed CypA as protection of
backbone protons decreases over time, when CsA present. The calculated dissoci-
ation constant is within two order of magnitudes of data previously presented and
within one order of magnitude of PLIMSTEX Kd’s. SUPREX offers better poten-
tial for data accuracy as measured changes in mass are bigger upon unfolding as
protection upon complexation. Automation will increase throughput and accuracy
of determined dissociation constants as more data points become available.
Automated SUPREX for the CypA-CsA complex exhibits good data repro-
ducibility and accuracy within reported margins for SUPREX. However, different
CypA species show different thermodynamical properties, therefore recombinant
human cyclophilin A comprising an additional N-terminal methionine, complexed
3 SUPREX AND PLIMSTEX OF THE IMMUNOPHILINS 110
with CsA demonstrates good agreement with data previously reported. The pre-and
post-transition baselines and the C
1/2
SUPREX values of CypA incubated in 18/2.3 %
methanol reveal a denaturing and stabilising effect. The solely denaturating prop-
erties of CsA, determined in the manual SUPREX approach is not supported by
automated SUPREX data, as relative stabilisation and m values expose. In com-
plex with KM184, CypA displays binding properties very close to results determined
with biological and other biophysical assays. Contextualising ES1234-CypA results
would suggest a stronger interaction of CypA with ES1234 than CsA judged on the
differences of the free energy of protein folding, which is contrasted by the lower
absolute stabilisation of the individual SUPREX curves. This could also reveal a
non-two state unfolding behaviour for CypA in the presence of ES1234.
The automated ESI-SUPREX methodology developed demonstrates the capabil-
ity of Kd determination within a reasonable margin to previously reported values.
Deviations might indicate that basic SUPREX assumptions of two state unfolding
and EX2 HDX conditions are not fulfilled. Meeting this criteria is crucial to gain
useable data from SUPREX derived methods, making it a very system-dependent
method unable to deliver accurate binding data on a priori screening approaches
of unknown protein ligand systems. Nevertheless, with well investigated and well
behaved enzyme-substrate systems good quality data can be achieved.
In terms of throughput, the developed ESI-MS-SUPREX approach utilises 5.5 days
for a complete screen of the apo protein in question comprising ten duplicate runs,
each run comprising nine experiments and 8.5 days for the holo system. Increased
throughput can be achieved at the expense of accuracy by decreasing the number of
different incubation times down to a single point SUPREX experiment for screening
a ligand library as performed by Fitzgerald and co-workers.
A comparison of apo CypA denatured in a SUPREX experiment with guani-
dinium hydrochloride and urea reveals that decreasing post-transition deuterium
levels are specific to denaturation with GDH. Furthermore a higher denaturation
efficiency of GDH over urea at the expense of lower deuterium levels in general,
has been demonstrated. However, changes in protection upon unfolding are similar,
suggesting identical CypA species pre- and post-transition with both denaturants.
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4 SUPREX of AGr2 and FH19-20
4.1 Introduction
This chapter describes the use of automated SUPREX (Section 2.7.3) for screen-
ing the ’unknown’ protein-ligand systems AGr2 and FH19-20 and potential binding
ligands. Anterior gradient 2 from biological samples (as described in Section 1.4.3)
was positively identified by Myung et al. [285] in 2008 by MS analysis. Thereby
two dimensional gel electrophoresis, in gel digestion and MALDI analysis revealed
a 100 % sequence coverage.
In 2007 Hupp et al. [286] demonstrated the binding capabilities of a short hexa-
peptide PTTIYY to AGr2 utilising a microarray assay based on the usage of pep-
tide aptamers. Based on these findings, peptide variants were developed to probe
binding properties with AGr2. Peptides such as RRMKWKKSGSG-PTTIYY and
RRMKWKKSGSG-PTTIYY comprise a SGSG linker unit and a cell penetrating
part RRMKWKK for in vivo analysis (personal communication). The linker unit
and the cell penetrating component will be abbreviated as ’Pen’ coining the hendeca-
tagged hexa-peptides to PTTIYY-Pen and PATIAA-Pen. Figure 4.1 displays min-
imum energy structures of PTTIYY-Pen and PATIAA-Pen employing Gaussian 03
with a semi-empirical PM3 method and a 3-21g basis set6. Images emphasise the
steric demand of the cell penetrating part of the hendeca-tagged hexa-peptide.
Competition fluorescence anisotropy experiments with the tagged peptides un-
dertaken by Hupp and co-workers have revealed a dissociation constant of 25-40µM (unpublished data). The dissociation constant for the interaction of AGr2 with
PATIAA-Pen has not been determined and remains, as yet unknown.
In this chapter two different batches of AGr2 are discussed, only differing in the
way of purification by H. Florance and J. Nicholson and are referred to as Nicholson-
and Florance-batch. For purification purposes the AGr2 protein comprises a 27 aa
long His-tag containing six histidines, as visualised in Appendix 11.1.
6kindly conducted by Ms. I. Pechtl
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(a) RRMKWKWKKSGSG-PTTIYY (b) RRMKWKWKKSGSG-PATIAA
Figure 4.1: AGr2 binding hendeca-tagged hexa-peptides. (a) PTTIYY-Pen structure optimised with
Gaussian 03 employing a PM3 method and a 3-21g basis set. Displayed structure did not reach self
consistency. (b) PATIAA-Pen structure identically optimised (kindly conducted by Ms. I Pechtl; pdb
files visualised with pymol (DeLano Scientific LLC - Palo Alto, USA)).
As described in Section 1.4.4 the C-terminal pair of CCP’s (CCP 19-20) has been
shown to interact with polyanions such as heparin, heparan sulfate, dextran sulfate
and sialic acid [222]. Herbert et al. determined a dissociation constant of 9.0 ± 2.5µM for heparin and fH19-20 employing two dimensional NMR titration techniques
[287]. Furthermore no aggregation of fH19-20 was observed in the presence of the
tetrasaccharide which suggests a specific and localised interaction, which causes lit-
tle, if any changes to the structure of the protein.
Ferreira et al. investigated the binding properties of wild type fH19-20 and sequence
variants with respect to C3b and polyanion binding via heparin affinity chromatog-
raphy and gel-mobility shift assays to conclude an increased binding potential of
mutated fH19-20 variants exhibiting a gain of positive charges [227].
Based on the finding that fH19-20 exhibited a Kd of 9.0 ± 2.5 µM with heparin,
the target was to investigate the binding properties of fH19-20 with the pentasac-
charide fondaparinux (FPX, Fig. 4.2), as no binding properties of this system have
been reported yet. Within this Chapter possible binding interactions of the fH19-
20-FPX system will be investigated with the manual- and automated ESI-SUPREX
methodology.






























Figure 4.2: Structure of the pentasaccharide, fondaparinux, as the deca-sodium salt (visualised with
ChemDraw - CambridgeSoft - Cambridge, USA).
4.2 Direct Infusion
Nano-ESI direct infusion experiments were conducted in positive ion mode to verify
protein and ligand masses before automated ESI-SUPREX was employed.
Each batch of AGr2 was sprayed under denaturing conditions comprising 5 % FA
(Section 2.3.4) culminating in identical charge state distributions, ranging from 9+
to 16+ and an identical deconvoluted mass of 21041 Da (Fig. 4.9a). The theoret-
ical mass according to its sequence (Appendix 11.1) is 21173.24 Da, resulting in a
difference of 132.24 Da. This suggests the absence of the N-terminal methionine
residue of the 27 aa His-tag. The presence of AGr2 dimer peaks in charge states
ranging from 20+ to 32+ under denaturing conditions, can be attributed to the
formation of a covalently bound dimer. Formation must occur upon storage at 4 ◦C
over time as automated SUPREX experiments conducted at an earlier stage do not
exhibit the dimeric species. The tendency of AGr2 forming aggregates, competent of
peptide binding, is further demonstrated in native DI-ESI-MS experiments by Faull
(unpublished PhD Thesis). However, under denaturing conditions only the AGr2
monomer is observable suggesting a non-covalent aggregation. Per contra, Clark
et al. brought evidence for a covalent dimer in the gas phase conducting FT-ICR
experiments in the gas phase (unpublished data).
The hendeca-tagged hexa-peptides were sprayed under native like conditions (Sec-
tion 2.3.4), demonstrating deconvoluted experimental masses of 2059.87 and 1845.83
Da for PTTIYY-Pen and PATIAA-Pen, respectively (Fig. 4.9b and c). Theoretical
masses of 2059.42 Da and 1845.20 Da for PTTIYY-Pen and PATIAA-Pen are in
very good agreement with experimental derived data.
4 SUPREX OF AGR2 AND FH19-20 114






















































Figure 4.3: Direct infusion spectrum of AGr2 and ligands. (a) Nicholson-Agr2 sprayed under denaturing
conditions from 10 mM NH4OAc with 5 % FA exhibiting monomer charge states (squares) from 9+
to 16+, dimer charge states (circles) from 20+ to 32+ resulting in a deconvoluted mass of 21041 and
42085 Da. (b) PTTIYY-Pen sprayed from native like conditions displaying charge states 2+ to 4+
with an associated mass of 2059.87 Da. (c) PATIAA-Pen sprayed from native like conditions displaying
charge states 2+ to 4+ and a deconvoluted mass of 1845.83 Da.
FH19-20 was sprayed under denaturing conditions with 10 % FA resulting in two
different species ranging from a 7+ to 9+ charge state with a deconvoluted mass of
14738.5 and 14938.8 Da. Apo fH19-20’s theoretical mass according to its sequence
(Appendix 11.2) is 14745.76 and 14945.9 Da in the oxidised form with four disulfide
bridges present. The difference of 200.3 Da is due to additional Glu-Ala (EA) aa
residues on 129 aa apo fH19-20, which is a well known phenomenon in using the
Pichia pastoris expression system [288]. The theoretical mass of the 131 aa fH19-20
is 14936.04 Da and therefore demonstrates good agreement with deconvoluted data
(Fig. 4.9a).
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The pentasaccharose FPX was sprayed from native-like conditions with 5 % MeOH
exhibiting different degrees of sodiation ranging from 6-10 sodium atoms in the 1+
charge state (Fig. 4.9b). The deconvoluted mass of FPX is 1726.77 Da and therefore
exhibits good agreement with the theoretical mass of 1728 Da of the deca-sodium
salt. The presence of salt complicates DI-ESI-MS analysis, however, is tolerated in
automated LC-ESI SUPREX experiments. A FPX fragment comprising different
amounts of sodium atoms was detected, however, could not be identified (red circles
Fig. 4.9).






































Figure 4.4: Direct infusion spectrum of fH19-20 and fondaparinux. (a) FH19-20 sprayed under dena-
turing conditions sprayed from 10 mM NH4OAc with 10 % FA exhibiting charge states from 7+ to 9+
(black squares) and fH19-20 with an additional EA expression artefact (red circles). (b) Fondaparinux
under native-like conditions sprayed from 10 mM NH4OAc with 5 % MeOH exhibiting the 1+ charge
state comprising 6 to 10 sodium atoms (black squares) and a series of FPX fragments comprising
various sodium adducts (red circles).
4.3 Labeling Experiments
AGr2 and fH19-20 systems were investigated via HDX labeling (Section 2.3.5) util-
ising the automated SUPREX setup (Section 2.7.3).
AGr2 comprises, according to its sequence including the His-tag (Appendix 11.1),
165 T1, 174 T2 and 1158 T3 hydrogen atoms. Figure 4.5 illustrates the deuterium
incorporation with regard to time for Nicholson apo AGr2 and in complex with
PTTIYY-Pen and PATIAA-Pen. All three systems exhibit similar exchange rates,
however, slightly different equilibrium deuterium levels. Apo AGr2 displays the
highest level with ˜77 deuterons incorporated, followed by AGr2-PATIAA-Pen with
˜75 deuterons and AGr2-PTTIYY-Pen with approximately 73 hydrogen atoms ex-
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changed. As all peptides were dissolved in water, all observed changes in deuterium
levels can solely be attributed to interaction with AGr2. This suggests an inter-
action of both hendeca-tagged peptides with the His-tagged AGr2, resulting in an
increased protection of AGr2 in complex with PTTIYY-Pen and PATIAA-Pen due
to conformational changes upon binding and/or shielding of the ligand. Thereby a
qualitatively stronger interaction can be attributed to the PTTIYY-Pen ligand in
comparison to PATIAA-Pen.
















Figure 4.5: Automated AGr2-ligand HDX labeling. Deuterium uptake versus time for apo Agr2 (black
squares), AGr2-PTTIYY-Pen (cyan circles) and AGr2-PATIAA-PEN (orange stars).
Temperature dependent HDX labeling experiments for AGr2 with the temper-
ature controllable ESI-SUPREX setup (Section 2.7.4) are illustrated in Figure 4.6.
Time course experiments were conducted at 14, 22 and 50 ◦C, where 22 ◦C is defined
as RT. Room temperature runs for apo-, PTTIYY-Pen- and PATIAA-Pen are also
included. At 14 ◦C apo AGr2 demonstrates the lowest exchange rate and deuterium
level, with an equilibrium deuterium level of about 71 deuterons. In contrast, an
increased sample temperature of 50 ◦C results in a high exchange rate and a high
initial equilibrium deuterium level for short incubation times. Over time the for-
mation of a covalent homodimeric AGr2 species is observed appearing after ˜160
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min, suggesting some degree of aggregation and precipitation occurring, as visually
confirmed after ˜18.5 h.

















Figure 4.6: Automated AGr2 temperature HDX labeling. Deuterium uptake versus time for apo
AGr2 at RT (black squares), apo AGr2 at 14 ◦C (red circles), monomeric apo AGr2 at 50 ◦C (blue
diamonds), dimeric apo AGr2 at 50 ◦C (magenta triangles), AGr2-PTTIYY-Pen at RT (cyan circles)
and AGr2-PATIAA-Pen at RT (orange stars).
FH19-20 has 129 T1, 119 T2 and 762 T3 hydrogen atoms for the 129 aa species and
131 T1, 121 T2 and 771 T3 hydrogen atoms for the 131 aa species, which contains
an additional Glu and Ala residue. HDX labeling data for the 129 aa species is visu-
alised in Figure 4.7 demonstrating exchange properties for apo and FPX complexed
fh19-20. The apo protein displays a lower exchange rate and deuterium level than
the FPX complexed one, resulting in an equilibrium deuterium level of ˜82 and ˜95
deuterons. Figure 4.8 illustrates the time course experiment for the 131 aa fH19-20
species exhibiting the same trend for exchange rates and deuterium levels as the
129 aa variant. Equilibrium HDX levels are ˜84-97 deuterium atoms for the 131 aa
species.
Interestingly, a high degree of HDX is observed for fH19-20 compared to previous
studies with CypA (Section 3.3) under identical experimental conditions. The de-
gree of amide backbone HDX is between 69-71 % for 129 and 131 aa fH19-20 and
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27.5 % for apo CypA, suggesting a more solvent accessible structure of the fH pro-
tein. A closer look at the fH19-20 structure (Fig. 1.13b) reveals a less structured
secondary structure in comparison to CypA. CCP module 19 exhibits six short β-
sheets connected by loops and a complete absence of α-helices, whereas CCP 20
comprises six β-sheets and one α-helix with approximately 1.5 turns involving ˜5
amino acid residues. These findings account for the high degree of deuteration of
fH19-20 and therefore we can attribute the lower deuterium levels in HDX labeling
experiments for CypA to be structure related, rather than back exchange under
identical experimental conditions (Section 3.3).
The comparison between apo- and FPX-complexed, fH19-20 of both the 129 and
131 aa species, demonstrates a higher degree of exchange in the complex than in
the free protein. This suggests conformational changes occur upon FPX binding to
CCP module 19-20, unshielding apo buried amide protons, which contrasts with the
heparin experiments of Herbert et al. [287]. The difference of ˜10 deuterons between
the apo and the complexed form of both species indicate a structural opening upon
complexation.


















Figure 4.7: Automated fH19-20-FPX HDX labeling. Deuterium uptake versus time for apo fH19-20
(129 aa) at RT (black squares) and in complex with FPX (blue triangles).
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Figure 4.8: Automated fH19-20-FPX HDX labeling. Deuterium uptake versus time for apo fH19-20
(131 aa) at RT (red circles) and in complex with FPX (green diamonds).
4.4 SUPREX - Manual
For manual ESI-SUPREX (Section 2.7.2) average intrinsic exchange rates were de-
termined, according the method mentioned in Section 2.7.5, to be 3.98 s−1 for AGr2
based on its sequence (Appendix 11.1) and 6.89 s−1 for both fH19-20 species (Ap-
pendix 11.2). For all experiments a total AGr2 and fH19-20 concentration of 2.5 µM
was utilised along with tenfold excess of hendeca-tagged hexapeptides and FPX.
4.4.1 AGr2 SUPREX
In conjunction with the devised manual ESI-SUPREX setup apo AGr2 from the
Florance batch was investigated, yielding SUPREX curves and midpoints for the
incubation times at 10, 40, 60 and 180 min. The complete set of SUPREX curves
is displayed in Appendix 11.3, whereas Figure 4.9a provides an overview of 10, 60
and 180 min incubation. Midpoint concentrations are calculated to be 2.18, 1.55
and 1.29 M for 10, 60 and 180 min incubation, respectively.
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Figure 4.9: Manual AGr2 SUPREX data. (a) Overview of apo AGr2 manual SUPREX curves for
incubation times 10, 60 and 180 min with C
1/2
SUPREX values of 2.18, 1.55 and 1.29 M. (b) Overview of
AGr2-PTTIYY-Pen manual SUPREX curves for incubation times 10, 60 and 180 min with C
1/2
SUPREX
values of 1.98, 1.98 and 1.25 M. (c) Free energy vs. C
1/2
SUPREX plot resulting in -31.05 ± 36.28
kJmol−1 for apo AGr2, -36.28 ± 7.23 kJmol−1 for the AGr2-PTTIYY-Pen complex and a m value of
4.77 ± 2.93 kJmol−1M−1 and 7.36 ± 4.06 kJmol−1M−1, resulting in a ∆∆Gf value of -5.23 ± 8.62
kJmol−1 and a Kd of 3.37 ± 5.55 µM.
AGr2 in complex with PTTIYY-Pen at the same incubation times is shown in
Figure 4.9b. The full set of SUPREX curves for the holo system is displayed in
Appendix 11.4. C
1/2
SUPREX values for holo fH19-20 are determined to be 1.98, 1.98
and 1.25 M for the 10, 60 and 180 min incubation period, resulting in a slight desta-
bilisation of the 10 and 180 min experiment and stronger stabilisation of 0.86 M for
the 40 min incubation experiment (Table 4.1). Plotting SUPREX midpoints vs. the
free energy of protein folding results in values of -31.05 ± 4.69 and -36.28 ± 7.23
kJmol−1 for apo- and PTTIYY-complexed AGr2 culminating in a Kd of 3.37 ± 5.55
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and 7.36 ± 4.06 kJmol−1M−1 for the complexed form, suggesting apo AGr2 exhibit-
ing a lower degree of unfolding upon denaturation and thereby demonstrating fewer
surface exposure. The limitation of experimental data points is, again, preventing
a more detailed and more accurate ESI-SUPREX data evaluation. The automated
ESI-SUPREX methodology offers a higher degree of automation therefore it ought
to give a more detailed insight into AGr2-ligand interactions.
4.4.2 FH19-20 SUPREX
Identical experimental procedures were used for manual ESI-SUPREX of apo fH19-
20 as for AGr2 in the previous Section. SUPREX curves for both, the 129 and
131 aa species were recorded and midpoints extracted for 10, 60 and 180 min in-
cubation (Fig. 4.10). For 10 min incubation with the chemical denaturant GDH,
C
1/2
SUPREX values are determined for the 129 and 131 aa species of 4.11 and 4.07 M,
respectively (Fig. 4.10a). Different deuterium levels of the pre-transition baseline
can be attributed to different solution structures of the two protein species and to
their relative lengths. Errors in timing and execution of the manual experiment
results in a big standard deviation in the transition region, where the methodol-
ogy is very sensitive to non-consistency in the experimental protocol. Incubation of
fH19-20 for 60 min in GDH culminates only in one midpoint for the 131 aa fH19-
20 species of 3.07 M, as for the 129 aa variant there is no transition observable
(Fig. 4.10b). This finding is supportive of the observations from HDX labeling
experiments (Section 4.3) suggesting a non-compact tertiary structure with a large
number of solvent accessible amide protons. This is further supported by the 180
min experiment demonstrating no transition at all, but a level of deuteration equal
to the post-transition on of the 10 min incubation experiment (Fig. 4.10c). This
suggests, that SUPREX is suitable to only a limited extent for the determination of
thermodynamical data of the complement control proteins 19-20. The decrease in
the deuterium level at high denaturant concentrations can be attributed to strong
interaction of GDH with the protein as demonstrated for CypA in Chapter 3.8.
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Table 4.1: Manual SUPREX results for AGr2 and FH19-20.





10 2.18 1.98 (-0.20) 4.11 4.07
40 1.12 1.98 (+0.86)
60 1.55 N/A N/A 3.07
180 1.29 1.25 (-0.04) N/A N/A
∆Gf/kJmol
−1 -31.05 ± 4.69 -36.28 ± 7.23 -38.66
∆∆Gf/kJmol
−1 -5.23 ± 8.62
m/kJmol−1M−1 4.77 ± 2.93 7.36 ± 4.06 4.23
Kd 3.37 ± 5.55 µM
a Florance expressed batch.
b 129 aa apo fH19-20.
c 131 aa apo fH19-20, comprising an additional EA expression artefact.
Nevertheless, plotting the two extracted SUPREX midpoints in a ∆Gf vs. C
1/2
SUPREX
plot results in a free energy of -38.66 kJmol−1 for the 131 aa fH19-20 species and a
m value of 4.23 kJmol−1M−1 (Fig. 4.10d) as tabulated in Table 4.1. In comparison
to CypA, fH19-20 seems to have a higher stability against denaturation as for the
10 min incubation given that the midpoint concentration was almost twice as much
as for CypA.
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Figure 4.10: Manual fH19-20 SUPREX data. (a) Apo fH19-20 manual SUPREX curves for 10 min
incubation with fH19-20 (black squares) and with an additional EA expression artefact (red circles)
resulting in C
1/2
SUPREX values of 4.11 and 4.07 M (error bars represent standard deviation of two sets
of experiments). (b) Apo fH19-20 manual SUPREX curves for 60 min incubation with fH19-20 (black
squares) and with an additional EA expression artefact (red circles), the latter resulting in a C
1/2
SUPREX
value of 3.07 M. (c) Apo fH19-20 manual SUPREX curves for 180 min incubation with fH19-20 (black
squares) and with an additional EA expression artefact (red circles). (d) Free energy vs. C
1/2
SUPREX
plot resulting in -38.66 kJmol−1 free energy of protein folding and a m value of 4.23 kJmol−1M−1.
4.5 SUPREX - Automated
4.5.1 AGr2 SUPREX
Automated ESI-SUPREX experiments were performed as described in Section 2.7.3
with both AGr2 batches at incubation times from 10 to 180 min. AGr2 from the
Florance batch exhibits (for all investigated incubation times) somewhat higher de-
naturing midpoint concentrations compared with the same protein expressed and
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purified by Nicholson. Since the proteins have identical masses (Section 4.2) this
must be attributed to buffer effects (detergent vs. non-detergent) and/or different
levels of oligomerisation caused by these buffer conditions, which reflects once more
the dependence of the relative stability of a protein on its environment. In the auto-
mated SUPREX experiments conducted at room temperature, no covalently bound
homodimeric AGr2 was observed. Therefore it was not considered in the data eval-
uation process, however, accounted for in discussing SUPREX results.
Figure 4.11a displays the two different AGr2 batches for a 10 min incubation pe-
riod, resulting in C
1/2
SUPREX values 1.55 and 1.06 M for Florance and Nicholson AGr2
under identical experimental conditions. At this point it is noteworthy that manual
SUPREX buffers for fH19-20 were not refractively verified, hence higher relative
midpoint concentrations are observed. However, this does not affect Kd calculations
as these are determined from relative ∆∆Gf values. SUPREX midpoints for both
proteins are summarised in Table 4.2, whereas an overview of the complete set of
SUPREX curves is illustrated in Appendix 11.5 and 11.6 for Florance and Nichol-
son expressed and purified AGr2. Figure 4.11b displays the 90 min incubation with
GDH, culminating in SUPREX midpoint concentrations of 2.02 and 0.90 M for Flo-
rance and Nicholson Agr2, respectively.
Both protein batches exhibit a similar trend in destabilisation with respect to the
incubation time in GDH, however, absolute stabilities vary due to different buffer
conditions. Florance AGr2 was treated with detergents, such as polysorbate prod-
ucts to prevent unspecific binding and increase solubility. Over time the purification
protocol was refined and the application of detergents was no longer necessary, as
in the Nicholson AGr2 batch. As previously described (Section 1.6), these absolute
differences in C
1/2
SUPREX values do not affect the calculated dissociation constant, as
the differences of SUPREX derived free energies, which are not comparable to other
techniques, are utilised for Kd calculations.
Evaluation of the SUPREX curves by assuming two-state unfolding and linear
fitting results in a ∆Gf value of -27.82 ± 1.30 kJmol−1 and an associated m value
of 3.64 ± 0.92 kJmol−1M−1 for Florance AGr2 (Fig. 4.11c). In contrast, plotting
∆Gf vs. C
1/2
SUPREX of the Nicholson batch offers three potential fitting possibilities,
as visualised in Figure 4.11d. Linear fitting all collected data points as performed
with the Florance batch (black line Fig. 4.11d) results in a free energy of protein
folding of -31.88 ± 4.48 kJmol−1 and a m value of 9.62 ± 5.23 kJmol−1M−1, indicat-
ing that the AGr2 in the Nicholson batch is more stable. The m value suggests in
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comparison a higher degree of unfolding and higher surface exposure upon unfolding
in the Nicholson batch, which is consistent with the deuterium level of the 10 min
incubation (Fig. 4.11a), however, not by the deuterium level upon unfolding in the
90 min incubation experiment (Fig. 4.11b).
Neglecting the 10 and 120 min incubation period in the SUPREX evaluation routine,
linear fitting culminates in a ∆Gf value of -109.75 ± 8.70 kJmol−1 and associated m
value of 98.49 ± 9.99 kJmol−1M−1 (blue fit Fig. 4.11d), indicating a high stability
and a high degree of unfolding upon denaturation in Nicholson AGr2. Error bars
are visualised where an error was possible to be calculated.
In the case where a sigmoidal curve interpretation was applied no ∆Gf value was
calculated (red line 4.11d). Nevertheless, these findings would suggest a non-two
state unfolding behaviour for apo Agr2 (Nicholson batch) probably caused by non-
covalent oligomerisation in solution as covalent aggregates are not evident in any of
the acquired SUPREX mass spectra, except high in temperature SUPREX experi-
ments (Section 4.6) and DI-ESI MS experiments of long-term-stored AGr2 (Section
4.2).
Contextualising Nicholson AGr2 findings with those obtained from the Florance
batch utilising polysorbates to prevent unspecific binding, a non-two state unfolding
behaviour caused by at least partial oligomerisation of AGr2 in the Nicholson batch
seems the most likely conclusion. Even though only monomeric AGr2 was detected,
aggregation plays, a yet unknown, role explaining previous findings.
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Figure 4.11: Automated apo AGr2 SUPREX data of the two batches. (a) Florance (black squares)
and Nicholson (red circles) apo AGr2 incubated for 10 min, resulting in C
1/2
SUPREX values of 1.55 M
and 1.06 M. (b) The Florance (black squares) and Nicholson (red circles) AGr2 incubated for 90 min,
result in 2.02 and 0.86 M SUPREX midpoints (error bars represent standard deviation of two sets of
experiments). (c) Florance AGr2, free energy vs. C
1/2
SUPREX plot resulting in a ∆Gf value of -27.82± 1.30 kJmol−1 and a m value of 3.64 ± 0.92 kJmol−1M−1. (d) ∆Gf vs. C1/2SUPREX plot resulting in
a free energy of protein folding of -31.88 ± 4.48 kJmol−1 and a m value of 9.62 ± 5.23 kJmol−1M−1,
if all experimental data is incorporated in the fit (black line). Neglect of 10 and 120 min incubation
results in a ∆Gf of -109.75 ± 8.70 kJmol−1 and a m value of 98.49 ± 3.99 kJmol−1M−1 (blue line).
Neglect of 120 min incubation and sigmoidal fitting would indicate non-two state unfolding behaviour
(red line).
ESI-SUPREX experiments with PTTIYY-Pen were conducted throughout with
Nicholson expressed and purified AGr2. All SUPREX curves of the complex are
available in Appendix 11.7. Figure 4.12a provides an overview of apo and PTTIYY-
Pen-complexed AGr2 for a 120 min incubation period, resulting in C
1/2
SUPREX values
of 0.48 and 0.88 M for apo and complexed AGr2. The 0.40 M stabilisation of AGr2
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at 120 min incubation is the only measured positive stabilisation (Table 4.2). All
other incubation times yield destabilisation of AGr2 in a range of 0.17 and 0.29 M
or exhibit similar SUPREX midpoint concentrations as the apo enzyme. Evaluation
of all acquired C
1/2
SUPREX values results in a ∆Gf of -33.97 ± 7.24 kJmol−1 and
a m value of 12.09 ± 8.62 kJmol−1M−1 with an associated ∆∆Gf value of -2.09± 4.64 kJmol−1, culminating in Kd of 24.52 ± 54.43 µM (red line Fig. 4.12b), which
is within the same order of magnitude as the manual determined Kd of 3.39 µM.
However, the fitting approach utilised does not represent experimental data very well
and the lack of error bars due to large deviations in the C
1/2
SUPREX value extraction,
further complicates quantitative analysis.
In contrast, plotting the free energy of protein folding vs. C
1/2
SUPREX values with the
neglect of the 180 min incubation time, a steep linear fit is extracted resulting in
a ∆Gf of -251.67 ± 71.50 kJmol−1 and a m value of 258.91 ± 81.09 kJmol−1M−1
(black line Fig. 4.12b). A ∆∆Gf value of -223.80 ± 71.50 kJmol−1 is not supported
by measured SUPREX midpoint concentrations of apo- and holo protein, where
just a single stabilisation of 0.40 M for the 120 min incubation time is observed. In
comparison, CypA in complex with CsA exhibits an average stabilisation of 1.5 - 2
M resulting in a ∆∆Gf value of -12.05 kJmol
−1. These thermodynamic parameters
do not encourage Kd calculations, as results would not reflect biological properties.
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Figure 4.12: Automated AGr2-PTTIYY-Pen SUPREX data. (a) Comparison of free (black squares)
and PTTIYY-Pen complexed (red circles) AGr2 at 120 min incubation, resulting in C
1/2
SUPREX values of
0.48 and 0.88 M, respectively (error bars represent standard deviation of two sets of experiments). (b)
Evaluation, neglecting 180 min incubation (black line), results in a ∆Gf of -251.67 ± 71.50 kJmol−1
and a m value of 258.91 ± 81.09 kJmol−1M−1, whereas incorporating all experimental data points
culminates in a ∆Gf of -33.97 ± 7.24 kJmol−1 and a m value of 12.09 ± 8.62 kJmol−1M−1 (red line).
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For the AGr2-PATIAA-Pen system ESI-SUPREX experiments were carried out
with Nicholson expressed and purified AGr2 and the complete set of SUPREX curves
is visualised in Appendix 11.8.
Extracted SUPREX inflexion points demonstrate almost identical C
1/2
SUPREX values
as for the AGr2-PTTIYY-Pen system apart from the 60 min incubation, exhibiting
a destabilisation of 0.19 M (Table 4.2). The most drastic change in protein stabil-
isation is identical to the PTTIYY-Pen experiment at 120 min incubation with a
stabilisation of 0.41 M, as illustrated in Figure 4.13a. Thermodynamic analysis of all
experimental data acquired reveals a free energy of protein folding of -32.25 ± 6.07
kJmol−1 and an associated m value of 10.50 ± 7.57 kJmol−1M−1 resulting in a Kd
of 198.98 ± 3278.00 µM (black line Fig. 4.13a). If 60 and 180 min incubation times
are neglected a ∆Gf of -128.07 ± 17.61 kJmol−1 and a m value of 118.99 ± 19.96
kJmol−1M−1 is observable, culminating in a large -96.19 ± 17.66 kJmol−1 stabilisa-
tion (blue line Fig. 4.13b), which is not supported by extracted C
1/2
SUPREX values.
Again, quantitative Kd evaluation is not advised as biological relevance would be
questionable.

















































Figure 4.13: Automated AGr2-PATIAA-Pen SUPREX data. (a) Comparison of free (black squares)
and PATIAA-Pen complexed (red circles) AGr2 at 120 min incubation, resulting in C
1/2
SUPREX values
of 0.48 and 0.89 M, respectively (error bars represent standard deviation of two sets of experiments).
(b) ∆Gf vs. C
1/2
SUPREX plot comprising all experimental data (black line), results in a free energy of
protein folding of -32.25 ± 6.07 kJmol−1 and a m value of 10.50 ± 7.57 kJmol−1M−1. Neglect of 60
and 180 min incubation, results in a ∆Gf value of -128.07 ± 17.61 kJmol−1 and a m value of 118.99± 19.96 kJmol−1M−1 (blue line).
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Qualitative comparison of m values of all five investigated sets of thermodynamic
data suggests an increased surface area upon denaturation for all holo-AGr2 systems
and all associated evaluation approaches, conclude a more open structure of AGr2
in the presence of the hendeca-tagged hexapeptides.
Besides large errors associated with the free energy calculation, the determined
dissociation constant of 24.52 ± 54.43 µM for PTTIYY-Pen complexed AGr2 shows
good agreement with Kd’s determined with competition fluorescence anisotropy of
25-40 µM (Section 4.1). The Kd for AGr2-PATIAA-Pen of 198.98 ± 3278.00 µM can
not yet be properly evaluated, as there is no comparable data available. However, in
vivo experiments might indicate a weaker binding of PATIAA-Pen in comparison to
PTTIYY-Pen (personal communication). These findings would exculpate the higher
dissociation constant of PATIAA-Pen. In addition DI-ESI-MS data by Faull does
not show any interaction of this peptide with AGr2 (unpublished PhD thesis).
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Table 4.2: Automated AGr2 SUPREX results (values in brackets denote shift in C
1/2
SUPREX due to stabili-
sation compared to apo AGr2a ).




10 1.55 1.06 0.89 (-0.17) 0.89 (-0.17)
15 2.09 0.90 0.89 (-0.01) 0.89 (-0.01)
25 1.71
30 0.87
60 0.96 0.87 0.88 (+0.01) 0.69 (-0.19)
90 2.02 0.88 0.87 (-0.01) 0.86 (-0.02)
120 0.47 0.48 0.88 (+0.40) 0.89 (+0.41)
180 0.84 0.55 (-0.29) 0.52 (-0.03)
∆Gf/kJmol
−1/c -27.82 ± 1.30 -31.88 ± 4.48 -33.97 ± 7.24 -32.25 ± 6.07
∆∆Gf/kJmol
−1/c -2.09 ± 4.64 -0.38 ± 6.19
m/kJmol−1M−1/c 3.64 ± 0.92 9.62 ± 5.23 12.09 ± 8.62 10.50 ± 7.57
Kd
c 24.52 ± 54.43 µM 198.98 ± 3278.00 µM
∆Gf/kJmol
−1/d -109.75 ± 8.70 -251.67 ± 71.50 -128.07 ± 17.61
∆∆Gf/kJmol
−1/d -223.80 ± 71.50 -96.19 ± 17.66
m/kJmol−1M−1/d 98.49 ± 9.99 258.91 ± 81.09 118.99 ± 19.96
Kd
d N/A N/A
a expressed and purified by H. Florance.
b expressed and purified by J. Nicholson.
c all experimental data incorporated.
d selected data points as individually visualised in Figure 4.11d, 4.12b and 4.13b.
4.5.2 FH19-20 SUPREX
Automated ESI-SUPREX experiments for fH19-20 were conducted according to Sec-
tion 2.7.3 with incubation times ranging from 10 to 180 min. All SUPREX curves
for the two apo and holo fH species are displayed in Appendix 11.9 and 11.10. Apo
fH19-20 SUPREX midpoint concentrations for both species are summarised in Table
4.3.
The 129 aa species displays an almost constant denaturing behaviour for the
incubation period between 10-60 min, followed by a decrease in the denaturing con-
centration for incubation times longer 180 min. In contrast, the 131 aa species
does exhibit a continuous destabilisation with increased incubation time. Thermo-
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dynamic analysis for both species reveal ∆Gf values of -30.38 ± 3.22 and -29.58± 3.10 kJmol−1 for the 129 and 131 aa variant. Associated m values are calcu-
lated to 3.30 ± 1.84 and 3.10 ± 0.71 kJmol−1M−1 for the 129 and 131 aa species,
respectively (Fig. 4.14c). Interestingly, lower m values are determined as for the
CypA- and AGr2-system, suggesting a lower surface exposure upon unfolding for the
fH19-20 protein. This finding is in agreement with fH19-20 possessing two disulfide
bonds per CCP module, culminating in 4 disulfide bonds for the complete fH19-20
enzyme, making it more stable against denaturation. The absolute denaturant con-
centration also reflects this stability, as values are twice as big as in protein systems
previously investigated. This stability is contrasted by the degree of HDX occurring
in labeling experiments (Section 4.3). FH19-20 retains on average 70 % of its amide
backbone deuterons in the conducted ESI-SUPREX experiments, indicating a very
solvent exposed tertiary structure, experiencing further deprotection upon binding
of FPX, as illustrated in Figure 4.14a. Thereby the 129 aa species at a 30 min incu-
bation time is displayed with and without FPX. In the presence of FPX, deuterium
levels of both, the pre- and post-transition baseline exhibit elevation, resulting in a
decrease of deuterium uptake upon denaturation. Remarkably, the presence of FPX
destabilises fH19-20 and shifts the SUPREX midpoints to lower concentrations. The
same trend is observable for the 131 aa variant at 10 min incubation as visualised in
Figure 4.14b with a destabilisation of 0.30 M compared to the apo protein. Ther-
modynamic analysis reveals a ∆Gf value of -27.82 ± 1.30 kJmol−1 and a m value
of 2.97 ± 0.84 kJmol−1M−1, resulting in a destabilisation of 2.55 ± 3.47 kJmol−1
for the 129 aa species (Fig. 4.14d). Analysis of the 131 aa variant culminates in a
single SUPREX point due to high s/n ratios, which is destabilised by 0.30 M. The
decreased m value indicates a further increase in surface exposure upon denatura-
tion, which well agrees with the deuterium levels of pre- and post-transition baseline
of apo and holo fH19-20 both species variants.
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The combination of possessing four disulfide bridges, gaining stability with the
accompanying structural restrictions and a secondary structure mainly comprising
loop regions, complicate general SUPREX quantification. Incubation times longer
60 min do not yield any useful data and the low change of mass incorporation upon
unshielding of amide backbone protons due to denaturation make fH19-20-FPX an
unsuitable protein-ligand system for investigation via SUPREX.
Table 4.3: Automated fH19-20 SUPREX results.




10 2.00 2.25 2.02 (+0.02) 1.95 (-0.30)
30 2.02 2.02 1.51 (-0.51) N/A




−1 -30.38 ± 3.22 -29.58 ± 3.10 -27.82 ± 1.30
∆∆Gf/kJmol
−1 +2.55 ± 3.47
m/kJmol−1M−1 3.30 ± 1.84 3.10 ± 0.71 2.97 ± 0.84
a 129 aa apo fh19-20.
b 131 aa apo fH19-20, comprising an additional EA expression artefact.
c FPX complexed with 129 aa apo fh19-20.
d FPX complexed with 131 aa apo fH19-20, comprising an additional EA expression artefact.
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Figure 4.14: Automated fH19-20-FPX SUPREX data. (a) SUPREX curves for apo fH (129 aa, black
squares) and in complex with FPX (red circles) at 30 min incubation, resulting in C
1/2
SUPREX values
of 2.02 M and 1.51 M for the apo and the complexed protein. (b) SUPREX curves for apo fH (131
aa, black squares) and in complex with FPX (red circles) at 10 min incubation, resulting in C
1/2
SUPREX
values of 2.25 M and 1.95 M for the apo and the complexed protein. (c) Free energy vs. C
1/2
SUPREX
values result in ∆Gf values of -30.38 ± 3.22 kJmol−1 and -29.58 ± 3.10 kJmol−1 for apo fH19-20 with
129 aa (black line) and 131 aa (red line), respectively. The m values are 3.30 ± 1.84 kJmol−1M−1 and
3.10 ± 0.71 kJmol−1M−1 for the 129 and 131 aa species. (d) Free energy vs. C1/2SUPREX plot of FPX
complexed fH19-20 results in a ∆Gf value of -27.82 ± 1.30 kJmol−1 and a m value of 2.97 ± 0.84
kJmol−1M−1 for the 129 aa fH19-20 species (black line). For the 131 aa species, a single SUPREX
midpoint at 1.95 M is displayed in red. Error bars, if present, represent standard deviation of two sets
of experiments.
4.6 Automated Temperature Dependent SUPREX of AGr2
AGr2 from the Nicholson batch was subjected a SUPREX experiment identical to
that in Section 4.5.1 at an incubation temperature of 50 ◦C with the developed
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temperature adjustable sample rack (Section 2.7.4).
Figure 4.15 provides an overview of an automated ESI-SUPREX experiment at the
shortest incubation of 10 min at 22 and 50 ◦C. Figure 4.15a shows the results of
the 22 ◦C experiment, resulting in a C
1/2
SUPREX value of 1.06 M. The 50
◦C exper-
iment is demonstrated in Figure 4.15b exhibiting SUPREX data points with large
discrepancies, especially in the pre-transition region, between two repeats of identi-
cal experiment. Derived SUPREX data does not allow midpoint extraction of the
50 ◦C run. The deuterium levels over the complete range of chemical denaturant
are equal to the post-transition baseline of apo AGr2 experiments at ambient tem-
perature (Appendix 11.6). This indicates that complete HDX has occurred at the
lowest incubation time and a zero concentration of GDH. Interestingly, the zero mo-
lar denaturant concentration exhibits the highest deuterium uptake, decreasing with
increasing GDH concentration, which further emphasises the increasing interaction
of GDH with the protein in question with increasing denaturant concentration, as
demonstrated with CypA in Chapter 3.8.
A lower temperature might result in extractable SUPREX data, however, the way
the temperature adjustable sample rack was developed (Section 2.7.4) a fine adjust-
ment of the temperature used is not possible. A thermostat with a pump attached
to the sample rack would circumvent this issue, however, this was not available.
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Figure 4.15: Automated temperature dependent AGr2 SUPREX data. (a) Automated SUPREX
experiment of apo AGr2 at 22 ◦C and 10 min incubation time, resulting in a C
1/2
SUPREX value of 1.06
M. (b) Automated SUPREX experiment of apo AGr2 at 50 ◦C and 10 min incubation time (error bars,
if present, represent standard deviation of two sets of experiments).
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4.7 Conclusion
DI-ESI experiments confirm the masses of both AGr2 batches and the hendeca-
tagged hexa-peptides. The fH19-20 protein is positively identified along with a
related fH19-20 species comprising an additional Glu and Ala amino acid residue
due to the expression in Pichia pastoris. The interaction of fH19-20 with fonda-
parinux has been studied.
HDX labeling experiments for AGr2 display an overall similar exchange be-
haviour for apo-, PTTIYY-Pen and PATIAA-Pen complexed AGr2. Nevertheless
a slightly lower deuterium level was found for PTTIYY-Pen and PATIAA-Pen as
for the apo protein, suggesting structural tightening/shielding upon interaction with
the ligand. Temperature controlled HDX time course experiments reveal irreversible
aggregation and precipitation of AGr2 after a 2.5 h period of incubation at 50 ◦C,
indicating a thermal instability of AGr2.
FH19-20 HDX labeling data exhibits a high degree of deuteration, which can be
attributed to the tertiary structure affected by the low degree of secondary struc-
ture, emphasising the solvent shielding effects of the CypA tertiary structure with
respect to the back exchange behaviour upon liquid chromatography handling. The
high deuterium level is further increased by the presence of the pentasaccharide
FPX suggesting a conformational opening in the fH19-20 protein contrasting previ-
ous findings. SUPREX experiments were performed to investigate, if the structural
opening is associated with a stabilising or destabilising effect on fH19-20-FPX pro-
tein stability.
Manual ESI-SUPREX experiments conclude a dissociation constant of 3.37± 5.55µM for the AGr2-PTTIYY interaction from the Florance batch.
Manual factor H 19-20 SUPREX experiments demonstrate a higher relative stability
of both, the 129 and 131 aa species in comparison with CypA. Furthermore, HDX
equilibrium is reached between 60 and 180 min in the absence of the chemical denat-
urant as no transition occurs upon unfolding, indicating either a very dynamic struc-
ture or a non-compact structure with a large number of solvent accessible backbone
hydrogen atoms. The latter finding is supported by the conformational restriction
of the protein via the four disulfide bonds.
Automated ESI-SUPREX experiments for apo AGr2 of the two different protein
batches offer multiple possible conclusions. Findings suggest either a non-two state
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unfolding behaviour of AGr2 or a two state unfolding event associated with large
experimental errors. The most likely event, if results from the two protein batches
are reviewed, seems to be a non-two state unfolding behaviour upon oligomerisation
of the AGr2 protein forming aggregates in solution. SUPREX experiments with
PTTIYY-Pen and AGr2 demonstrate large experimental errors and multiple eval-
uation approaches. Nevertheless, if all acquired data is incorporated and two-state
unfolding behaviour assumed, a dissociation constant close to a previously reported
one can be extracted from the developed automated ESI-SUPREX approach. Ex-
periments with the second hendeca-tagged hexa-peptide PATIAA-Pen indicate one
order of magnitude weaker binding and postulate the first reported dissociation
constant for this interactions. Absolute values might be considered with care as
two-state unfolding is questionable, however, magnitudes of reported values agree
well with data reported in the literature so far.
SUPREX experiments with the automated ESI-setup reveal a higher relative
stability of both fH19-20 species in comparison with the resulting free energy of
protein folding, suggesting a low degree of unfolding during denaturation, caused by
the four disulfide bonds in fH CCP module 19 and 20. In the presence of FPX a
destabilisation of both, the relative stability and the free energy of protein folding
is observed complicating the determination of a dissociation constant. Gaining sta-
bility via the disulfide bridges, which also restricts the degree of unfolding, and the
good solvent accessibility culminating in a high degree of HDX prior denaturation
make fH19-20 an unsuitable candidate for general SUPREX applications.
Temperature dependent SUPREX experiments at 50 ◦C and 10 min incubation
already display post-transition deuterium levels, suggesting thermal denaturation
occurs before chemical assisted denaturation, or both contribute.
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5 SUPREX of CypA and GroEL
5.1 Introduction
The molecular chaperonin groEL/groES and its effect on other proteins has been
well studied with various biochemical and biophysical methods over the last four
decades. Mutagenisis [165] and cryo-electron studies [164] gave insight into the
mechanism of action. Denaturing studies with urea and solution x-ray scattering
revealed the reassembly properties of the E. coli chaperonin, indicating concentra-
tion dependent distinct partial dissociation and cooperative unfolding [289]. The
effects on other proteins have been investigated i.a. with CD [161], fluorescence-
denaturation [177] and fluorescence anisotropy experiments [175], just to name a few.
In the field of MS the E. coli chaperonin system groEL/groES has been of keen
interest. Robinson, Gross and Ashcroft et al. investigated the chaperonin and
chaperon-bound protein properties utilising ESI-MS [290, 291, 292, 293, 294, 295].
More recently van Duijn and Heck et al. probed groEL-substrate behaviour em-
ploying tandem [296], ESI [170] and ESI ion mobility mass spectrometry techniques
[89]. Direct MALDI-MS was employed by Ohtsu et al. to identify large enzymes,
i.a. groEL and groES on immunoblotting membranes [297].
Three different classes of exchange speed were observed for CypA exhibiting
fast, moderate and slow exchange behaviour [270]. In 1994 Zahn et al. [298] inves-
tigated the HDX behaviour of amide protons by NMR, concluding three associa-
tion/dissociation cycles are needed to completely exchange the T2 hydrogen atoms
in CypA, indicating a destabilisation of the entire protein in the complex with groEL.
These findings have been confirmed by Zahn in 1996 by conducting experiments on
only the apical domain of the groEL protein [178] and by Wüthrich et al. [179] in
1997. The speed of complex formation of groEL-CypA is pH dependent and has
been found to occur between 5.0 and 7.0, whereas lower pH conditions trigger ag-
gregation of CypA. Furthermore the dissociation of the complex is assisted by low
temperature conditions (6 ◦C), whereas ambient temperatures favour association
[179].
In conclusion, it has been shown that CypA undergoes reversible global unfold-
ing once bound to groEL. The unfolded state of CypA is stabilised by binding of
the hydrophobic side chains in the central cavity of the groEL cylinder. Multi-
5 SUPREX OF CYPA AND GROEL 138
ple denaturation/renaturation cycles would allow misfolded, kinetically trapped or
folding-incompetent species to find a folding-pathway, resulting in the proper folded
state [179].
The ambition here is to unfold CypA with groEL7 in the absence of the co-
factors and utilising the developed ESI-SUPREX approach to detect the unfolded
CypA species stabilised in the groEL-CypA complex.
5.2 Direct Infusion
After groEL was expressed, purified and positively identified by SDS-PAGE (Chap-
ter 2.2.2) a DI-MS experiment was conducted for further characterisation. Therefore
groEL was prepared under denaturing conditions containing 10 % FA to a final con-
centration of 10 µM as described in Chapter 2.3.1 and subjected to DI-nano-ESI-MS
on a QTOF2 mass spectrometer (Section 2.3.4). There was no evidence for the groEL
tetradecamer but this was not expected under non-native ESI conditions. Never-
theless Heck et al. reported the oligomeric species under almost identical buffer
conditions [89]. Furthermore gel filtration purification (Section 2.2.2 Fig. 2.4) sug-
gests the presence of the groEL tetradecamer.
Figure 5.1 illustrates a wide charge state distribution ranging from 25+ to 70+ of a
single groEL subunit. Deconvolution results in a mass of 57211 ± 13 Da indicating
a methionine loss, compared to the full 548 aa sequence (Appendix 12.1) with a
mass of 57329 Da. The theoretical mass lacking one methionine residue is 57197
Da being within the margin of error of the DI-ESI-MS data acquired, culminating
in a mass for the intact groEL of 800954 ± 182 Da, which is further utilised for
automated ESI-SUPREX experiments. The assumption of expressed groEL lacking
a methionine is strengthened by the fact that van Duijn et al. report an identical
apo groEL mass of 57197 Da for the individual subunit and 800.758 kDa for the
intact groEL [89].
7utilisation of the term groEL refers to the tetradecameric form of groEL
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Figure 5.1: Direct infusion spectrum of apo groEL. Sprayed under denaturing conditions from 10 mM
NH4OAc containing 10 % FA at a total concentration of 10 µM with charge states 25+ to 70+.
5.3 Labeling Experiments
The groEL-CypA system was subjected to HDX labeling experiments (Section 2.3.5)
with the devised automated SUPREX setup (Section 2.7.3) at a final CypA concen-
tration of 5 µM probing exchange behaviour of both proteins. As the ESI-SUPREX
method developed is based on HPLC analysis of quenched/denatured proteins, the
sheer size of groEL complicates a stoichiometric use of groEL, as upon denaturation
for each equivalent of intact groEL 14 equivalents of subunits are observed. A com-
promise between massively overloading the guard column and still detecting CypA
resulted in the utilisation of the oligomeric groEL at a third of the CypA start-
ing concentration, however, a stoichiometric application would have been desirable.
The LC-programs/conditions employed were identical to the HDX labeling studies
previously presented (3.3, 4.3), enabling direct data comparison.
Figure 5.2a visualises the deuterium uptake with regard to time for apo CypA in
the presence of groEL and 18/2.3 % MeOH for comparison. Apo CypA displays
the slowest exchange rate and the lowest deuterium level with ˜43 Da. Exchange
rates for CypA in complex with groEL and in the presence of methanol are higher,
compared to the free protein, however almost similar, as are the deuterium levels of
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˜57 Da and ˜59 Da. These findings suggest similar degrees of denaturation upon al-
cohol denaturation and unfolding of CypA via groEL resulting in stabilisation of an
unfolded state in the groEL-CypA complex. The non-stoichometric application of
groEL with CypA might have disfavoured stabilisation of the entire unfolded CypA
population. Nevertheless, the comparison with CypA HDX labeling experiments
(Section 3.3), in particular the time course experiment with ES1234 and 1 M GDH,
suggests a lower degree of unfolding and HDX of CypA in the groEL complex than
when denatured with GDH (Fig. 5.2a). As proposed by Wüthrich et al. one would
assume a similar degree of exchange as groEL complexed CypA undergoes unfold-
ing with the stabilisation of a globally unfolded state [179]. CypA HDX labeling
experiments conducted in the presence of tetradecameric groEL do not support this
idea of stabilisation of globally unfolded CypA.
According to its sequence (Appendix 12.1) lacking one methionine residue, groEL
comprises a total of 4126 hydrogen atoms, split in 380 T1, 533 T2 and 3213 T3 hy-
drogen atoms for each of the 14 subunits. Deuterium uptake versus time is displayed
in Figure 5.2b indicating an equilibrium deuterium level of 269 incorporation after
approximately 204 min. Upon these findings 50 % of the amide backbone protons
are subjected to back exchange and/or experienced solvent protection by virtue of
the tertiary structure of the enzyme. Interestingly the HDX-rate and deuterium
level increases by 29 Da to 298 after complexation with CypA, suggesting that in
the complex more T2 protons are solvent accessible on grounds of deprotection and
conformational changes upon CypA binding. This contrasts somewhat with the idea
of a more compact conformation and an increased amide protection due to binding
of CypA in the inner cavity of groEL.
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Figure 5.2: HDX labeling experiments for the CypA-groEL system. (a) Deuterium uptake vs. time of
apo CypA (black squares), CypA in the presence of groEL (red circles), CypA in 18/2.4 % MeOH (blue
triangles) and CypA with ES1234 in 1M GDH (orange stars). (b) Deuterium uptake vs. time of apo
groEL (green diamonds) and groEL in the presence of CypA (magenta triangles).
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5.4 SUPREX - Automated
Automated ESI-SUPREX was conducted as described in Section 2.7.3. To simul-
taneously observe CypA and groEL in a SUPREX experiment with GDH it was
necessary to further decrease the chaperonin concentration to a tenth of the CypA
concentration, which was for all groEL-CypA SUPREX experiments 5 µM (CypA).
In vivo the basal level of groEL is ˜4 µM, whereas the concentration of nascent
protein-chains is ˜35 µM [159], resulting in a chaperonin/unfolded protein ratio of
˜11 %. Hence, experimental conditions are comparable to those in vivo with respect
to the chaperonin/unfolded protein ratio.
ESI-SUPREX data for apo CypA and in the complex with CsA is displayed in
Chapter 3.7 and summarised in Table 3.4.
5.4.1 Apo GroEL
Freshly expressed and purified groEL was subjected to ESI-SUPREX analysis and
C
1/2
SUPREX values are determined for 10, 30, 45, 60, 90, 120 and 180 min incubation
and are summarised in Table 5.1. Figure 5.3a demonstrates the destabilisation of
the chaperonin with the associated shift to lower C
1/2
SUPREX values with increasing
incubation time with GDH for 30 and 120 min. The complete set of ESI-SUPREX
curves acquired is arranged in Appendix 12.2. Incubation times longer than 180
min do not yield useful SUPREX data due to very high s/n ratios associated with
protein degradation of both proteins. Analysis of SUPREX inflexion points results
in values of -32.55 ± 4.23 kJmol−1 for ∆Gf and a resulting m value of 5.90 ± 2.94
kJmol−1M−1 utilising a linear fit assuming two state unfolding (Fig. 5.3b and Ta-
ble 5.1). Large deviations on C
1/2
SUPREX values vs. ∆Gf either indicate large errors
associated with the determination of C
1/2
SUPREX values or unfolding of groEL does
not exhibit two-state unfolding behaviour. The deuterium level of the pretransition
baseline is between ˜112 and 130 Da for the investigated incubation times, whereas
the posttransition baseline exhibits levels between ˜275-300 Da, resulting in a de-
protection of ˜167 amide protons. Interestingly the SUPREX curves for 10-120 min
do not exhibit uniform sigmoidal behaviour, moreover they reveal a slight increase
in the deuterium level before complete denaturation occurs. This agrees with de-
naturation/reassembly studies of groEL conducted by Munehito et al. in 2003. It is
reported, that groEL exhibits partial denaturation at concentrations of urea <3 M
and cooperatively unfolds at concentrations >3 M [289]. As GDH is a more efficient
denaturant, ESI-SUPREX denaturation experiments demonstrate partial unfold-
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ing below 1 M GDH and completely unfolding between 1.0-1.5 M depending on the
incubation time. These findings further indicate that ESI-SUPREX derived thermo-
dynamic data would not be accurate as accuracy of SUPREX is based on two state
unfolding behaviour. Nonetheless, a qualitative comparison between ESI-SUPREX
derived data should shed some light into the PPIase-chaperonin interaction.
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Figure 5.3: Automated SUPREX data for apo groEL. (a) SUPREX curves for apo groEL for 30 (black
squares) and 120 min (red circles) incubation. (b) Free energy of protein folding vs. C
1/2
SUPREX plot,
with ∆Gf -32.55 ± 4.23 kJmol−1 and an m value of 5.80 ± 2.94 kJmol−1M−1.
5.4.2 CypA-GroEL
ESI-SUPREX derived thermodynamic parameters are displayed in Table 5.1 on page
149, indicating CypA experiences a stabilisation of 0.31, 0.54, 0.49, 0.42, 0.41 and
0.39 M for incubation times 10, 30, 45, 60, 90, 120 and 180 min. For 30 min incuba-
tion the stabilisation of 0.54 M of CypA in the groEL-CypA complex is visualised
in Figure 5.4a. ∆Gf is calculated to be -39.54 ± 2.26 kJmol−1 with a m value of
13.81 ± 2.13 kJmol−1M−1, resulting in a stabilisation of -7.11 ± 4.77 kJmol−1. The
stabilisation is similar to CypA in 18/2.3 % MeOH with -6.32 kJmol−1 and more
than half the value of the CypA-CsA complex with -12.05 ± 4.73 kJmol−1 solely
attributed to the interaction with groEL. On the other hand an increased m value
of 13.81 ± 2.13 kJmol−1M−1 compared to 12.38 ± 3.01 kJmol−1M−1 in apo CypA
and 7.11 ± 1.63 kJmol−1M−1 in the CypA-CsA complex, suggests a higher degree
of unfolding during the denaturation step. These findings agree with the theorem of
the denaturing properties of groEL in conjunction with stabilising a highly unfolded
species via hydrophobic interactions in the Anfinson’s cage (Fig. 5.5).
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Figure 5.4: Automated SUPREX data for CypA in the presence of groEL. (a) SUPREX curves of
30 min incubation of apo CypA (black squares; from Chapter 3.7.1) and in complex with groEL (red
circles). (b) Free energy of protein folding vs. C
1/2
SUPREX plot, with ∆Gf -39.54 ± 2.26 kJmol−1 and
an m value of 13.81 ± 2.13 kJmol−1M−1, resulting in a -7.11 ± 4.77 kJmol−1 stabilisation.
Evaluation of SUPREX curves for the E. coli chaperonin in the presence with CypA
(Appendix 12.4) reveals a stabilisation between 0.04-0.69 M for identical incubation
times (Table 5.1). Figure 5.6a illustrates the stabilisation of groEL upon denatura-
tion in the presence of the PPIase for a 120 min incubation time. The pre-transition
baseline is similar for free and CypA complexed groEL and significantly decreases
for the post-transition baseline of the complexed groEL. This decrease indicates
an increased protection of amide protons in the groEL-CypA complex as a result
of CypA being bound and stabilised in groEL’s inner cavity (Fig. 5.5). These
SUPREX results clearly demonstrate the stabilisation of CypA by groEL, whereas
this information cannot be obtained directly from HDX labeling studies alone.
To enable a direct comparison to the apo protein the ∆Gf vs. C
1/2
SUPREX plot
was linear fitted, though two-state unfolding was questionable. The resulting ∆Gf
value is extrapolated to be -35.86 ± 10.84 kJmol−1 with a m value of 6.49 ± 6.15
kJmol−1M−1, culminating in a ∆∆Gf of -3.10 ± 11.63 kJmol−1 (Fig. 5.6b). Large
errors of ∆Gf and m values are associated with linear fitting of acquired SUPREX
data. However, comparing the m values of groEL with and without CypA concludes
a lower surface exposure of CypA-complexed groEL upon denaturation and/or a
more stepwise fashion of unfolding, rather than one cooperative event. The calcu-
lated stabilisation of -3.10 ± 11.63 kJmol−1 is not quantitative per se, notwithstand-
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ing a stabilisation of groEL upon CypA binding is evident as C
1/2
SUPREX values are
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Figure 5.5: The groEL-cyclophilin A interaction. GroEL (blue) interacting with CypA (coloured) and
binding of a partially unfolded CypA species in the central cavity, resulting in detectable stabilisations of
both proteins in automated ESI-SUPREX experiments (pdb files 1cwa and 1oel displayed and modified
with pymol (DeLano Scientific LLC - Palo Alto, USA)).




















































Figure 5.6: Automated SUPREX data for groEL in the presence of CypA. (a) SUPREX curves of 30
min incubation of apo groEL (black squares) and in complex with CypA (red circles). (b) Free energy
of protein folding vs. C
1/2
SUPREX plot, with ∆Gf -35.86 ± 10.84 kJmol−1 and an m value of 6.49± 6.15 kJmol−1M−1, resulting in a -3.10 ± 11.63 kJmol−1 stabilisation.
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5.4.3 CypA-CsA-GroEL
To probe effects of CsA on the groEL-CypA complex, automated ESI-SUPREX
experiments were conducted. Samples were prepared and experiments executed ac-
cording to Section 2.7.1 and 2.7.3. After 20 min CypA-CsA incubation groEL was
added and further incubated for 20 min, before SUPREX buffers were added and
samples subjected to the SUPREX routine. The final groEL concentration was iden-
tical to that used in previous experiments at a tenth of the CypA concentration.
Four incubation times were probed from 10-90 min, resulting in SUPREX curves
visualised in Appendix 12.5. For longer incubation times no SUPREX data was
recovered due to degradation of the enzymes utilised.
SUPREX inflexion points for 10, 30, 60 and 90 min incubation demonstrate an
increased stability compared to apo CypA (Table 5.1). When considered along with
the CypA-CsA experiments described in the previous Section, a lower degree of
stabilisation is observed for all investigated incubation times, ranging from -0.01 to
-0.44 M (Table 5.1). This destabilisation indicates an interaction of groEL with the
pre-formed CypA-CsA complex. One possibility might be direct interaction of the
CypA-CsA complex with groEL, destabilising the tight CypA-CsA binding without
dissociating it. C
1/2
SUPREX values over 2 M GDH for incubation times between 10-
60 min support the existence of the CypA-CsA complex in the presence of groEL.
Thereby CypA conformation might be altered, lowering the strength of CypA-CsA
interaction but still preserving the characteristics necessary for CsA binding.
The deuterium levels of the pre-transition baselines exhibit similarities to those in
the apo CypA and CypA-CsA-complex, whereas the post-transition baselines are
non consistent. The four incubation times show post-transition deuterium levels
between 35-100 Da, increasing with incubation time from 10-60 min and decreasing
for the 90 min incubation. These findings are different from those for apo CypA and
CypA-CsA from Chapter 3.7, suggesting an increased degree of unfolding of CypA
with prolonged incubation times followed by an event, which disables cooperative
unfolding in the presence of groEL.
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Figure 5.7: Automated SUPREX data for CypA in the presence of CsA and groEL. (a) Comparison
of apo CypA (black squares), CypA-CsA (red circles) and CypA-CsA in the presence of groEL (blue
triangles) at a 30 min incubation time. Apo CypA and CypA-CsA data is taken from Chapter 3.7.1.
CypA is incubated with CsA for 20 min before groEL is added and incubated for further 20 min. (b)
Free energy of protein folding vs. C
1/2
SUPREX plot, complicating linear fit analysis.
ESI-SUPREX data for groEL in the presence of the CypA-CsA complex was ex-
tracted from the same experiment conducted for CypA. SUPREX parameters for
groEL in the presence of the CypA-CsA complex are visualised in Table 5.1, demon-
strating an inverse shift of C
1/2
SUPREX values with regards to time. Comparison with
the apo protein indicates that groEL gets more and more stabilised in the pres-
ence of the CypA-CsA complex upon denaturation vs. time as visualised in Figure
5.8a. The comparison of CypA-bound vs. CypA-CsA-bound groEL does exhibit on
average a less stabilisation of CypA-CsA bound groEL. Nevertheless, CypA in com-
plexed with groEL displays a similar trend at 10-60 min incubation before decreasing
appropriately for incubation times over 60 min (Table 5.1). Figure 5.8b displays the
resulting ∆Gf vs. C
1/2
SUPREX plot, showing an inversed trend which impedes ther-
modynamical analysis. However, thermodynamic parameters are calculated (Table
5.1) but are out of context for acquired data.
These observations indicate a conformational change in the groEL protein due to
the presence of the CypA-CsA complex and GDH, resulting in a more stable form.
However, no evidence has been yet reported to support these findings.
The deuterium levels of the pre-transition baseline of groEL in the presence
of the CypA-CsA complex are higher compared to the apo protein but similar to
those obtained in the groEL-CypA ESI-SUPREX experiments. The post-transition
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baseline is significantly lower compared to the apo protein and displays a similar
deuterium level as in CypA-groEL experiments, leading to the conclusion that the
CypA-CsA complex possesses some degree of affinity for the groEL’s inner cavity, as
indicated by the analysis of CypA in the CsA-complex and the presence of groEL.
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Figure 5.8: Automated SUPREX data for groEL in the presence of CypA and CsA. (a) SUPREX
curves for groEL in the presence of the CypA-CsA complex at a 90 min incubation. CypA and CsA are
incubated for 20 min before groEL addition (red circles), whereas black squares represent apo groEL.
(b) Free energy of protein folding vs. C
1/2
SUPREX plot, with ∆Gf -5.61 ± 4.73 kJmol−1 and an m
value of -9.71 ± 2.59 kJmol−1M−1, resulting in a 26.82 ± 6.36 kJmol−1 destabilisation, which is not























Table 5.1: Automated CypA-CsA-groEL SUPREX results (C
1/2
SUPREX values are visualised for bold printed proteins).




10 1.00 1.56 2.57 (1.57) 1.31 (0.31) 1.79 (0.23) 2.16 (-0.41) 1.57 (0.01/-0.22)
15 0.68 2.39 (1.71)
30 0.63 1.55 3.02 (2.39) 1.17 (0.54) 1.87 (0.32) 2.58 (-0.44) 1.66 (0.11/-0.21)
45 0.54 1.49 2.68 (2.14)
60 0.55 1.68 2.64 (2.09) 1.04 (0.49) 2.00 (0.32) 2.63 (-0.01) 2.00 (0.32/±0.00)
90 0.48 1.52 0.90 (0.42) 1.56 (0.04) 1.65 (N/A) 2.00 (0.48/+0.44)
120 0.60 1.02 2.53 (1.93) 1.01 (0.41) 1.71 (0.69)
150 0.51
180 0.44 1.03 2.39 (1.95) 0.83 (0.39) 1.56 (0.53)
420 0.62
∆Gf/kJmol
−1 -32.43 ± 1.88 -32.55 ± 4.23 -44.48 ± 4.35 -39.54 ± 2.26 35.86 ± 10.84 -5.61 ± 4.73*
∆∆Gf/kJmol
−1 -12.05 ± 4.73 -7.11 ± 4.77 -3.10 ± 11.63 26.82 ± 6.36*
m/kJmol−1M−1 12.38 ± 3.01 5.90 ± 2.94 7.11 ± 1.63 13.81 ± 2.13 6.49 ± 6.15 -9.71 ± 2.59*
a visualised in Section 3.7.1 Fig. 3.14 and Appendix 10.6.
b visualised in Section 5.4.1 Fig. 5.3 and Appendix 12.2.
c visualised in Section 3.7.3 Fig. 3.16 and Appendix 10.8. Values in brackets denote change of C
1/2
SUPREX compared to apo protein.
d visualised in Section 5.4.2 Fig. 5.4 and Appendix 12.3. Values in brackets denote change of C
1/2
SUPREX compared to apo protein.
e visualised in Section 5.4.2 Fig. 5.4 and Appendix 12.4. Values in brackets denote change of C
1/2
SUPREX compared to apo protein.
f visualised in Section 5.4.3 Fig. 5.7 and Appendix 12.5. Values in brackets denote change of C
1/2
SUPREX compared to CypA-CsA complex.
g visualised in Section 5.4.3 Fig. 5.8 and Appendix 12.6. Values in brackets denote change of C
1/2
SUPREX compared to apo protein and in complex
with CypA.
* Thermodynamic SUPREX parameters are out of context to other parameters as an inverse trend in the ∆Gf vs. C
1/2
SUPREX plot is observed (Fig.
5.8b).
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5.5 Conclusion
DI-ESI-MS analysis of expressed groEL further emphasises the success of protein
expression and purification and indicates a lack of one methionine residue consis-
tent with recent reported data.
In HDX labeling experiments cyclophilin A in complex with groEL in a 3:1 stoi-
chiometry clearly exhibits denaturation. However the degree of denaturation is lower
compared to alcohol induced denaturation with methanol and denaturation in the
presence of the chemical denaturant guanidinium hydrochloride. Nevertheless, the
observed denaturation properties of CypA can solely be attributed to the interaction
with groEL, albeit that a globally unfolded and stabilised CypA species could not
be observed.
Labeling experiments with groEL display a decreased protection of amide hydrogen
atoms and therefore a higher deuterium uptake in the chaperonin in the presence
of CypA, suggesting that conformational alterations occur upon CypA complexa-
tion culminating in a more solvent-accessible conformation of the E. coli chaperonin.
Apo ESI-SUPREX experiments demonstrate non-two state unfolding behaviour
for the E. coli chaperonin groEL, as partial unfolding is observed for almost all
incubation times utilised at guanidinium hydrochloride concentrations below 1 M.
Above this concentration cooperative unfolding is observed. Non-two state con-
ditions compromise data accuracy for ESI-SUPREX, however, a qualitative com-
parison is possible. The SUPREX determined thermodynamic parameters are not
directly comparable per se, except determined Kd’s.
For CypA in complex with groEL the denaturing properties and stabilisation
of the denatured CypA species in the groEL-CypA-complex are confirmed by ESI-
SUPREX. Thermodynamic data determined demonstrates similarities to alcohol
induced denaturation with methanol, however, solely attributed to the interaction
with groEL. Contextualising apo groEL SUPREX data, CypA still exhibits two
state unfolding behaviour.
GroEL in complex with CypA displays the same non-two state unfolding behaviour
as apo groEL indicating dynamic partial dissociation before cooperative unfolding.
Moreover a stabilisation of groEL in the presence of CypA is evident, as confirmed
by SUPREX curves and non-two state free energies of protein folding. Comparison
of apo- and CypA-complexed groEL SUPREX curves and associated deuterium lev-
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els, contradict the HDX labeling experiments performed, concluding an increased
protection of amide protons and/or conformational tightening upon CypA binding.
CypA in complex with CsA in the presence of groEL exhibits a stabilisation in
comparison to the apo protein, which is lower than the stabilisation in the CypA-
CsA complex. GroEL alters the CypA conformation in the complex with CsA when
interacting with the inner cavity of the chaperonin resulting in a partial destabili-
sation of the CypA-CsA complex, however, not resulting in ligand dissociation.
Results for groEL ESI-SUPREX experiments are not conclusive as data exhibits
an inverse trend of stabilisation upon denaturation with guanidinium hydrochloride
over time, impeding thermodynamic analysis. Qualitatively, a change in conforma-
tion of groEL upon penetration with denaturant and the presence of the CypA-CsA
complex to a more stable/compact state would account for the observations reported.
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6 Summary
This thesis details the advancement and development of a liquid chromatogra-
phy interface for electrospray ionisation mass spectrometry to enable investiga-
tion of protein-ligand interactions. Thermodynamic properties of various protein-
ligand systems can be measured in a high-throughput fashion. The method em-
ploys hydrogen-deuterium exchange and titration an adaptation of PLIMSTEX and
SUPREX. The major challenge of this work was to develop a liquid chromatography
setup delivering reproducible data for rapidly investigating a given protein-ligand
system (Chapter 2). Initially the hardware developed was tested with the well inves-
tigated, self expressed and purified, cyclophilin A-cyclosporin A protein system and
PLIMSTEX and SUPREX experiments were conducted (Chapter 3). Then a set of
’unknown’ proteins and ligands were investigated with ESI-SUPREX: The potential
oncogene anterior gradient 2 exhibiting binding potential to a set of hexapeptides
and two modules of the complement control protein 19-20 (fH19-20), which shows
great promise to bind to polyanions, such as fondaparinux (Chapter 4). For these
enzyme systems the SUPREX approach was enhanced by conducting experiments
at different temperatures. Finally the E. coli chaperonin groEL was expressed and
purified and subjected ESI-SUPREX analysis in conjunction with CypA and CsA
to demonstrate the chaperoning effects of groEL on the peptidyl-prolyl-isomerase
(Chapter 5).
The development and progress of the manual and the automated ESI-PLIMSTEX
and SUPREX approach is documented in Chapter 2 along with various optimisa-
tion steps with respect to sample handling and hydrogen deuterium exchange op-
timisation. PLIMSTEX and SUPREX methodologies were tested on their general
applicability with insulin and myoglobin exhibiting the expected PLIMSTEX and
SUPREX behaviour. The self expressed and purified proteins cyclophilin A and
groEL are positively identified by biological methods and by direct infusion electro-
spray ionisation mass spectrometry.
Experimental HDX labeling data presented in Chapter 3 reveals lower deuterium
levels of CypA in complex with CsA, KM184 and ES1234 qualitatively indicating an
interaction of these ligands with CypA. Manual PLIMSTEX experiments of CypA
and CsA demonstrated dissociation constants within a factor of ten of that found
with biological assays [282, 252, 283, 284, 141, 145] and a factor of four to MALDI-
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SUPREX data [268]. Evaluation of automated, bulk and individually incubated
PLIMSTEX does not demonstrate useful binding data due to the fact that associ-
ated errors are within the margin of the deuterium uptake due to protection upon
ligand binding. These findings call into question the general applicability of PLIM-
STEX and emphasise the necessity of measurable amide protection. The larger this
protection is the more reproducible and reliable PLIMSTEX data is acquired mak-
ing PLIMSTEX highly system dependent and unsuitable for a priori protein-ligand
high throughput screening.
Manual and automated ESI-SUPREX exhibited better data reproducibility than
PLIMSTEX and dissociation constants determined for the CypA-CsA interaction
were within a factor of ten and eight to Kd’s determined with biological [282, 252,
283, 284, 141, 145] and MALDI-SUPREX methodologies [268], respectively. For
the interaction with KM184 a dissociation constant was found that is almost iden-
tical to values determined by surface plasmon resonance [252, 141]. By contrast the
CypA-ES1234 interaction either exhibits a, by a factor of four, tighter binding with
respect to CsA or suggests non-two state unfolding behaviour as the dissociation
constant contradicts the individual SUPREX midpoint concentrations. Again this
finding throws into question the validity of high-throughput HDX-MS strategies for
screening applications.
In terms of throughput, automation of the ESI-SUPREX approach doubled the
number of analysed samples in a 24 hour period, compared to the manual experi-
ment, in conjunction with elimination of errors associated with manually timing and
execution.
The investigation of ’unknown’ protein-ligand systems, anterior gradient 2 and
factor H, with the developed ESI-SUPREX setup in Chapter 4 exhibited a dualistic
trend of data acquired for AGr2. Findings suggest either a non-two state unfolding
or a large experimental error associated with a two-state unfolding event. Given the
preliminary nature of these findings the latter is more likely. Multiple approaches
of data evaluation and fitting were discussed comprising individual hand selected
data sets. However, if all the experimental data collected was subjected data anal-
ysis based on two-state unfolding and EX2 exchange conditions, an ESI-SUPREX
dissociation constant (24.52 µM) close to the competition fluorescence anisotropy
one was determined (25-40 µM; unpublished data) for the hendeca-tagged hexapep-
tide PTTIYY-Pen and the 27 amino acid long His-tagged AGr2. The interaction
with PATIYY-Pen was quantified with a dissociation constant of 198.98 µM. Care
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must be taken attesting quantitative binding information to the AGr2-PTTIYY in-
teraction on grounds of both compounds comprising massive cell penetrating tags
(Chapter 4), which may well affect protein-ligand interactions. However, at the
beginning of investigating new protein-ligand systems these measures are necessary
and often the only way to access the biological species of interest and will be refined
as more information becomes available.
Temperature dependent HDX labling and ESI-SUPREX experiments demonstrated
posttransition deuterium levels at all denaturant concentrations for the shortest
possible SUPREX incubation time and an aggregation and precipitation of AGr2 at
50 ◦C.
For factor H ESI-SUPREX experiments, the limits of general SUPREX applicability
were demonstrated as incubation times longer than 60 minutes exhibited no further
transition upon denaturation as HDX equilibrium was already reached. These find-
ings emphasise the solvent accessibility, in conjunction with a low difference in mass
incorporation upon denaturation and the rigidness of fH19-20 due to the four disul-
fide bonds. ESI-SUPREX experiments with the pentasaccharose fondaparinux and
the two fH variants did not yield a dissociation constant due to the lack of SUPREX
midpoint denaturing concentrations of the holo system. However, HDX labeling ex-
periments suggest a gain in solvent accessibility and conformational opening upon
interaction with fondaparinux.
Meeting the criteria of two-state unfolding behaviour and following EX2 conditions
as well as a decent ’protection’ against complete hydrogen/deuterium exchange,
seems to be guarantor for reliable and reproducible thermodynamical data and disso-
ciation constants. When these requirements are not fulfilled or unknown, SUPREX
is proposed to still deliver reliable data. The work on AGr2 and fH19-20 along
with their ligands demonstrated the outcome, if one or both of these requirements
were not met, the universal applicability of SUPREX for a priori screening of not
well characterised proteins and their potential ligands is questionable. On the other
hand SUPREX has been demonstrated to deliver qualitatively good thermodynam-
ical data for Kd calculations with well investigated protein ligand-systems following
the SUPREX requirements, and so we can conclude that successful SUPREX anal-
ysis is system dependent.
In Chapter 5 the experimental HDX labling data of CypA in the presence of the
E. coli chaperonin groEL revealed the unfolding capabilities of the chaperonin and
the resulting stabilisation of a partially unfolded CypA species, however, a globally
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unfolded CypA was not detected under experimental conditions. ESI-SUPREX ex-
periments on the CypA-groEL system further emphasised the stabilisation of a CypA
species in complex with groEL, as SUPREX midpoint concentrations demonstrated.
Apo groEL conducted automated ESI-SUPREX experiments displayed non-two state
unfolding behaviour for the E. coli chaperonin, as partially unfolding was observed
for concentrations below one molar of the chemical denaturant, whereas above this
concentration cooperative unfolding was evident. In the complex with CypA, groEL
also exhibited a stabilisation in comparison with the apo protein.
Cyclophilin A in complex with CsA in the presence of groEL demonstrated a desta-
bilisation of the CypA-CsA complex without dissociation due to the interaction with
groEL. On the contrary, experiments conducted with groEL in the presence of the
CypA-CsA complex, interestingly, exhibited an inverse trend of the SUPREX free
energy of protein folding versus midpoint concentrations curve, suggesting CypA
in complex with CsA stabilises groEL over time despite the chemical denaturant.
These findings suggest a specific interaction of the CypA-CsA complex with groEL
in conjunction with the presence of guanidinium hydrochloride, altering the confor-
mation of the chaperonin to a more stable one.
In conclusion, the utilised, modified and developed HDX methodologies are
highly system dependent and ad hoc not applicable for general protein-ligand screen-
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91. Bonhöffer, K. F.; Klar, R., Ueber den austausch von schweren wasserstoffatomen zwischen
wasser und organischen verbindungen. Naturwissenschaften 1933, 22, 45. (Cited on pages 16
and 17.)
92. Hvidt, A.; Linderstrøm-Lang, K., Exchange of hydrogen atoms in insulin with deuterium
atoms in aqueous solutions. Biochim. Biophys. Acta 1954, 14, 574–575. (Cited on page 16.)
7 REFERENCES 162
93. Hvidt, A.; Linderstrøm-Lang, K., The kinetics of the deuterium exchange of insulin with d2o.
an amendment. Biochim. Biophys. Acta 1955, 16, 168–169. (Cited on page 16.)
94. Dempsey, C. E., Hydrogen exchange in peptides and proteins using nmr spectroscopy. Prog.
Nucl. Magn. Res. Spec. 2001, 39, 2, 135–170. (Cited on pages 16, 17, 19, and 20.)
95. Katta, V.; Chait, B. T.; Carr, S., Conformational changes in proteins probed by hydrogen-
exchange electrospray-ionization mass spectrometry. Rapid Comm. Mass Spectrom. 1991, 5,
4, 214–217. (Cited on page 16.)
96. Kaltashov, I. A.; Eyles, S. J., Studies of biomolecular conformations and conformational
dynamics by mass spectrometry. Mass Spectrom. Rev. 2002, 21, 1, 37–71. (Cited on page 16.)
97. Hoofnagle, A. N.; Resing, K. A.; Ahn, N. G., Protein analysis by hydrogen exchange mass
spectrometry. Annu. Rev. Biophys. Biomol. Struct. 2003, 32, 1–25. (Cited on page 16.)
98. Wales, T. E.; Engen, J. R., Hydrogen exchange mass spectrometry for the analysis of protein
dynamics. Mass Spectrom. Rev. 2006, 25, 1, 158–170. (Cited on pages 16 and 18.)
99. Englander, S. W., Hydrogen exchange and mass spectrometry: A historical perspective. J.
Am. Soc. Mass Spectrom. 2006, 17, 11, 1481–1489. (Cited on page 16.)
100. Englander, S. W.; Sosnick, T. R.; Englander, J. J.; Mayne, L., Mechanisms and uses of
hydrogen exchange. Curr. Op. Struc. Biol. 1996, 6, 1, 18–23. (Cited on page 17.)
101. Englander, S. W.; Kallenbach, N. R., Hydrogen exchange and structural dynamics of proteins
and nucleic acids. Q. Rev. Biophys. 1983, 16, 04, 521–655. (Cited on page 18.)
102. Woodward, C. K.; Hilton, B. D., Hydrogen isotope exchange kinetics of single protons in
bovine pancreatic trypsin inhibitor. Biophys. J. 1980, 32, 1, 561–575. (Cited on page 18.)
103. Bai, Y.; Milne, J. S.; Mayne, L.; Englander, S. W., Protein stability parameters measured by
hydrogen exchange. Proteins 1994, 20, 1, 4–14. (Cited on page 18.)
104. Hvidt, A.; Nielsen, S. O., Hydrogen exchange in proteins. Adv. Protein Chem. 1966, 21,
287–386. (Cited on page 18.)
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M. D., Structure of human cyclophilin and its binding site for cyclosporin a determined by
x-ray crystallography and nmr spectroscopy. Nature 1991, 353, 6341, 276–279. (Cited on
page 22.)
128. Kallen, J.; Walkinshaw, M. D., The x-ray structure of a tetrapeptide bound to the active site
of human cyclophilin a. FEBS Lett. 1992, 300, 3, 286–290. (Cited on page 22.)
129. Spitzfaden, C.; Weber, H. P.; Braun, W.; Kallen, J.; Wider, G.; Widmer, H.; Walkinshaw,
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8.2 Thermodynamics
The Internal Energy and Enthalpy
Due to the first law of thermodynamics the internal energy of a system is governed by volume
work and heat.
dU = δW + δQ (24)
The internal energy U is
U = f(T, V, ni) (25)






dU = δQ − pdV (27)
assuming a closed system and isobar conditions:
dU = δQ − pdV ⇒ UII − UI = Q − p(VII − VI) (28)
Solving for the exchanged heat:
Q = UII − UI + p(VII − VI) = U + pV (29)
The enthalpy H is a state function f(T, p, ni):
H = U + pV (30)
The enthalpy for isobaric systems equals the amount of heat exchanged with the surrounding:
(HII − HI)p = Qp (31)
Heat Capacities
The heat needed to warm a system is proportional to the temperature difference and the number
of moles n:
Q = C(T2 − T1) = c · n(T2 − T1) (32)
Hereby the proportionality factor C is termed the heat capacity, and c the molar heat capacity
(c = C/n).
The partial differentials of U and T with respect to T delivers the heat capacities. According to
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the first law of thermodynamics (eq. 27) and writing the total differentials for U and I:







































































The heat capacity results by inserting eq 37 into 32 and is defined as the heat needed to warm up



























Entropy, Free Enthalpy and Energy
According to the second law of thermodynamics the entropy (S) is constant in an isolated system
for reversible processes, and increases for irreversible ones.
(S2 − S1)U,V ≥ 0 (40)
An assumption that a system is in contact with a big thermostat enables the usage of the ther-
modynamic basic equations and resolves the duality of the driving forces of entropy increase and
energy decrease.








≥ 0 (V, T const) dS(system) −
dH
T
≥ 0 (p, T const) (43)
The free energy A (Helmholtz) is defined as:
A = U − T · S (44)
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and the free enthalpy G (Gibbs):
G = H − T · S (45)
with equation 43 the criteria for spontaneous processes become:
dAV,T ≤ 0 dGp,T ≤ 0 (46)
All equations and derivations adapted from [52].
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9 Appendix 2
9.1 Bradford Assay for Cyclophilin A




















Concentration [ g/ L]
9.2 Direct Infusion Chromatogram




















9 APPENDIX 2 183
9.3 HPLC-MS Elution Chromatogram


















9.4 Manual PLIMSTEX CypA Mass Spectrum
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9.5 LC Program for HDX Labeling
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9.6 LC Program for Bulk PLIMSTEX
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9.7 LC Program for Individual PLIMSTEX
TempCtrl = On
Temperature.Nominal = 20.0 [°C]
Temperature.LowerLimit = 5.0 [°C]
Temperature.UpperLimit = 85.0 [°C]
EquilibrationTime = 0.5 [min]
ReadyTempDelta = 5.0 [°C]
Pressure.LowerLimit = 2 [bar]
Pressure.UpperLimit = 400 [bar]
MaximumFlowRampDown = 300000 [µl/min²]













































































Data_Collection_Rate = 2 [Hz]
Response = 0.1 [s]
UV_VIS_1.Wavelength = 214 [nm]
UV_VIS_1.Step = 0.50 [s]
UV_VIS_1.Average = On
0.000Autozero
Flow = 30 [µl/min]
%B = 0.0 [%]
%C = 0.0 [%]
Curve = 5




Flow = 30 [µl/min]
%B = 0.0 [%]




0.490Flow = 30 [µl/min]
%B = 0.0 [%]
%C = 0.0 [%]
Curve = 5
0.500Flow = 30 [µl/min]
%B = 100.0 [%]
%C = 0.0 [%]
Curve = 5
15.500Flow = 30 [µl/min]
%B = 100.0 [%]
%C = 0.0 [%]
Curve = 5
15.510Flow = 30 [µl/min]
%B = 0.0 [%]




Flow = 30 [µl/min]
%B = 0.0 [%]
%C = 0.0 [%]
Curve = 5
End
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9.8 The PLIMSTEX Modelling Procedure
Derivation of the PLIMSTEX fitting equation8. In the case of a 1:1 protein ligand binding equi-
librium
P + L⇀↽PL (47)






where cθ = 1 M. [P], [L] and [PL] are subject to the two conditions
[P ] + [PL] = [P ]0 (49)
[L] + [PL] = [L]0 (50)




([P ]0 − [PL])([L]0 − [PL])
. (51)
Now define Λ = K[P ]0/c




(1 − f)(x − f)
. (52)
Where f is the fraction of protein that is complexed with the ligand, and it can be found by solving
equation (52) to yield
f(x) =
[1 + Λ(1 + x)] −
√
1 + 2Λ(1 + x) + Λ2(1 − x)2
2Λ
. (53)
The measured experimental data is a linear combination of ’free’ and ’complex’ signals, and is
given by
∆m(x) = ∆mfree[1 − f(x)] + ∆mcomplexf(x). (54)
Equations 53 and 54 define an analytical expression which was fitted to the experimental PLIMS-
TEX data to obtain values of ∆mfree, ∆mcomplex and K = Λc/[P ]0 (Fig. 1.14, chapter 1.5). For
further 1:1 protein ligand systems equation (54) was used for data analysis (2.6.5).
8by Dr. Phillip Camp, University of Edinburgh
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9.9 Human Insulin Sequence
10 50
GIVEQCCTSI SSLYQLENYC NFVNQHLCGD HLVEALYLVC GERGFFYTPL
T
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9.10 SUPREX LC Method Apo Sample List
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9.11 SUPREX LC Method Holo Sample List (Even)
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9.12 SUPREX LC Method Holo Sample List (Odd)
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9.13 Automated SUPREX CypA Mass Spectrum















9.14 Derivation of SUPREX Equations
Derivation of the SUPREX equation based on principles of HDX (1.3.2). In case of a folded protein





For amide protons exhibiting exchange via a global unfolding mechanism, 1/Kop or Kcl (the
equilibrium constant for the closing reaction) is equal to Kf , the equilibrium constant for the
















At the inflection point of a SUPREX curve the HDX has progressed to one half-life. Equation 58
describes the relation between HDX time, t, and kex. Substitution of eq 58 in 57 yields:





Assuming all kint values for global exchanging hydrogen atoms can be approximated by 〈kint〉t.
The most common method to analyse traditional solvent-induced denaturation curves is the linear
extrapolation method (LEM, [2], [299]) based on equation 60:
− RT lnKf = m[Denaturant] + ∆Gf (60)
With R, gas constant, T is the temperature in Kelvin, Kf the apparent equilibrium folding con-
stant, m is δ∆Gf/δ[Denaturant] with [Denaturant] the molar concentration of the denaturant and
∆Gf the free energy of protein folding in the absence of the denaturant. At this point it is worth
pointing out that equation 60 is only valid for a two-state unfolding process. Substitution of [De-
naturant] in eq 60 with C
1/2
SUPREX the midpoint denaturing concentration of a SUPREX curve.
Again SUPREX C
1/2











SUPREX + ∆Gf (61)

















SUPREX + ∆Gf (62)










Hereby [L] is the molar concentration of the ligand, n the number of independent binding sites and





MGLSDGEWQQ VLNVWGKVEA DIAGHGQEVL IRLFTGHPET LEKFDKFKHL
KTEAEMKASE DLKKHGTVVL TALGGILKKK GHHEAELKPL AQSHATKHKI
PIKYLEFISD AIIHVLHSKH PGDFGADAQG AMTKALELFR NDIAAKYKEL
GFQG
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9.16 Automated Myoglobin SUPREX Curves
10 min 15 min









 [GDH] / molL-1























 [GDH] / molL-1
 m





















 [GDH] / molL-1 
 
 m
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90 min 120 min







 [GDH] / molL-1 
  m







 [GDH] / molL-1 
  m
180 min
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10 Appendix 3
10.1 Cyclophilin A Sequence
Additional N-terminal methionine illustrated in red.
MMVNPTVFFD IADVGEPLGR VSFELFADKV PKTAENFRAL STGEKGFGYK
GSCFHRIIPG FMCQGGDFTR HNGTGGKSIY GEKFEDENFI LKHTGPGILS











MRGSHHHHHH HGSMMGVEIE TISPGDGRTF PKKGQTCVVH YTGMLQNGKK
FDSSRDRNKP FKFRIGKQEV IKGFEEGAAQ MSLGQRAKLT CTPDVAYGAT
GHPGVIPPNA TLIFDVELLN LE
10.3 CypA Manual SUPREX Curves
10 min 40 min
















 [GDH] / M
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60 min 120 min















 [GDH] / M
















10.4 CypA-CsA Manual SUPREX Curves
10 min 40 min































 [GDH] / M
60 min 120 min































 [GDH] / M 
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10.5 CypA-ES1234 Manual SUPREX Curves
10 min 40 min















 [GDH] / M















 [GDH] / M
60 min 120 min
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10.6 Apo CypA Automated SUPREX Curves
10 min 15 min
















[c] GDH / M















 [c] GDH / M
30 min 45 min















 [c] GDH / M















 [c] GDH / M
60 min 90 min















 [c] GDH / M















 [c] GDH / M
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120 min 150 min















 [c] GDH / M















 [c] GDH / M
180 min 420 min















 [c] GDH / M















 [c] GDH / M
10.7 CypA-36.88 % MeOH Automated SUPREX Curves
10 min 30 min















 [c] GDH / M















 [c] GDH / M
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60 min 120 min















 [c] GDH / M















 [c] GDH / M
10.8 CypA-CsA Automated SUPREX Curves
10 min 15 min















 [c] GDH / M















 [c] GDH / M
30 min 45 min















 [c] GDH / M















 [c] GDH / M
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60 min 120 min















 [c] GDH / M















 [c] GDH / M
180 min















 [c] GDH / M
10.9 CypA-KM184 Automated SUPREX Curves
10 min 15 min















 [c] GDH / M















 [c] GDH / M
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30 min 45 min















 [c] GDH / M















 [c] GDH / M
60 min 90 min















 [c] GDH / M















 [c] GDH / M
120 min 180 min















 [c] GDH / M















 [c] GDH / M
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10.10 CypA-ES1234 Automated SUPREX Curves
10 min 15 min















 [c] GDH / M















 [c] GDH / M
30 min 45 min















 [c] GDH / M















 [c] GDH / M
60 min 90 min















 [c] GDH / M















 [c] GDH / M
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11 Appendix 4
11.1 Anterior Gradient 2 Sequence






MSYYHHHHHH LESTSLYKKA GFEGDRTMRD TTVKPGAKKD TKDSRPKLPQ
TLSRGWGDQL IWTQTYEEAL YKSKTSSKPL MIIHHLDECP HSQALKKVFA
ENKEIQKLAE QFVLLNLVYE TTDKHLSPDG QYVPRIMFVD PSLTVRADIT





EAEFGKCGPP PPIDNGDITS FPLSVYAPAS SVEYQCQNLY QLEGNKRITC
RNGQWSEPPK CLHPCVISRE IMENYNIALR WTAKQKLYSR TGESVEFVCK
RGYRLSSRSH TLRTTCWDGK LEYPTCAKR
11.3 Apo AGr2Nicholson Manual SUPREX Curves
10 min 40 min
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60 min 180 min



























11.4 AGr2Nicholson-PTTIYY-Pen Manual SUPREX Curves
10 min 60 min
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11.5 Apo AGr2Florance Automated SUPREX Curves
10 min 15 min



































 [c] GDH / M
25 min 60 min



































[c] GDH / M
90 min 120 min

















 [c] GDH / M

















[c] GDH / M
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11.6 Apo AGr2Nicholson Automated SUPREX Curves
10 min 15 min

















[c] GDH / M


















30 min 60 min

















[c] GDH / M


















90 min 120 min



































[c] GDH / M
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180 min


















11.7 AGr2Nicholson-PTTIYY-Pen Automated SUPREX Curves
10 min 15 min




































60 min 90 min
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120 min 180 min




































11.8 AGr2Nicholson-PATIAA-Pen Automated SUPREX Curves
10 min 15 min




































60 min 90 min
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120 min 180 min




































11.9 Apo FH19-20 Automated SUPREX Curves
10 min 30 min


























60 min 120 min
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180 min












[c] GDH / M
11.10 FH19-20-Fondaparinux Automated SUPREX Curves
10 min 30 min


























60 min 120 min
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180 min






































MAAKDVKFGN DARVKMLRGV NVLADAVKVT LGPKGRNVVL DKSFGAPTIT
KDGVSVAREI ELEDKFENMG AQMVKEVASK ANDAAGDGTT TATVLAQAII
TEGLKAVAAG MNPMDLKRGI DKAVTAAVEE LKALSVPCSD SKAIAQVGTI
SANSDETVGK LIAEAMDKVG KEGVITVEDG TGLQDELDVV EGMQFDRGYL
SPYFINKPET GAVELESPFI LLADKKISNI REMLPVLEAV AKAGKPLLII
AEDVEGEALA TLVVNTMRGI VKVAAVKAPG FGDRRKAMLQ DIATLTGGTV
ISEEIGMELE KATLEDLGQA KRVVINKDTT TIIDGVGEEA AIQGRVAQIR
QQIEEATSDY DREKLQERVA KLAGGVAVIK VGAATEVEMK EKKARVEDAL
HATRAAVEEG VVAGGGVALI RVASKLADLR GQNEDQNVGI KVALRAMEAP
LRQIVLNCGE EPSVVANTVK GGDGNYGYNA ATEEYGNMID MGILDPTKVT
RSALQYAASV AGLMITTECM VTDLPKNDAA DLGAAGGMGG MGGMGGMM
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12.2 Automated Apo GroEL SUPREX Curves
10 min 30 min



















[c] GDH / M


















 [c] GDH / M
45 min 60 min


















 [c] GDH / M


















 [c] GDH / M
90 min 120 min


















 [c] GDH / M


















 [c] GDH / M
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180 min

















 [c] GDH / M
12.3 CypA-GroEL Automated SUPREX Curves for CypA
10 min 30 min













[c] GDH / M












 [c] GDH / M
60 min 90 min












 [c] GDH / M












 [c] GDH / M
12 APPENDIX 5 218
120 min 180 min












 [c] GDH / M












 [c] GDH / M
12.4 CypA-GroEL Automated SUPREX Curves for GroEL
10 min 30 min















 [c] GDH / M















 [c] GDH / M
60 min 90 min















 [c] GDH / M















 [c] GDH / M
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120 min 180 min















 [c] GDH / M















 [c] GDH / M
12.5 CypA-CsA-GroEL Automated SUPREX Curves for CypA
10 min 30 min












 [c] GDH / M












 [c] GDH / M
60 min 90 min












 [c] GDH / M












 [c] GDH / M
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12.6 CypA-CsA-GroEL Automated SUPREX Curves for GroEL
10 min 30 min















 [c] GDH / M















 [c] GDH / M
60 min 90 min

















[c] GDH / M















 [c] GDH / M
